NZ611365B2 - Fused aminodihydrothiazine derivatives useful as bace inhibitors - Google Patents
Fused aminodihydrothiazine derivatives useful as bace inhibitors Download PDFInfo
- Publication number
- NZ611365B2 NZ611365B2 NZ611365A NZ61136512A NZ611365B2 NZ 611365 B2 NZ611365 B2 NZ 611365B2 NZ 611365 A NZ611365 A NZ 611365A NZ 61136512 A NZ61136512 A NZ 61136512A NZ 611365 B2 NZ611365 B2 NZ 611365B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- amino
- thiazin
- tetrahydro
- trifluoromethyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 80
- VNTNANCAPVJRJP-UHFFFAOYSA-N 3,4-dihydrothiazin-2-amine Chemical class NN1CCC=CS1 VNTNANCAPVJRJP-UHFFFAOYSA-N 0.000 title abstract description 14
- 101700051112 BACE1 Proteins 0.000 title abstract description 12
- 239000003112 inhibitor Substances 0.000 title description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 304
- 239000011780 sodium chloride Substances 0.000 claims abstract description 85
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- -1 monofluoromethyl Chemical group 0.000 claims abstract description 61
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 31
- 206010053643 Neurodegenerative disease Diseases 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 20
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 11
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 125000006001 difluoroethyl group Chemical group 0.000 claims abstract description 5
- 229910052731 fluorine Chemical group 0.000 claims abstract description 4
- 239000011737 fluorine Chemical group 0.000 claims abstract description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 79
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 201000010374 Down syndrome Diseases 0.000 claims description 8
- 206010044688 Trisomy 21 Diseases 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N Pyrazinamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 5
- 125000001207 fluorophenyl group Chemical group 0.000 claims 4
- 229960005206 Pyrazinamide Drugs 0.000 claims 2
- 230000000626 neurodegenerative Effects 0.000 claims 1
- 102100015650 BACE1 Human genes 0.000 abstract description 11
- ZKKFSFUYHYWFFE-FWVNDXEPSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SC[C@@H]2[C@H](OC3)C(F)(F)F)N)=CC=1NC(=O)C1=CN=C(C(F)F)C=N1 ZKKFSFUYHYWFFE-FWVNDXEPSA-N 0.000 abstract 2
- FMBFQIOLYLQHTO-ACWOFJMJSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SC[C@@H]2[C@H](OC3)C(F)(F)F)N)=CC=1NC(=O)C1=CC=C(C#N)C=N1 FMBFQIOLYLQHTO-ACWOFJMJSA-N 0.000 abstract 2
- MTAAMFBCQCSRBX-DJCROIMJSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H]([C@H](OC2)C(F)(F)F)CSC(N)=N3)=C1 MTAAMFBCQCSRBX-DJCROIMJSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 177
- 238000006243 chemical reaction Methods 0.000 description 154
- 239000000243 solution Substances 0.000 description 96
- 239000002904 solvent Substances 0.000 description 95
- 235000019439 ethyl acetate Nutrition 0.000 description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
- 238000005160 1H NMR spectroscopy Methods 0.000 description 69
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 68
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 62
- 239000002253 acid Substances 0.000 description 61
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 61
- 210000004556 Brain Anatomy 0.000 description 56
- 101700067048 CDC13 Proteins 0.000 description 49
- 239000011541 reaction mixture Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 37
- 235000019341 magnesium sulphate Nutrition 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 238000003756 stirring Methods 0.000 description 33
- 210000004027 cells Anatomy 0.000 description 32
- 210000003169 Central Nervous System Anatomy 0.000 description 31
- 210000002381 Plasma Anatomy 0.000 description 31
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 31
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 30
- 239000002585 base Substances 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 238000010992 reflux Methods 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- 238000004166 bioassay Methods 0.000 description 25
- 239000008079 hexane Substances 0.000 description 25
- 230000035484 reaction time Effects 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 25
- 206010012289 Dementia Diseases 0.000 description 24
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 22
- 230000035695 Efflux Effects 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 20
- 239000000556 agonist Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 239000010410 layer Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 230000000051 modifying Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 230000003042 antagnostic Effects 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 17
- 230000035515 penetration Effects 0.000 description 17
- 230000001603 reducing Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 230000002194 synthesizing Effects 0.000 description 17
- 229940079593 drugs Drugs 0.000 description 16
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 15
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000004896 high resolution mass spectrometry Methods 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- 239000012190 activator Substances 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 101700044176 BACE Proteins 0.000 description 11
- 235000019253 formic acid Nutrition 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 150000004703 alkoxides Chemical class 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000002609 media Substances 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 210000004369 Blood Anatomy 0.000 description 9
- 230000003281 allosteric Effects 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 102100017796 APP Human genes 0.000 description 8
- 108060000460 APP Proteins 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 206010061536 Parkinson's disease Diseases 0.000 description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- 230000003412 degenerative Effects 0.000 description 8
- 230000036026 efflux ratio Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000008096 xylene Substances 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 208000005145 Cerebral Amyloid Angiopathy Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 150000003738 xylenes Chemical class 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 102100006129 CDK5 Human genes 0.000 description 4
- 206010057668 Cognitive disease Diseases 0.000 description 4
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 4
- 102100010782 EGFR Human genes 0.000 description 4
- 101700039191 EGFR Proteins 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- 210000004558 Lewy Bodies Anatomy 0.000 description 4
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 4
- DLBFLQKQABVKGT-UHFFFAOYSA-L Lucifer yellow Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 4
- 102100015874 MAP2K4 Human genes 0.000 description 4
- 108090000028 MMP12 Proteins 0.000 description 4
- 102100009139 NGF Human genes 0.000 description 4
- 102000003729 Neprilysin Human genes 0.000 description 4
- 229940053128 Nerve Growth Factor Drugs 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 206010036631 Presenile dementia Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 206010048327 Supranuclear palsy Diseases 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive Effects 0.000 description 4
- 230000001476 alcoholic Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000001054 cortical Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neurons Anatomy 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108060002036 pde-2 Proteins 0.000 description 4
- KEDPUQKUZHYBGW-UHFFFAOYSA-O phosphanium;hexafluorophosphate Chemical compound [PH4+].F[P-](F)(F)(F)(F)F KEDPUQKUZHYBGW-UHFFFAOYSA-O 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2H-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 3
- 206010002023 Amyloidosis Diseases 0.000 description 3
- 206010002022 Amyloidosis Diseases 0.000 description 3
- 230000037267 BRAIN TISSUE BINDING Effects 0.000 description 3
- 230000035592 Brain Concentration Effects 0.000 description 3
- 210000003710 Cerebral Cortex Anatomy 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 230000036422 Fraction unbound Effects 0.000 description 3
- 102100009274 IDE Human genes 0.000 description 3
- 108090000828 Insulysin Proteins 0.000 description 3
- 101710027749 MAP2K4 Proteins 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- CZFNISFYDPIDNM-UHFFFAOYSA-N N,N-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 3
- KRKPYFLIYNGWTE-UHFFFAOYSA-N N,O-Dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 3
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 description 3
- PULGYDLMFSFVBL-SMFNREODSA-N Nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 230000036660 Plasma protein binding Effects 0.000 description 3
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 3
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 3
- 230000036437 Unbound plasma Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 230000003078 antioxidant Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 239000003540 gamma secretase inhibitor Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 3
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 102400001111 nociceptin Human genes 0.000 description 3
- 108090000622 nociceptin Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- 239000001184 potassium carbonate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 3
- WADGHWKXQZVKFK-UHFFFAOYSA-N thiazin-2-amine Chemical compound NN1SC=CC=C1 WADGHWKXQZVKFK-UHFFFAOYSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-N-(2-methoxyethyl)-N-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NINVWDFNTXENDC-DNVCBOLYSA-N 6-[(3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl]-1-(oxan-4-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C([C@H]([C@@H](C1)C2=NC(=O)C3=CNN(C3=N2)C2CCOCC2)C)N1CC1=CC=CC=C1 NINVWDFNTXENDC-DNVCBOLYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 2
- 101700056202 ACACA Proteins 0.000 description 2
- 102100009225 ACHE Human genes 0.000 description 2
- 229940022698 Acetylcholinesterase Drugs 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N Aminomethylphosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- 208000006141 Amyloid angiopathy Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100004057 CYP3A4 Human genes 0.000 description 2
- 101710007540 CYP3A4 Proteins 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M Caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M Caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 210000001715 Carotid Arteries Anatomy 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100010213 DAO Human genes 0.000 description 2
- 108060002104 DAO Proteins 0.000 description 2
- 102000037829 Excitatory amino acid transporters Human genes 0.000 description 2
- 108091006271 Excitatory amino acid transporters Proteins 0.000 description 2
- 230000037021 Free Brain Concentration Effects 0.000 description 2
- 102100007020 GPR3 Human genes 0.000 description 2
- 102100006614 GRM3 Human genes 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 102000004311 Liver X Receptors Human genes 0.000 description 2
- 108090000865 Liver X Receptors Proteins 0.000 description 2
- 229960003987 Melatonin Drugs 0.000 description 2
- 210000004688 Microtubules Anatomy 0.000 description 2
- 102000028664 Microtubules Human genes 0.000 description 2
- 108091022031 Microtubules Proteins 0.000 description 2
- 101710041493 NEDD9 Proteins 0.000 description 2
- 238000010934 O-alkylation reaction Methods 0.000 description 2
- 101700084262 PDE1C Proteins 0.000 description 2
- 101700018813 PK2 Proteins 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- 229940012957 Plasmin Drugs 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- NIPZZXUFJPQHNH-UHFFFAOYSA-N Pyrazinoic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 2
- 230000036885 QTc Effects 0.000 description 2
- 230000036028 QTc interval Effects 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J Tin(IV) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N Trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N acrylaldehyde Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N bis(tri-t-butylphosphine)palladium (0) Substances [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 125000001108 carbamothioyl group Chemical group C(N)(=S)* 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;N,N-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 2
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 2
- RQBKGJOQACIQDG-UHFFFAOYSA-N difluoro(triphenyl)silanuide;tetrabutylazanium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC.C=1C=CC=CC=1[Si-](F)(C=1C=CC=CC=1)(F)C1=CC=CC=C1 RQBKGJOQACIQDG-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 230000003551 muscarinic Effects 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 238000006146 oximation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 2
- 230000000896 plasminic Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- YJBKVPRVZAQTPY-UHFFFAOYSA-J tetrachlorostannane;dihydrate Chemical compound O.O.Cl[Sn](Cl)(Cl)Cl YJBKVPRVZAQTPY-UHFFFAOYSA-J 0.000 description 2
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2R,3R)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AQZRARFZZMGLHL-REOHCLBHSA-N (2S)-2-(trifluoromethyl)oxirane Chemical compound FC(F)(F)[C@@H]1CO1 AQZRARFZZMGLHL-REOHCLBHSA-N 0.000 description 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinone Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- YJUUZFWMKJBVFJ-UHFFFAOYSA-N 1,3-dimethylimidazolidin-4-one Chemical compound CN1CN(C)C(=O)C1 YJUUZFWMKJBVFJ-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- 238000002223 1H--13C heteronuclear multiple bond coherence Methods 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- KYTNDPGVIBDGFO-UHFFFAOYSA-N 2,4,4a,5-tetrahydro-1H-furo[3,4-d][1,3]thiazin-2-amine Chemical compound C1SC(N)NC2=COCC21 KYTNDPGVIBDGFO-UHFFFAOYSA-N 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- OSSBKXMASZTOSG-UHFFFAOYSA-N 2-(trifluoromethyl)oxolane Chemical compound FC(F)(F)C1CCCO1 OSSBKXMASZTOSG-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M 2-bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KQGBNNCXCHAHEG-UHFFFAOYSA-N 4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-2-amine Chemical compound C1SC(N)=NC2COCC21 KQGBNNCXCHAHEG-UHFFFAOYSA-N 0.000 description 1
- BKUJEHHWQQBLTE-UHFFFAOYSA-N 5-(fluoromethyl)pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=C(CF)C=N1 BKUJEHHWQQBLTE-UHFFFAOYSA-N 0.000 description 1
- RMSAQCLOEUZHLC-UHFFFAOYSA-N 5-(methoxymethyl)pyrimidine-2-carboxylic acid Chemical compound COCC1=CN=C(C(O)=O)N=C1 RMSAQCLOEUZHLC-UHFFFAOYSA-N 0.000 description 1
- NJHGVAYLDHROPT-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=N1 NJHGVAYLDHROPT-UHFFFAOYSA-N 0.000 description 1
- 108091005523 5-HT4 receptors Proteins 0.000 description 1
- 108091005482 5-HT6 receptors Proteins 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 description 1
- LQMBFTKKBNTWEF-UHFFFAOYSA-N 5-ethoxypyrazine-2-carboxylic acid Chemical compound CCOC1=CN=C(C(O)=O)C=N1 LQMBFTKKBNTWEF-UHFFFAOYSA-N 0.000 description 1
- YVGVOPNUEFTVQO-UHFFFAOYSA-N 5-methoxypyrazine-2-carboxylic acid Chemical compound COC1=CN=C(C(O)=O)C=N1 YVGVOPNUEFTVQO-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 230000035698 Apparent permeability Effects 0.000 description 1
- 241000287523 Ara Species 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 102100012919 BCHE Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004938 Bipolar disease Diseases 0.000 description 1
- 229940116229 Borneol Drugs 0.000 description 1
- 208000008581 Brain Disease Diseases 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 229940084030 CARBOXYMETHYLCELLULOSE CALCIUM Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229960003135 Donepezil hydrochloride Drugs 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 206010014623 Encephalopathy Diseases 0.000 description 1
- 206010014625 Encephalopathy Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 230000036328 Free drug Effects 0.000 description 1
- 102100006616 GRM2 Human genes 0.000 description 1
- 108091007473 GSKs Proteins 0.000 description 1
- 229960003980 Galantamine Drugs 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010072075 Gerstmann Straussler Scheinker syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- SYKWLIJQEHRDNH-CKRMAKSASA-N Glutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-CKRMAKSASA-N 0.000 description 1
- 229940096919 Glycogen Drugs 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 102100002612 HTR3A Human genes 0.000 description 1
- 108060004362 HTR3A Proteins 0.000 description 1
- 241000506654 Haemulon album Species 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 108040008094 JUN kinase activity proteins Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- YGPSJZOEDVAXAB-UHFFFAOYSA-N Kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710027724 MAGEC3 Proteins 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 102100005531 MAPK8 Human genes 0.000 description 1
- 101710029924 MAPK8 Proteins 0.000 description 1
- 101700062165 MKK4 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 229940105132 Myristate Drugs 0.000 description 1
- FBGJJTQNZVNEQU-UHFFFAOYSA-N N,3-dimethylaniline Chemical compound CNC1=CC=CC(C)=C1 FBGJJTQNZVNEQU-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N N,N-dimethyl-2H-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N N,N-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- SLYCYWCVSGPDFR-UHFFFAOYSA-N Octadecyltrimethoxysilane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OC)(OC)OC SLYCYWCVSGPDFR-UHFFFAOYSA-N 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 230000035980 PAA Effects 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010011302 Peripheral nerve injury Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N Phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 230000037164 Plasma conc Effects 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 Prazosin Drugs 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 102100007015 SERPINE1 Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 210000003752 Saphenous Vein Anatomy 0.000 description 1
- 208000008864 Scrapie Diseases 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 206010040003 Sensation of pressure Diseases 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M Sodium thiopental Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042211 Stress disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 240000000280 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000036743 UNBOUND FRACTION Effects 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 230000036729 Unbound concentration Effects 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047931 Whipple's disease Diseases 0.000 description 1
- 101700051122 XYLD Proteins 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- ADSXDBCZNVXTRD-UHFFFAOYSA-N [Mg]C1=CC=CC=C1 Chemical compound [Mg]C1=CC=CC=C1 ADSXDBCZNVXTRD-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- FZENGILVLUJGJX-UHFFFAOYSA-N acetaldehyde oxime Chemical compound CC=NO FZENGILVLUJGJX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001741 anti-phlogistic Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229930006709 borneol Natural products 0.000 description 1
- 230000000059 bradycardiac Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical class C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000000855 fungicidal Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000006142 intramolecular cycloaddition reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TYBGOSICSDCCEA-UHFFFAOYSA-N methyl 5-(methoxymethyl)pyrazine-2-carboxylate Chemical compound COCC1=CN=C(C(=O)OC)C=N1 TYBGOSICSDCCEA-UHFFFAOYSA-N 0.000 description 1
- CVVMLRFXZPKILB-UHFFFAOYSA-N methyl 5-chloropyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=N1 CVVMLRFXZPKILB-UHFFFAOYSA-N 0.000 description 1
- KNAAFIKYVYERNG-UHFFFAOYSA-N methyl 5-formylpyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=C(C=O)C=N1 KNAAFIKYVYERNG-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-M myristate Chemical compound CCCCCCCCCCCCCC([O-])=O TUNFSRHWOTWDNC-UHFFFAOYSA-M 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 230000000802 nitrating Effects 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 229920003258 poly(methylsilmethylene) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-M pyrazine-2-carboxylate Chemical compound [O-]C(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-M 0.000 description 1
- IUDVBGFRDKKVLA-UHFFFAOYSA-O pyrrolidin-1-ylphosphanium;hexafluorophosphate Chemical compound [PH3+]N1CCCC1.F[P-](F)(F)(F)(F)F IUDVBGFRDKKVLA-UHFFFAOYSA-O 0.000 description 1
- 229910052904 quartz Inorganic materials 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035812 respiration Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 239000003751 serotonin 6 antagonist Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- CQXDYHPBXDZWBA-UHFFFAOYSA-N tert-butyl 2,2,2-trichloroethanimidate Chemical compound CC(C)(C)OC(=N)C(Cl)(Cl)Cl CQXDYHPBXDZWBA-UHFFFAOYSA-N 0.000 description 1
- VJQNYNXTXXJHAY-VOTSOKGWSA-N tert-butyl 5-[(E)-2-(dimethylamino)ethenyl]pyrazine-2-carboxylate Chemical compound CN(C)\C=C\C1=CN=C(C(=O)OC(C)(C)C)C=N1 VJQNYNXTXXJHAY-VOTSOKGWSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- LJZFDDUGNSHNTA-UHFFFAOYSA-O tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[PH+](N(C)C)N(C)C LJZFDDUGNSHNTA-UHFFFAOYSA-O 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 101700086913 try-5 Proteins 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000002034 xenobiotic Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Disclosed are fused aminodihydrothiazine derivatives of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or cyano; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia. Examples of compounds of formula (I) are: N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-cyanopicolinamide; N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide and N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide. mpound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia. Examples of compounds of formula (I) are: N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-cyanopicolinamide; N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2-carboxamide and N-(3-((4aS,5S,7aS)-2-amino-5-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide.
Description
FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS
The present ion relates to a fused aminodihydrothiazine tive and
pharmaceutical use thereof. More particularly, the present invention relates to a fused
aminodihydrothiazine tive which has an amyloid-B nafter referred to as AB)
protein tion inhibitory effect or a beta-site arnyloid-B sor protein cleavage
enzyme 1 (hereinafter referred to as BACEl or beta-secretase) inhibitory effect and is
effective for treating a neurodegenerative disease caused by AB protein, in particular,
Alzheimer-type dementia, Down’s syndrome or the like, and to a pharmaceutical
composition comprising the fused aminodihydrothiazine derivative as an active
ient.
Alzheimer's disease is a disease characterized by degeneration and loss of
neurons as well as formation of senile plaques and neurofibrillary tangles. Currently,
only the symptoms of mer’s disease are treated using a symptom‘improving agent
typified by an acetylcholinesterase tor, and a fundamental remedy to inhibit
progression of the disease has not yet been developed. It is ary to develop a
method for controlling the cause of the onset of pathology in order to create a
fundamental remedy for mer's disease.
It is assumed that AB-proteins as breakdown products of amyloid precursor
proteins (hereinafter referred to as APP) are highly involved in degeneration and loss of
neurons and onset of symptoms of dementia. AB—proteins have, as main components,
AB4O consisting of 40 amino acids and AB42 with two amino acids added at the C—
terminal. The AB4O and AB42 are known to be highly prone to aggregation and to be
the main components of senile plaques. Further, it is known that the AB40 and AB42
are increased by mutations in APP and presenilin genes which is observed in familial
Alzheimer's disease. Accordingly, a compound that reduces production of AB40 and
AB42 is expected to be a disease progression inhibitor or prophylactic agent for
Alzheimer's disease.
AB is produced by the ge of APP by beta-secretase (BACEl) and
subsequently by secretase. For this reason, ts have been made to create
gamma—secretase and beta—secretase inhibitors in order to inhibit AB production.
Published International patent application WOZOl 1/005738 (Eli Lilly and
Company) describes compounds of formula (A) and their use as BACE inhibitors:
NH2 (A)
(R3)p
where RI n and p are defined therein.
, R2, R3, X, m,
Fused ihydrothiazine compounds of formula (B) have already been
disclosed in published International patent application W02009/O91016 (Eisai R&D
Management Co., Ltd):
R5 R5 R1
N N
z \Y ‘R2 e
Y ,s
R4 R3
wherein ring A represents a €6-14ary1 group or the like; L represents —NReCO— in
R8 represents a hydrogen atom or the like] or the like; ring B represents a €6-14aryl
group or the like; X represents a C1-3alkylene group or the like; Y represents a single
bond or the like; Z ents a C1_3alkylene group or the like; R1 and R2 independently
represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a
hydrogen atom, a halogen atom or the like.
r fused aminodihydrothiazine compounds of formula (C) have been
sed in published International patent application WOZOlO/O38686 (Eisai R&D
Management Co._. Ltd):
R5 R6 R1
% Y” e
R4 R3
wherein ring A represents a C6_l4aryl group or the like; L represents ~NReCO— [wherein
R6 represents a hydrogen atom or the like] or the like; the ring B represents a C(y14aryl
group or the like; X represents a C1_3alkylene group or the like; Y represents a single
bond or the like; Z represents an oxygen atom or the like; R1 and R2 each independently
represents a hydrogen atom or the like; and R3, R4, R5 and R6 each ndently
represents a hydrogen atom, a halogen atom or the like.
The present invention represents a selection from the genus of compounds
sed in W02009/091016.
An object of the present invention is to provide further compounds that have an
AB production inhibitory effect or a BACEl inhibitory effect and are useful as
prophylactic or therapeutic agents for a neurodegenerative disease caused by AB and
typified by Alzheimer-type ia, which compounds are fused
ihydrothiazine derivatives. The above object is to be read disjunctively with
the object of the invention to at least provide the public with a useful alternative.
Thus, the t invention provides the compound of formula (I):
/A Y
got iN
X NH
F (1)
F30
wherein
X is hydrogen or fluorine;
A is CH or N;
Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl,
difluoroethyl, methoxy, ethoxy, methoxymethyl or —C EN;
and pharmaceutically acceptable salts thereof.
In one embodiment of the present invention, X is hydrogen.
In another embodiment of the present invention, A is N.
In another embodiment of the present ion, Y is methyl, oromethyl,
difluoromethyl, trifluoromethyl or methoxy.
One favoured group of compounds of the t invention is the compound of
formula (Ia) and pharmaceutically acceptable salts thereof:
N Y
on/ rN
F (la)
N NH2
0 Y
where Y is as hereinbefore defined. Preferably, Y is methyl, monofluoromethyl,
difluoromethyl, trifluoromethyl, oethyl, methoxy, ethoxy or methoxymethyl.
In one embodiment the present invention provides a compound of a (Ia)
wherein Y is methoxy or monofluoromethyl.
Another favoured group of compounds of the present invention is the compound
of formula (Ib) and pharmaceutically acceptable salts thereof:
N Y
0%;1//|N
F NH
F 0b)
N NH2
0 Y
where Y is as before defined. Preferably, Y is methyl, monofluoromethyl,
difluoromethyl or methoxy.
1 O A further favoured group of compounds of the present invention is the
compound of formula (10) and pharmaceutically able salts f:
O \
F ('0)
N NH2
0 Y
where Y is as hereinbefore defined. Preferably, Y is methyl, ethyl, trifluoromethyl,
methoxy or -CEN.
Preferred compounds of the present ion are:
N-(3—((4aS,SS,7aS)—2—amino-5~(trifluoromethyl)—4a,5,7,7a—tetrahydro—4H—furo[3,4-
d][1,3]thiazin-7a-y1)—4—fluorophenyl)—5-methoxypyrazine-2—carboxamide:
WO 98213
O \N
N—(3—((4aS,SS,7aS)—2-amino(trifluor0methyl)—4a,5,7,7a—tetrahydro-4H-furo[3,4—
d] [1,3]thiazin—7a—yl)—4—flu0r0pheny1)—5~cyanopicolinamide:
O \
N NH2
0 1/
F PH
F ;
N-(3-((4aS,SS,7aS)-2—amino(trifluoromethy1)—4a,5 ,7,7a-tetrahydro-4H—furo[3 ,4-
d][1,3]thiazin-7a-y1)-4—flu0rophenyl)~5—(difluoromethy1)pyrazine—Z—carboxamide:
N;\[H\F
O \N
N—(3~((4aS,5S,7aS)—2-amino—5~(trifluoromethy1)—4a,5 ,7,7a-tetrahydro-4H—furo[3 ,4—
d][1 ,3] thiazin-7a-y1)—4—fluoropheny1)—5 - (trifluoromethy1)picolinamide:
N-(3—((4aS,SS,7aS)~2—amino-5—(trifluoromethyl)—4a,5,7,7a—tetrahydro—4H—furo[3,4-
d] [1 ,3] thiazin-7a~y1)—4—fluorophenyl)~5~methy1pyrazine—Z—carboxanfide:
N-(3-((4aS,SS,7aS)amino-S-(trifluoromethyl)—4a,5,7,7a-tetrahydro—4H—furo[3,4—
d][1,3]thiazin-7a—y1)-4—fluoropheny1)—5-methylpicolinmnide:
o \1
N NH2
o I
FFFH
N—(3-((4aS,SS,7aS)amino~5—(trifluor0methyl)~4a,5,7 trahydro-4H-furo[3,4—
d] [1 ,3] thiazin—7a-y1)fluorophenyl)—5—ethy1picolinamide:
O \
2012/050833
N-(3—((4aS,SS,7aS)~2—amin0—5—(trifluoromethyl)—4a,5,7,7a—tetrahydro-4H—furo[3,4—
d] [ 1 ,3] thiazin-7a—y1)-4—fluoropheny1)(fluoromethyl)pyrazine-Z-carboxamide:
N ’ F
OVVN|
N-(3—((4aS,SS,7aS)-2~amino(trifluoromethyl)—4a,5,7,7a-tetrahydro—4H-furo[3,4—
d][1,3]thiazin-7a—y1)-4—fluorophenyl)~5~meth0xypicolinamidez
N/ O\
O \I
N NH2
O \Y
1 O N-(3—((4aS ,SS ,7as)~2~amino~5-(trifluoromethyl)—4a,5 ,7 ,7a—tetrahydro—4H—furo[3 ,4-
d] [ 1 ,3] thiazin—7a—yl)—4-flu0ropheny1)-5—ethoxypyrazine—Z—carboxamide:
NWow
N-(3-(:(4aS,SS,7aS)—2—amino-S-(trifluoromethyl)—4a,5 ,7,7a—tetrahydro—4H—furo[3,4-
l 5 d]L1,3]thiazin—7a—yl)-4—fluorophcnyl)—5—(1,1-difluorocthyl)pyrazinc-2—carboxamidc:
PCT/EPZO 12/050833
(4aS,SS,7aS)—2—amin0(trifluoromethyl)—4a,5,7,7a—tetrahydro-4H—furoI3,4—
d][1,3]thiazin—7a—y1)—4—flu0r0pheny1)-5—(trifluoromethyl)pyrazine-Z—carboxamide:
F F
Néféf:
O \ N
N NH2
O ‘Y
F F ;
N-(3-((4aS,SS,7aS)~2—amino(trif1uoromethy1)—4a,5,7,7a-tetrahydro-4H-furo[3,4-
d][l ,3]thiazin—7a—y1)—4—fluoropheny1)—5—(methoxymethy1)pyrazine-Z—carboxamide:
N NH2
O ‘Y
N—{3—[(4aS,SS,7aS)—2—amino—5-(trifluoromethyl)-4a:5—dihydro—4H—furo[3,4
d][1,3]thiazin-7a(7H)—y1]—4—flu0r0pheny1}—5—[(2H3)methyloxy]pyrazine—Z-carboxamide:
o 2H
N,“.r v:
ow\N H
N-(3{(421858,7218)—2—amino—5-(trifluoromethyl)-4a,5,7,7a—tetrahydr0—4H—fur0[3 ,4—
d] [1 ,3]thiazin—7a-yl)-4,5 -difluoropheny1)-5 oromethyl)pyrazine-Z-carboxamide:
0 \N
N—(3—((4aS,SS,7aS)—2-amino~5~(trifluoromethyl)~4a,5 ,7,7a-tetrahydro—4H—furo[3 ,4-
d] [1,3]thiazin-7a—y1)—4,5—difluor0pheny1)~5-methoxypyrazine-Z-carboxamide:
NwOMe
ow\N
l 0 N—(3{(421358_,7aS)amino-5—(trif1u0r0methy1)-4a,5,7,7a-tetrahydro-4H—fur0[3 ,4—
d] [1 ,3]thiazinv7a-y1)—4,5-difluor0pheny1)-5—methylpyrazine-Z—carboxamide:
N¢\lrMe
OYK/N
N-(3-((4aS,SS,7aS)—2—amino-S-(trifluoromethyl)—4a,5,7,7a-tetrahydro—4H—furo[3,4-
l 5 d][1,3]thiazin-7a—y1)-4,5-dif1uor0pheny1)—5-(fluoromethyl)—pyrazine-2—carboxamide:
2012/050833
N“I:
o§)\/N
and pharmaceutically acceptable salts thereof.
In one embodiment, the present invention provides a compound which is N-(3-
((4aS,SS,7aS)—2—amino-5—(trifluoromethyl)-4a,5,7,7a—tetrahydro-4H—furo[3,4—
d][l ,3]thiazin—7a—yl)—4—fl uoropheuyl)—5~methoxypyrazine-Z-carhoxamide, or a
pharmaceutically able salt thereof.
In another embodiment, the present invention provides a compound which is N—
(3—((4aS,SS,7aS)amino-5—(tritluoromethyl)-4a,5,7=7a—tetrahydro—4H-furo[3,4—
d][1 ,3]thiazin-7a—yl)-4—fluorophenyl)—5—(fluoromethyl)pyrazine—2—earboxarnide, or a
pharmaceutically acceptable salt thereof.
c compounds within the scope of this invention include those named in
the Examples below and their pharmaceutically acceptable salts.
As used herein, the term "difluoroethyl" refers to an alkyl group having two
carbon atoms and substituted with two fluorine atoms. Examples of the group are
CH3—CF2-, CHgF-CHF- and CHFQ-CH3-. In the present invention, the group is
preferably CH3—CF2—.
The compound of a (I) is not limited to a specific isomer and includes all
possible isomers (such as a keto-enol isomer, an imine—enamine isomer and a rotamer)
and mixtures thereof. For e, the compound of formula (1) includes the
following tautomers:
A Y
\j/ A Y
YEN/ l 0%/ 0 1/
X NH X NH
F F
N NH
H NH
O O Y
W3 8
F30 H
The compounds of the t invention contain three chiral centers located on
the ydrofuro—thiazinyl ring within formula (I). The stereochemical configuration at
each of these chiral centers is preferably S, i.e. they are (4aS,SS,7aS) stereoisomers. For
the avoidance of doubt the (4aS.SS.7aS) stereoisomers of the t invention may be
present as a mixture with one or more of the other possible stereoisomers, for example
in a racemic mixture.
In one ment, the present ion provides a compound of formula (I)
which is stereochemically pure at the (4aS,SS,7aS) chiral centers. In the context of the
present specification, the term chemically pure denotes a compound which has
80 % or greater by weight of the (4aS,SS,7aS) stereoisomer and 20% or less by weight
of other stereoisomers. In a further embodiment, the compound of formula (I) has 90 %
or greater by weight of the S.7aS) stereoisomer and 10% or less by weight of
other stereoisomers. In a yet r embodiment, the nd of formula (I) has 95 %
or greater by weight of the S,7aS) stereoisomer and 5% or less by weight of other
stereoisomers. In a still further embodiment, the compound of formula (I) has 97 % or
greater by weight of the (4aS,SS,7aS) stereoisomer and 3% or less by weight of other
stereoisomers.
In the present specification, although crystal polymorphs of the compound may
be present, the compound is similarly not limited thereto and may be present as a single
crystal form or a mixture of single crystal forms. The compound may be an anhydride
or a hydrate. Any of these forms is included in the claims of the present cation.
The present invention also includes isotopically—labelled compounds, which are
identical to the compounds of formula (I), except that one or more atoms are replaced
by an atom having an atomic mass or mass number different from the atomic mass or
mass number usually found in nature. Examples of isotopes that can be incorporated
into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen,
fluorine, phosphorous, chlorine, technetium and iodine, such as 2H, 3H, 11C, 14C, ”N.
150.. 181:, 3-1), 99mTC, 123I and 1311.
Compounds of the present invention and pharmaceutically acceptable derivatives
(e. g. salts) of said compounds that contain the aforementioned isotopes and/or other
isotopes of other atoms are Within the scope of the present invention. Isotopically—
3O labelled compounds of the t invention, for example those into which radioactive
isotopes such as H and/or 14C are incorporated, are useful in drug and/or substrate
tissue distribution assays. H and 14C are considered useful due to their ease of
preparation and detectability. 11C, 15Oand 18F es are considered useful in PET
ron emission tomography), and 99mTc, 1231 and 1311 isotopes are considered useful
in SPECT (single photon enrission computerized tomography), all useful in brain
imaging. Substitution with heavier isotopes such as 2H can afford certain therapeutic
advantages resulting from greater metabolic ity, for example increased in viva
half—life or reduced dosage ements and, hence, are considered useful in some
stances. Isotopically labelled compounds of formula (I) of this invention can
generally be prepared by ng out the procedures disclosed in the s and/or in
the Examples below, by substituting a readily available ically labelled reagent for
a non-isotopically labelled reagent.
The fused aminodihydrothiazine derivative of the formula (I) according to the
present invention may be a pharmaceutically acceptable salt. Pharmaceutically
acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm.
Sci, 1977, 766, 1—19. Specific examples of the pharmaceutically acceptable salt
include inorganic acid salts (such as sulfates, es, orates, phosphates,
carbonates, bicarbonates. hydrofluorides, hydrochlorides, hydrobromides and
hydroiodides), c carboxylates (such as es, oxalates, maleates, tartrates,
fumarates, citrates, malonates and lactates), organic sulfonates (such as
methanesulfonates, trifluoromethanesulfonates, ethanesulfonates, benzenesulfonates,
toluenesulfonates and camphorsulfonates), amino acid salts (such as aspartates and
glutamates), nary amine salts, alkali metal salts (such as sodium salts and
potassium salts) and alkali earth metal salts (such as magnesium salts and calcium salts).
The compound of the formula (1) according to the present invention can be
converted to a pharmaceutically acceptable salt by a conventional method where
necessary. The salt can be prepared by a method in which methods lly used in
the field of organic tic chemistry and the like are riately combined.
Specific examples of the method include neutralization titration of a free solution of the
compound of the present invention with an acid solution.
The fused aminodihydrothiazine derivative of the formula (I) or
pharmaceutically acceptable salt according to the present invention may be a solvate
thereof. Examples of a solvate include a hydrate.
The compound of the formula (1) according to the present invention can be
converted to a solvate by subjecting the compound to a solvate g reaction known
per 56 where ary.
The present invention further es a compound of formula (I) or a
3O pharmaceutically acceptable salt thereof for use in therapy.
The fused aminodihydrothiazine derivative or pharmaceutically acceptable salt
thereof or solvate thereof according to the present ion has an excellent AB
production inhibitory effect or BACEl inhibitory effect and is useful as a prophylactic
or therapeutic agent for a neurodegenerative disease caused by AB and typified by
Alzheimer-type dementia. The compounds of the invention reduce both AB4O and AB42.
Furthermore, the compounds of the present invention may have a BACE 2 inhibitory
effect.
WO 98213
Thus, in another aspect, the present invention provides a compound of formula
(I) as defined above, or a pharmaceutically acceptable salt thereof, for inhibiting
production of amyloid-B protein.
In a further aspect, the present invention provides a nd of formula (I) as
d above, or a pharmaceutically acceptable salt thereof, for inhibiting ite
amyloid—B precursor protein cleaving enzyme 1 (BACE 1).
In a further , the present invention provides a compound of formula (I) as
d above, or a pharmaceutically acceptable salt thereof, for ng a
neurodegenerative disease. Examples of neurodegenerative diseases include
Alzheimer—type dementia (AD), Down’s syndrome, cerebrov ascular amyloid
angiopathy (CAA), mild cognitive impairment (MCI), memory loss, presenile dementia,
senile dementia, hereditary cerebral hemorrhage with amyloidosis, and other
degenerative dementias such as dementias of mixed ar and degenerative origin,
dementia associated with supranuclear palsy, ia associated with cortical basal
degeneration, dementia associated with Parkinson's Disease (PD), and dementia
associated with diffuse Lewy Body type of AD. In one embodiment, the
neurodegenerative disease is Alzheimer—type dementia (AD).
In another aspect, the invention provides the use of a compound of formula (I) as
defined above, or a ceutically able salt thereof, for the manufacture of a
medicament for the treatment or tion of a neurodegenerative disease, such as
Alzheimer—type ia (AD), Down’s syndrome, cerebrovascular d
angiopathy (CAA), mild cognitive impairment (MCI), memory loss, presenile dementia,
senile dementia, hereditary cerebral hemorrhage with amyloidosis, and other
degenerative dementias such as dementias of mixed vascular and degenerative origin,
dementia associated with supranuclear palsy, dementia associated with cortical basal
degeneration, dementia associated with Parkinson's Disease (PD), and dementia
associated with e Lewy Body type of AD. In one ment, the
neurodegenerative disease is Alzheimer~type dementia (AD).
In another aspect, the invention provides a method of inhibiting production of
amyloid—B protein and/or of ng or preventing a neurodegenerative disease, such as
Alzheimer-type dementia (AD), Down’s syndrome, cerebrovascular amyloid
athy (CAA), mild cognitive impairment (MCI), memory loss, presenile dementia,
senile dementia, hereditary cerebral hemorrhage with amyloidosis, and other
degenerative dementias such as ias of mixed vascular and degenerative origin,
dementia associated with supranuclear palsy, dementia associated with cortical basal
degeneration, dementia associated with Parkinson's Disease (PD), and dementia
associated with diffuse Lewy Body type of AD to a human
, involving administering
subject in need thereof a therapeutically or prophylactically effective amount of a
20121’050833
compound of formula (I) or a pharmaceutically acceptable salt thereof. Examples of
neurodegenerative diseases include those listed above. In one ment, the
neurodegenerative disease is Alzheimer-type dementia (AD). “Effective amount” means
an amount sufficient to cause a benefit to the subject or at least to cause a change in the
subject’s condition.
onal conditions which may be treated by the compounds of the present
invention include type 2 diabetes, Creutzfield-Jakob Disease (CJD), peripheral nerve
injury, peripheral neuropathy, progressive supra-nuclear palsy, stroke, amyotrophic
lateral sclerosis (ALS), autoimmune diseases, inflammation, arterial thrombosis, anxiety
disorders, psychotic disorders, epilepsy, seizures, convulsions, stress disorders, ar
amyloidosis, pain, Gerstmann—Straeussler—Scheinker syndrome, scrapie, encephalopathy,
spino cerebellar ataxia, Wilson‘s e, Graves Disease, gton's Disease,
Whipple's Disease, Kostmann Disease, glaucoma, hereditary cerebral hemorrhage with
amyloidosis, cerebral hemorrhage with amyloidosis, vascular amyloidosis, brain
inflammation, e X syndrome, stroke, Tourette's syndrome, inclusion body myositis,
stress ers, depression, bipolar disorder and obsessive compulsive disorder.
In one aspect the present invention further provides a compound of formula (I) as
defined above, or a pharmaceutically acceptable salt thereof, for treating type 2 diabetes.
In a further aspect the present invention further provides the use of a compound of
formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for the treatment or prevention of type 2 diabetes.
In a yet furher aspect the present invention further provides a method of
inhibiting production of amyloid—B protein and/or of treating or ting type 2
diabetes involving administering to a human subject in need thereof a eutically or
prophylactically effective amount of a compound of a (I) or a pharmaceutically
acceptable salt thereof.
A r aspect of the invention provides a pharmaceutical composition
comprising a compound of formula (I) as d above, or a pharmaceutically
acceptable salt thereof, as active ingredient in association with a pharmaceutically
acceptable carrier. The composition may be in any suitable form, depending on the
intended method of administration. It may for example be in the form of a tablet,
capsule or liquid for oral stration, or of a solution or suspension for
administration parenterally.
The fused aminodihydrothiazine derivative or pharrnaceutically acceptable salt
thereof according to the present invention can be formulated by a conventional method.
Preferable examples of the dosage form include s, coated tablets such as film
s and sugar-coated s, fine granules, es, s, capsules, syrups,
s, inhalants, suppositories, injections, ointments, eye drops, nasal drops, ear drops,
asms and lotions.
These solid preparations such as tablets, capsules, granules and s can
contain generally 0.01 to 100 wt%, and preferably 0.1 to 100 wt% of the fused
aminodihydrothiazine derivative or pharmaceutically able salt thereof according
to the present invention as an active ingredient.
The active ingredient is formulated by blending ingredients generally used as
materials for a pharmaceutical preparation and adding an excipient, a disintegrant, a
binder, a lubricant, a colorant and a corrective typically used, and adding a stabilizer, an
emulsifier, an absorbefacient, a surfactant, a pH adjuster, a preservative and an
antioxidant where necessary, for example, using a conventional method. es of
such ingredients e animal and vegetable oils such as soybean oil, beef tallow and
synthetic glyceride; hydrocarbons such as liquid paraffin, squalane and solid paraffin;
ester oils such as odecyl myristate and isopropyl myristate; higher alcohols such
as earyl alcohol and behenyl alcohol; a ne resin; silicone oil; surfactants such
as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, ol fatty acid ester,
polyoxyethylene an fatty acid ester, polyoxyethylene hydrogenated castor oil and
a polyoxyethylene—polyoxypropylene block copolymer; water—soluble polymers such as
hydroxyethylcellulose, polyacrylic acid, a carboxyvinyl polymer, polyethylene glycol,
polyvinylpyrrolidone and methylcellulo se; lower alcohols such as ethanol and
isopropanol; polyhydric alcohols such as glycerol, ene glycol, dipropylene glycol
and ol; sugars such as glucose and sucrose; inorganic powders such as silicic
anhydride, magnesium aluminum silicate and aluminum silicate; and purified water.
Examples of the excipient used include lactose, corn starch, saccharose, glucose,
mannitol, sorbitol, crystalline cellulose and silicon dioxide. es of the binder
used include nyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum
arabic, tragacanth, n, shellac, hydroxypropylmethylcellulose,
hydroxypropylcellulose, polyvinylpyrrolidone, a polypropylene glycol-polyoxyethylene
block copolymer and nieglumine. Examples of the disintegrant used include starch,
agar, gelatin , crystalline cellulose, calcium carbonate, sodium bicarbonate,
m citrate, dextrin, pectin and carboxymethylcellulose calcium. Examples of the
lubricant used include magnesium stearate, talc, polyethylene , silica and
hydrogenated vegetable oil. Examples of the colorant used include those permitted to
be added to pharmaceuticals. Examples of the corrective used include cocoa powder,
menthol, empasm, mentha oil, borneol and cinnamon powder. Obviously, the
ients are not limited to the above additive ingredients.
For example, an oral preparation is prepared by adding the fused
aminodihydrothiazine derivative or pharmaceutically acceptable salt thereof according
-15_
PCT/EP20121050833
to the present invention as an active ingredient, an ent and, where ary, a
binder, a disintegrant, a lubricant, a colorant, a corrective and the like, and then forming
the mixture into powder, fine granules, granules, s, coated tablets, capsules or the
like by a conventional method. Obviously, tablets or granules may be appropriately
coated, for example, sugar coated, where necessary.
For example, a syrup or an injection preparation is prepared by adding a pH
adjuster, a solubilizer, an isotonizing agent and the like, and a solubilizing agent, a
stabilizer and the like where necessary by a conventional method. The injection may
be a previously prepared solution, or may be powder itself or powder containing a
le additive. which is dissolved before use. The injection can contain usually 0.01
to 100 wt%, and preferably 0.1 to 100 wt% of the active ingredient. Further, a liquid
preparation for oral stration such as a suspension or a syrup can contain usually
0.01 to 100 wt%, and preferably 0.1 to 100 wt% of the active ingredient.
For example, an al preparation can be prepared by any tional
method without specific limitations. As a base material, any of s materials
usually used for a pharmaceutical, a quasi drug, a cosmetic or the like can be used.
Examples of the base material e materials such as animal and vegetable oils,
mineral oils, ester oils. waxes, higher alcohols, fatty acids, silicone oils, surfactants,
phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals and
purified water. A pH adjuster, an antioxidant, a chelator, a preservative and fungicide,
a colorant, a flavor or the like can be added where necessary. r, ingredients such
as an ingredient having a entiation inducing effect, a blood flow enhancer, a
bactericide, an antiphlogistic, a cell activator, Vitamin, amino acid, a humectant and a
keratolytic agent can be blended where necessary.
The dose of the fused aminodihydrothiazine derivative or pharmaceutically
acceptable salt thereof according to the present invention varies according to the degree
of symptoms, age, sex, body weight, mode of administration, type of salt and specific
type of disease, for example. Typically, the active ingredient is orally administered to
an adult at about 30 pg to 10 g, ably 100 pg to 5 g, and more preferably 100 pg to
l g per day, or is administered to an adult by injection at about 30 pg to 1 g, preferably
100 pg to 500 mg, and more preferably 100 pg to 300 mg per day, in one or several
doses, respectively.
nds of the formula (I) may be used in ation with other
therapeutic agents, for example medicaments claimed to be useful as either disease
modifying or symptomatic treatments of a neurodegenerative disease such as
Alzheimer’s disease. Thus, in a further aspect, the present invention provides a
pharmaceutical product comprising, in combination, a first active ingredient which is a
compound of formula (I) or a pharmaceutically able salt thereof and at least one
~16-
20121050833
r active ingredient useful in treating a neurodegenerative disease. In one
embodiment of the invention, the neurodegenerative disease is Alzheimer—type
dementia (AD). Suitable examples of such further active ingredients may be
symptomatic agents, for example those known to modify ergic transmission such
as M1 and M3 muscarinic or agonists or allosteric modulators, M2 muscaiinic
antagonists, M4 ts or positive allosteric modulators (PAMs), acetylcholinesterase
inhibitors (such as ydroaminoacridine, donepezil hydrochloride and rivastigrnine),
nicotinic receptor agonists or allosteric modulators (such as 0:7 agonists or allosteric
modulators or (1432 agonists or allosteric modulators), PPAR agonists (such as PPARy
ts), 5—HT4 receptor agonists or partial agonists, histamine H3 antagonists, 5—HT6
receptor antagonists or SHTIA receptor ligands and NMDA receptor antagonists or
modulators, 5-HT3A antagonists, 5—HT7 nists, Dl agonists or PAMs, D4 agonists
or PAMs, D5 agonists or PAMs, GABA—A (15 e agonists or negative allosteric
modulators (NAMs), GABA-A (12/3 agonists or PAMs, mGluRZ modulators (PAMs or
NAMs), mGluR3 PAMs, mGluRS PAMs, PDE 1 inhibitors, PDE 2 inhibitors, PDE 4
inhibitors, PDE 5 inhibitors, PDE 9 inhibitors, PDE 10 tors, GlyTl tors,
DAAO inhibitors, ASCl inhibitors, AMPA modulators, SIRTl activators or inhibitors,
AT4 antagonists. GalRi nists, GalR3 ligands, adenosine A1 antagonists,
adenosine A2a antagonists, (12A antagonists or agonists, selective and unselective
norepinephrine reuptake inhibitors (SNRIS), or potential disease modifying agents such
as gamma secretase inhibitors or modulators, alpha secretase activators or tors,
amyloid aggregation inhibitors, amyloid antibodies, tau aggregation inhibitors or tau
orylation/kinase inhibitors, tau dephosphorylation / atase activators,
mitogen—activated protein kinase kinase 4 (MKK4/MEK4/MAP2K4) inhibitors, c~Jun
N—terminal kinase (JNK) inhibitors, casein kinase inhibitors, MKZ (mitogen activated
protein —activated protein kinase 2) inhibitors, MARK (microtubule affinity
regulating kinase) inhibitors, CDKS (cyclin dependent kinase 5) inhibitors, GSK—3
(glycogen synthase kinase~3) inhibitors and tau-tubulin kinase—l (TTBKl) inhibitors.
Further examples of such other therapeutic agents may be calcium channel blockers,
3O A (3-hydroxy—3—rnethyl~glutaryl-COA) reductase inhibitors (statins) and lipid
lowering , NGF (nerve growth factor) mimics, antioxidants, GPR3 ligands,
plasmin activators, neprilysin (NEP) activators, IDE (insulin degrading enzyme)
activators, melatonin MTl and/or MT2 agonists, TLX/NRZEl (tailless X receptor)
ligands, GluRl ligands, RAGE (receptor for advanced ion end—products)
antagonists, EGFR (epidermal growth factor receptor) inhibitors, FPRL-l (formyl
peptide-like receptor-1) ligands, GABA antagonists, and MICAL (molecule interacting
with casL) inhibitors, eg. oxoreductase inhibitors, CB1 antagonists/inverse agonists,
non—steroidal nflammatory drugs (NSAIDs), anti-inflammatory agents (for
-17_
example agents that could be used to treat neuroinflarnmation either by enhancing or
reducing neuroinflammation). amyloid sor protein (APP) ligands, anti-amyloid
vaccines and / or antibodies, agents that promote or enhance amyloid efflux and / or
clearance, histone deacetylase (HDAC) inhbitors, EP2 antagonists, ll—beta HSDl
(hydroxysteroid dehydrogenase) inhibitors, liver X receptor (LXR) agonists or PAMs,
lipoprotein receptor-related protein (LRP) mimics and / or ligands and/or ers
and/or inhibitors, butyryl cholinesterase inhibitors, kynurinic acid antagonists and / or
inhibitors of kynurenine aminotransferease (KAT), orphanin FQ / nociceptin (NOP) /
opioid—like receptor 1 (ORLl) antagonists, excitatory amino acid transporter (EAAT)
ligands (activators or inhibitors), and plasminogen activator inhibitor-1 )
inhibitors, niacin and /or GPR109 agonists or PAMs in combination with cholesterol
ng agents and / or HMGCoA reductase inhibitors (statins), dimebolin or similar
agents, antihistamines, metal binding / ing , antibiotics, growth hormone
secretagogues, cholesterol lowering agents, vitamin E, cholesterol absorption tors,
cholesterol efflux promoters and / or tors, and insulin upregulating agents.
In one embodiment, the present invention provides a ceutical product
sing, in combination, a first active ingredient which is a compound of formula (1)
or a pharmaceutically acceptable salt thereof and at least one further active ingredient
selected from:-
0 cholinesterase inhibitors, e.g. donepezil, galantamine, rivastigamine,
tetrahydroaminoacricline and phartnaceutically acceptable salts thereof,
0 5—HT6 antagonists, e.g. 457 and pharmaceutically acceptable salts thereof,
0 HMGCOA reductase inhibitors e.g. lovastatin, statin, atorvastatin,
simvastatin, fluvastatin, pitavastatin, pravastatin and pharmaceutically
able salts thereof.
The individual components of such combinations may be administered either
sequentially or simultaneously in separate or combined pharmaceutical formulations.
Consequently, the pharmaceutical product may, for example be a pharmaceutical
composition comprising the first and further active ients in admixture.
3O Alternatively, the pharmaceutical product may for example comprise the first and
further active ingredients in separate ceutical preparations suitable for
simultaneous, sequential or separate administration to a patient in need thereof
The combinations referred to above may conveniently be presented for use in the
form of a pharmaceutical formulation and thus pharmaceutical formulations comprising
a ation as defined above together with a pharmaceutically acceptable carrier or
excipient comprise a further aspect of the invention.
When a compound of formula (I) or a pharmaceutically able salt thereof is
used in combination with a second therapeutic agent active, the dose of each compound
—18-
may differ from that when the compound is used alone. Appropriate doses will be
readily appreciated by those skilled in the art.
Thus, an additional aspect of the invention provides a method of preparation of a
pharmaceutical composition, involving admixing at least one nd of formula (I)
as defined above, or a pharmaceutically acceptable salt therof, with one or more
ceutically acceptable adjuvants, diluents or carriers and/or with one or more
other therapeutically or prophylactically active agents.
In one embodiment, the present invention es a ceutical
composition comprising a compound of formula (I) or a pharmaceutically acceptable
salt thereof, one or more other agents for the treatment of Alzheimer’s disease, such as
an M1 and M3 muscarinic receptor agonist or eric modulator, an M2 muscarinic
nist, an acetylcholinesterase tor, a nicotinic receptor agonist or allosteric
tor, a PPAR agonist, a 5~HT4 receptor agonist or partial agonist, a histamine H3
antagonist, a 5—HT6 receptor antagonist, a SHTIA receptor ligand, a NMDA receptor
antagonist or modulator, a 5-HT2A antagonist, a 5—HT; antagonist, a D1 agonist or
positive allosteric modulator (PAM), a D4 agonist or PAM, a GABA—A a5 inverse
agonist or negative allosteric modulator (NAM), a GABA—A (12/3 agonist or PAM, a
mGluR2 modulator (PAM or NAM), a mGluR3 PAM, a mGluRS PAM, a PDE 1
inhibitor, a PDE 2 inhibitor, a PDE 4 inhibitor, a PDE 5 inhibitor, a PDE 9 inhibitor, a
PDE 10 inhibitor, a GlyTl inhibitor, a DAAO inhibitor, a ASCl inhibitor, a AMPA
tor, a SIRTl activator or inhibitor, a AT4 antagonist, a GalRl antagonist, a
GalR3 , an adenosine A1 antagonist, an adenosine A221 antagonist, an a2A
antagonist or agonist, a selective or unselective norepinephrine reuptake inhibitor
(SNRI), a gamma secretase inhibitor or modulator, an alpha secretase activator or
tor, an amyloid aggregation inhibitor, an d antibody, a tau aggregation
inhibitor, a tau orylation inhibitor, a MK2 (mitogen activated protein ldnase—
activated protein kinase 2) inhibitor, a MARK (microtubule affinity regulating kinase)
inhibitor, a CDK5 (cyclin dependent kinase 5) inhibitor, 21 GSK—3 (glycogen se
-3) inhibitor, a calcium channel blocker, a HMG—CoA (3—hydroxymethyl~
3O glutaryl—COA) reductase inhibitor (statin) and a lipid lowering agent, a NGF (nerve
growth factor) mimic, an antioxidant, a GPR3 ligand, 21 plasmin tor, a neprilysin
(NEP) activator, an lDE (insulin degrading enzyme) activator, a melatonin MTl and/or
MT2 agonist, a TLX (tailless X receptor) ligand, a GluRl ligand, a RAGE (receptor for
advanced glycation end-products) antagonist, an EGFR (epidermal growth factor
receptor) inhibitor, a FPRL—l (formyl peptide-like receptor—l) ligand, a GABA
antagonist or a MICAL ule interacting with casL) tor such as an
oxoreductase inhibitor, in association with a ceuticalyy acceptable r. In a
further embodiment the present invention provides a combination comprising a
compound of formula (I) or a pharmaceutically acceptable salt thereof, er with a
further therapeutic agent as described herein above for sequential or simultaneous
administration in separate or combined pharmaceutical formulations.
In a further aspect, the invention provides a method of inhibiting production of
amyloid—[3 protein and/or of ng or ting a neurodegenerative disease, such as
Alzheimer—type dementia (AD), Down’s syndrome, cerebrovascular amyloid
angiopathy (CAA), mild cognitive impairment (MCI), memory loss, presenile dementia,
senile dementia, hereditary cerebral hemorrhage with amyloidosis, and other
degenerative dementias such as dementias of mixed vascular and degenerative origin,
dementia associated with supranuclear palsy, dementia associated with cortical basal
degeneration, dementia associated with Parkinson's Disease (PD), and dementia
associated with diffuse Lewy Body type of AD, the method involving administering to a
human subject suffering from the condition a therapeutically or prophylactically
ive amount of the pharmaceutical composition described above or of a compound
of formula (I) as defined above, or a pharmaceutically acceptable salt thereof.
tive amount” means an amount sufficient to cause a benefit to the subject or at
least to cause a change in the subject’s ion.
Alzheimer’s Disease (AD) is characterized pathologically by the presence of
neurofibrillary tangles (NFTs) and plaques, consisting of amyloid (AB) es of
varying length, for e 42 amino acids (A642) and 40 amino acids . In
on to these pathological markers, brain y is also evident. The build up of
plaques is believed to be due to the ation of AB peptides. AB peptides are
formed in the brain by the sequential cleavage of amyloid precursor protein (APP) by {3-
secretase l) and 'y—secretase. Therefore potential AD drugs aimed at inhibiting
amyloid formation by inhibiting BACE—l or ’y—secretase, must be able to achieve
adequate exposure in the brain, in order to exert an effect on AD.
Although BACE~l represents an attractive target to halt or slow the production
of amyloid peptides, various groups have found it challenging to identify BACE-l
inhibitors that can penetrate the central nervous system (CNS) and thus inhibit the
3O enzyme at the site of action.
The brain is protected by several barriers including the blood brain barrier (BBB)
and transporters (Hitchcock and Pennington, J Med Chem 2006, 29, 7559; Ueno, Curr.
Med. Chem. 2007, I4, ll99; Gloor et al., Brain Res. Rev. 2001, 36, 258). Several
efflux transporters have been terised which prevent nds entering the brain.
One of the best characterised and most prominent in preventing the CNS penetration of
xenobiotics is P~g1ycoprotein (ng) ara and Sugiyama, Drug Discovery Today,
2001, 6, 150', Mahar Doan et al., J. Pharm. Expt. Ther. 2002, 303, 1029; Lin, Drugs of
Today 2004, 40, 5; Lin & Yamazaki, Clin Pharmacokinet. 2003, 42, 59; Schinkel, Adv.
PCT/EP20121050833
Drug Deliv. Rev. 1999, 36, 179). It has been shown that ng efflux is important for
BACE—l inhibitors (Hussain et 211., J. Neurochem. 2007, 100, 802). Thus. ming
ng efflux is important.
Those skilled in the art will iate that there are l ways to measure or
predict CNS penetration in vitro or in. vivo. The potential for CNS penetration can be
assessed in vitro by determining r a compound can be ted to ng efflux, i.e.
by conducting an in vitro ng assay. Those skilled in the art will appreciate that a
number of cell lines can be used and that these cell lines may or may not affect the
results of the assay. One such assay is described below (Cyprotex UK).
The following MDR-J MDCK assay was used to assess ng efi‘lax. The assay was
conducted at Cyprotex Discovery Ltd. 15 Beech Lane, Macclesfield, Cheshire, UK,
SKIO ZDR
MDRl-MDCK Permeability (Bi-directional; pH 7.4/pH 7.4)
Protocol Summary
MDCK cells are an lial cell line of canine kidney origin. These cells can
be transfected to stably express active P—glycoprotein (MDRl-MDCK) and are ideal for
studying drug efflux. Test nd was added to either the apical or basolateral side
of a confluent monolayer of MDRl—MDCK cells and permeability was measured by
monitoring the appearance of the test compound on the opposite side of the membrane
using LC—MS/MS. From this an apparent permeability (Papp) coefficient and efflux
ratio was measured/calculated.
Objective
To measure the permeability of test compound in the apical to basolateral (AB)
and basolateral to apical (B—A) direction across MDRl-MDCK cells. A ratio of B—A
and A-B permeabilities was calculated (efflux ratio) to show whether the compound
undergoes P-glycoprotein efflux.
nds were provided as a 200 uL solution of 10 mM test compound in
DMSO.
Experimental Procedure
MDRl—MDCK cells obtained from the NIH (Rockville, MD, USA) were used.
Following culture to confluency, the monolayers were prepared by g both
basolateral and apical surfaces twice with pH 7.4 buffer at 37°C. Cells were then
ted with pH 7.4 buffer in both apical and basolateral compartments for 40 min to
stabilise physiological parameters.
PCT/EP20121’050833
Buffer at pH 7.4 was then removed from the apical compartment and replaced
with test compound dosing solutions. The solutions were prepared by diluting 10 mM
test compound in DMSO with buffer to give a final test compound concentration of 10
uM (final DMSO tration adjusted to 1%). The fluorescent integrity marker
Lucifer yellow was also included in the dosing solution. The apical compartment.
inserts were then placed into ‘companion’ plates containing fresh buffer at pH 7.4.
Analytical standards were made from dosing ons.
For basolateral to apical (B—A) experiments the experiment was initiated by
replacing buffer in the s then g them in companion plates containing dosing
solutions. Incubations were carried out in an atmosphere of 5% CO; with a relative
humidity of 95% at 37°C for 60 minutes.
After the incubation period, the companion plate was d and apical and
basolateral samples diluted for analysis by LC-MS/MS. Test compound permeability
was ed in duplicate. On each plate compounds of known permeability
characteristics were run as controls.
Test and control compounds were quantified by LC—MS/MS cassette analysis
using a 5-point calibration with appropriate dilution of the samples. Cyprotex generic
analytical conditions were used. The starting tration (CO) was determined from
the dosing solution and the experimental recovery calculated from C0 and both apical
and teral compartment concentrations.
The integrity of the monolayers throughout the experiment was checked by
monitoring r yellow permeation using fluorimetric analysis. Lucifer yellow
permeation is low if monolayers have not been damaged. If a r yellow Papp
value was above QC limits in one individual test compound well, then an n=l result was
reported. If Lucifer yellow Papp values were above QC limits in both replicate wells
for a test compound, the compound was re—tested. If on repeat. high Lucifer yellow
permeation was observed in both wells then toxicity or inherent fluorescence of the test
compound was assumed. No further experiments were performed in this ce.
Data Analysis
The permeability cient for each compound (Paw) was calculated from the
ing equation:
Papp = (dQ + dt) + (C0 x A)
Where dQ/dt is the rate of permeation of the drug across the cells, C0 is the donor
compartment concentration at time zero and A is the area of the cell monolayer. Co
was obtained from analysis of the dosing solution at the start of the experiment.
In addition, an efflux ratio (ER) was calculated from mean A-B and B-A data.
This is derived from:
PCT/EP20121050833
ER = ((Papp (B “ A» + ((Papp (A _ B»
Two control compounds were screened ide the test compounds,
propranolol (highly permeable) and prazosin (a substrate for P-glycoprotein).
Suipi'isingly, compounds from the present invention wene found to display a
lower ng efflux ratio than compounds exemplified in W02009/091016 indicating that
they have the potential to show higher CNS penetration. Data for ed examples
are shown in Table 1 below.
1 0 Table I: MDR-I MDCK P I assa data
Exam-1e Pu ER
Comparative Example 1 26.2
Comarative Exam-1e 2 16.6
Com. arative Exam 1e 3 24.0
Com - arative Exam le 4 20.7
Com - arative Exam n 16 5
Com-arative Examle 6 53.439??? mqqooq
18 t—‘Qf‘f‘t‘pt‘t‘FLFOQOOONQOOOUI
Note: Example 14 is intentionally not included.
Comparative Examples 1 to 6 are covered by hed International patent application
W02009/091016; Comparative Examples 1 to 4 are specifically described in
WO2009/091016 as Examples 32, 35, 54 and 73 respectively.
Comparative Examples 5 and 6 are
N—(3—((4aS,SS,7aS)—2—amino—5—(fluoromethyl)—4a,5,7,7a-tetrahydro—4H-furo[3,4-
d][l ,3]thiazin—7a—y1)-4—flu0ropheny1)—5-ethoxypicolinarnide, and
N—(3-((4aS,5R,7aS)—2—aminomethyl-4a,5,7,7a—tetrahydr0-4H—furo[3,4-d][1,3]thiazin—
7a—yl)fluorophenyl)—5«ethoxypicolinamide
respectively.
The data demonstrate that compounds of the present invention and specific
examples 1 - 13 and 15 ~ 18 have lower ng efflux and therefore potentially higher CNS
penetration than representative examples from W02009/091016 using the
aforementioned recognized method of assessing CNS penetration. For example,
Comparative Examples 1 to 6 have higher ng efflux ratios than compounds of the
present invention. Furthermore, Comparative Examples 5 and 6 have higher ng
efflux ratios than a close analogue, Example 10 of the present invention, which clearly
demonstrates the beneficial effect the trifluoromethyl group on the tetrahydrofuran ring
exerts on ng efflux, i.e. the trifluoromethyl group reduces ng efflux.
Those skilled in the art will iate that the in vitro ng assay bed
above is a predictive assay of in vivo CNS penetration. It is thus also highly desirable
if the decreased ng-mediated efflux translates to the in. viva situation. Those skilled
in the art will appreciate there are many ways to assess the CNS penetration of
compounds in viva. For example, one can quantify compound concentrations in blood
or plasma and brain and calculate a blood (BrzBl) or brainzplasma (BrzPl) ratio.
This method has been used historically and has been widely accepted as a method of
determining CNS penetration (Summerfield et al., J col. Expt. Ther. 2007, 322,
205). Those skilled in the alt will appreciate that this type of assay could be conducted
at steady state, a single time point, multiple time points or could be done by quoting
Area Under the Curve (AUC) ratios. All methods are equally valid but each may have
3O certain caveats that will be appreciated by those skilled in the art. Recent literature has
been published to suggest that it is important to er the free concentrations in vivo
and that when no efflux occurs from the brain the free plasma concentration should be
the same or equivalent to the free brain concentration (Kalvass and ,
Biopharmaceutics & Drug Disposition 2002, 23, 327; Mauer et a1, Drug Metab.
Disposition 2005, 33, 175; r Expert Opin. Drug Discov. 2007, 2, 51). Thus, a
compound that can freely penetrate the CNS and is not ted to active efflux, for
example by ng or another orter, should demonstrate a free free plasma
(Brfr: Pifr) or an unbound brainzunbound plasma (Bru : Plu) of approximately 1:1.
WO 98213
Those skilled in the art will appreciate that the free or unbound concentrations can be
calculated by multiplying the total brain or total plasma concentration by the fraction
unbound in brain tissue or plasma, which can be measured by the assay described below.
Those skilled in the art will appreciate that the fraction unbound may change with
experimental factors, for example concentration, or ature, etc. Those skilled in
the art will be able to assess this and select the most appropriate set of conditions.
Those skilled in the art will also appreciate that as long as the ions are the same
for each compound screened then the assay will give consistent data for the range of
compounds tested thus minimising any discrepancies. It has also been proposed that
drug concentrations in cerebrospinal fluid (CSF) are equivalent to free brain
concentrations for compounds which are not actively effluxed from the brain (He et al.,
Xenobiotica 2009, 39, 687). Thus another method of determining CNS penetration
would be to assess the CSF2free plasma (CSF : Pifr) or CSF :unbound plasma (CSF :
Plu). If the free drug in plasma is able to permeate into the CNS and is not actively
influxed or effluxed then the CSFZPIfi» or CSF:P1u should be approximately 1:1. Those
skilled in the art will appreciate the issues associated with ining CSF drug
concentrations and extracting CSF, for e CSF can be contaminated by blood
depending on the method of awal. also the CSF concentrations may be of lower
accuracy, depending on the dose used.
Thus it has been shown that a BACE inhibitor from GlaxoSmithKline
(GSK188909), BACE-l leo SnM, which has low CNS exposure was ineffective at
lowering A1340 production in the brains of TASTPM mice (which overexpress both
[MS961
human APPsweKj95N and PS—1M146V) upon acute administration (Hussain et al., J.
Neurochem. 2007, 100, 802 — 809). Following an oral dose of 250mg/kg the brain
tration of GSKl88909 in TASTPM mice was 0.62uM. When a ng inhibitor
(GF120918) was dosed 5 hours before the oral administration of GS Kl 88909, the brain
concentration of GSK188909 was found to be 5.43uM following an oral dose of
250mg/kg, i.e. the inistration of a ng inhibitor caused an almost 9-fold increase
in CNS penetration, showing ng efflux is an important mechanism in preventing
BACE inhibitors from penetrating the CNS. Furthermore, in the absence of a ng
inhibitor, 21 250mg/kg oral dose of GSK188909 did not have any effect on brain A840
levels in TASTPM mice, whereas when a ng inhibitor was inistered (5 hours
prior to the stration of 909) a 68% reduction in brain A840 levels
relative to vehicle treated mice was observed.
r paper has reported a similar effect with three BACE-l inhibitors from
Bristol-Myers Squibb (Meredith et al., J. Pharm. Expt. Ther. 2008, 326, 502-513). The
three reported compounds were found to be ng substrates in vitro. When dosed to
mice, the three compounds showed low CNS penetration and did not lower amyloid
2012/050833
levels in the brain but were able to lower plasma amyloid levels. When the same three
compounds were administered to ng knockout (KO) mice, the level of CNS
penetration increased and the nds were able to lower amyloid levels in the brain.
Researchers at Schering-Plough have also published papers oh et al._.
Bioorg. Med. Chem. Lett. 2008, 18, 418) to show that BACE-l inhibitors from their
series (e.g. example 11 from the aforementioned reference), are subject to ng efflux, as
a result of which the compound was found to display a low BrzPl (<01) in the rat.
The literature cited above emphasises the difficulties in identifying BACE—l
inhibitors which are not subjected to ng efflux. Such inhibitors would be highly
desirable and many research groups have attempted to discover such compounds
without success. Thus BACE-l tors which are not ng substrates and can
therefore readily penetrate the CNS and lower amyloid in the brain would be ble.
More recently, researchers at. Wyeth have reported extensive work to overcome
ng efflux in a series of cyclic acylguanidine BACE~1 inhibitors (Malamas et al, Bioorg.
Med. Chem. Lett. 2010, 20, 6597). Compounds were discovered that were weak ng
substrates and with BrzPl approaching 1: 1. However, two lead examples with d
ng efflux (84 and 89 from the aforementioned reference), did not lower A040 in the
brain of Tg2576 mice 8 hours after a 30 mg/kg oral dose. The lack of efficacy was
attributed to the fact the compounds showed high brain tissue binding. Thus, it is
important to discover BACE-l tors that are not ng substrates but still have a
reasonable unbound fraction in brain tissue and are able to lower amyloid in the brain.
It has also been shown that BACE inhibitors that are not ng substrates in vitro
can penetrate the CNS (e.g. TC-l from Merck), and can lower A040 levels in the brain
of C mice and monkeys (Sankaranarayanan et al., J. Pharmacol. Expt. Ther.
2009, 328, 0). Thus, in vitro ng assays showed TC-l not to be a ng substrate
and when TC-l was dosed to APP~YAC mice (lOOmg/kg i.p.) it was able to modestly
penetrate the CNS as shown by the brain concentrations and the brainzplasma ratio and
this ability ed in moderate lowering of brain amyloid.
Time Plasma conc. Brain conc. Br:Pl Reductionin brain
(HM) (HM) A40 (%)
_——m—
Brain and plasma concentration of T01 following lOOmg/kg i.p. dose and corresponding effects on brain
Ab40 levels, in APP—YAC mice.
In separate experiments it was shown that TC-l could penetrate the CSF of
monkeys when co—administered with a CYP3A4 tor (ritonavir). In these
—26~
PCTIEP2012/050833
experiments the e plasma concentration of TC-l was found to be 2.7uM, whilst
the CSF concentration was found to be 0.025uM. However. as TC—l is ~99% bound to
plasma proteins the free plasma concentration was calculated to be ~0.027nM. It was
found that CSF A040 levels showed a 42% decrease relative to a vehicle treated l
group. Thus, a BACE inhibitor that can freely penetrate the CNS would be expected
to be able to lower amyloid levels in the CNS. It would be beneficial not to have to be
co—dosed with a CYP3A4 inhibitor.
The compounds of the present invention have been shown to lower AB
production in cellular assays which correlates with their ability to lower AB production
in animals. Thus, the compounds of the present invention will have utility in lowering
AB production in humans and thus will be useful in the treatment of neurodegenerative
diseases such as Alzheimer’s disease.
Rat in viva CNS penetration
Male Sprague Dawley rats were acquired from Charles River UK Ltd. (Margate,
UK) and housed according to UK Home Office guidelines. Drugs were made up to the
appropriate concentrations in 0.5% methyl ose. Animals were dosed orally
(2mL/kg) by gavage at the doses outlined in Tables 2 to 4 below.
At the time points post-dosing, specified in Tables 2 to 4 below the animals were
administered an i.p. injection of sodium pentobarbitone (approximately 330mg/kg for
terminal anaesthesia).
Using a tine. the animals were decapitated and trunk blood ted into
15ml Falcon tubes containing 100 IU heparin. Blood was ed followed by
fugation at 6000rpm, 4°C for 5 minutes. Plasma was collected for DMPK and
ELISA assays and stored at —80°C until use. Brains were dissected out and divided
along the midline, weighed and stored at -80°C until further use.
Method for Analysis of Plasma3 Brain and CSF Samples
ation of Acetonitrile Working Solutions
Test compound was prepared as a 1 mg free base/ml. on in DMSO,
ed and sonicated for 5 min. The 1 mg/mL DMSO solution was diluted to 10 and
ug/mL acetonitrile stocks, by adding 10 uL to 990 uL acetonitrile and 30 pL to 970
uL acetonitrile. respectively. The 10 and 30 ug/mL acetonitrile stocks were then
serially diluted 1:9 (v/v) (100 uL stock into 900 uL acetonitn'le) to give the following
solutions: 0.003, 0.01. 0.03, 0.1, 0.3, l, 3, 10 and 30 ug/mL itrile.
Pre aration of Plasma Standards. Blanks and Sam les
2012/050833
Control male e Dawley rat plasma and the study plasma samples were
stored at —80°C until the day of analysis when they were thawed at room temperature.
Control plasma was centrifuged (2,000g for 10 min) and aliquoted (90 nL) into
eppendorf tubes for preparation of standards and blank samples. Study samples were
previously ted (100 nL) into eppendorf tubes immediately following collection of
the plasma.
An aliquot (10 uL) of the appropriate acetonitrile stock was added to the control
plasma (to give a final volume of 100 uL) to give the required calibration standards
covering the range 1 — 3000 ng/mL. Double blank and blank s were prepared
by adding 10 uL of acetonitrile to 90 uL of blank plasma.
Preparation of Brain Standards. Blanks and s
Control male Sprague Dawley rat brain and the study brain samples were
weighed after tion and stored at —80°C until the day of is when they were
thawed at room temperature. Once thawed brains were d with water (4 mL per
gram of tissue) and homogenised using a mechanical homogeniser. An t (100
uL) of each study sample was taken into Micronics tubes ready for analysis and
sufficient aliquots (90 pL) of control brain homogenate prepared for preparation of
standards and blanks.
An aliquot (10 uL) of the appropriate acetonitrile stocks was added to the control
brain homogenate (to give a final volume of 100 uL) to give the required calibration
standards covering the range 1.5 — 5000 ng/g. Double blank and blank samples were
prepared by adding 10 til. of acetonitrile to 90 uL of blank brain homogenate.
Extraction of Plasma and Brain Samples. Standards and Blanks
Each plasma and brain homogenate sample, standard and blank (100 uL) was
extracted with an aliquot (300 nL) of acetonitrile (containing 0.1% formic acid and 100
ng/mL of an appropriate internal standard). Double blanks were extracted with an
aliquot (300 uL) of acetonitrile containing 0.1% formic acid). All samples, standards
3O and blanks were then vortex mixed and centrifuged (2000g for 15 min). An aliquot
(50 uL) of the resulting supernatant was then taken into a 2 mL p well plate and
diluted with acetonitrilezwater (50:50 v/v) (150 uL) ready for analysis by a specific LC-
MS/MS method.
Preparation of CSF Samples. Standards and Blanks
Control male Sprague Dawley rat CSF and the study CSF samples were stored at
-80°C until the day of analysis when they were thawed at room ature. An
aliquot (50 uL) of each study sample was taken into Micronics tubes ready for analysis
~28-
and sufficient ts (45 pL) of control CSF prepared for ation of standards and
blanks.
An aliquot (5 uL) of the appropriate acetonitrile stocks was added to the control
CSF (to give a final volume of 50 nL) to give the required calibration standards
covering the range 1 ~ 1000 ng/mL. Double blank and blank samples were prepared
by adding 5 uL of acetonitrile to 45 pL of blank CSF.
Extraction of CSF Samples. Standards and Blanks
Each CSF sample, standard and blank (50 uL) was extracted with an aliquot (150
nL) of acetonitrile (containing 0.1% formic acid and 100 ng/mL of an riate
internal standard). Double blanks were ted with an aliquot (150 pL) of
acetonitrile containing 0.1% formic acid. All samples were then vortex mixed and an
aliquot (50 pL) of each was then further diluted in 150 nL of acetonitrilezwater (50/50
v/v) in a 2 mL 96-deep well block ready for LC~MSIMS analysis.
All samples were then analysed using a Waters Acquity UPLC coupled to a
Waters Xevo TQ mass spectrometer.
LC Conditions:
Column: Acquity UPLC BEH C18, 1.7 um, 2.1 x 50 mm, maintained at 40°C
Mobile Phase: A = 95% Water : 5% MeOH containing 0.01M Ammonium e
B : 5% Water : 95% MeOH containing 0.01M Ammonium acetate
Gradient:
Flow rate: 0.6 mL/min; injection volume 5 uL; mpler temperature 6°C
LC flow was diverted to waste for the first 0.3 min of each injection
MS/MS transitions were optimised automatically by Waters QuanOptimise software.
Amxloid detection
DEA! NaCl Extraction of Afl peptides from rat brain:
2012/050833
100ml of chilled 0.2% diethyl amine (DEA) in 50 mM NaCl (pH 10) was freshly
prepared and lull/25mg brain tissue was added to each hemisphere (i.e. 40x brain
volume). The brains were immediately homogenized using a Polytron PT 1200 for 1.5
minutes and samples left to incubate on ice for one hour after homogenisation. 3ml of
the homogenate was transferred to a polyallomer tube (Beckman 3) and spun at
133000 x g (55,0001pm) for 45 min at 4° C. The supernatant was then neutralised to
pH 8—8.3 by adding 1/10 volume 0.5M Tris/HCl, pH 6.8. The samples can be used
fresh or snap frozen on dry~ice and stored at —80°C until ed for is
1 0 Human] Rat fiAmyloid (40‘! ELISA (Wake Kit}
The Wako AB40 ELISA kit (Code No. 294-62501) uses the monoclonal
antibody BNT77, raised against epitope AB(l 1-28) and the monoclonal antibody BA27,
which specifically s the C-terminal portion of AB40. This kit is used for the
quantitative determination of human or rat ABM-40) and also N—terminally truncated
l 5 AB40 s (AB(x—40)) in biological matrices such as tissue culture medium, tissue
homogenate, CSF and plasma.
For analysis, plasma and brain samples are diluted 1:1 with the standard diluent
contained in the kit and CSF samples are d 1:8 with the standard diluent contained
in the kit. The assay is carried out according to manufacturers instructions and
2 0 samples are analysed in duplicate. Data is analysed using Microsoft Excel 2003 and
statistical analysis is carried out. using Genstat. 9Lb Edition.
Thus, when Comparative Example 4 was administered at a dose of g p.0.
and plasma, brain and CSF samples were collected 2, 4, 6 and 8 hours post-dose the
following concentrations were measured (Table 2):
Table 2: Data for Comarative Exam le 4
(h) (nM) (11M) (11M) (11M) (nM)
III--0.“-24 1162 O7 0.14
_---
M---
1 Calculated by multiplying the [Pl] by P1 bu.
2 Calculated by multiplying the [Br] by Br Fu.
From the above study, Comparative Example 4 showed a 59% and 64%
ion of A1340 in the brain at 4 and 6 hours respectively; and a 76% and 70%
reduction of AB40 in the CSF at 4 and 6 hours respectively.
WO 98213
Certain compounds of the present invention have been assessed in vivo in the rat
to corroborate the levels of CNS penetration; these data are presented in the tables
below.
Surprisingly, it has been found that compounds of the present ion show
increased CNS penetration in the rat relative to compounds from W02009/091016 by
any of the aforementioned recognixed s of determining CNS penetration. Thus,
the compounds of the t invention may show improved profiles in that they more
readily target the site of action, the brain, and therefore may show improved efficacy or
efficacy at lower concentrations or doses or sed peripherally mediated side effects,
by way of preferential CNS partitioning, or a combination of any or all of these aspects.
Thus, when Example 8 of the present invention was administered at a dose of
10mg/kg p.o. and plasma, brain and CSF samples were collected 2, 4, 6 and 8 hours
post-dose the following concentrations were ed (Table 3):
Table 3: Data for Examtle 8
(h) (HM) (11M) (HM) (HM) (HM)
mama-
_-----E-
1 Calculated by multiplying the [Pl] by Pl F‘u.
2 ated by multiplying the [Br] by Br Fu.
3. Not quantifiable. Concentrations close to or below the lower limit of quantification and could not be
accurately quantified.
2O 4. Not determined.
From the above study, Example 8 showed a 68% and 72% reduction of A340 in
the brain at 4 and 6 hours respectively; and an 82% and 74% reduction of A340 in the
CSF at 4 and 6 hours respectively.Thus compounds of the present invention show
decreased ng efflux relative to previous disclosures whilst trating efficacy in
the CNS. The efficacy is thus achieved with lower circulating plasma concentrations.
When Example 1 of the present invention was administered at a dose of 10mg/kg
p.o. and plasma, brain and CSF samples were collected 2, 4, 6 and 8 hours post-dose,
the following concentrations were measured (Table 4):
Table 4: Data for Examle l
(11) (11M) (11M) (HM) (11M) (HM)
2012/050833
_-_-__---
_-_-__-_-
1 Calculated by multiplying the [Pl]]by P1 Fu.
2 ated by multiplying the [Br] by Br Fu.
From the above study, Example 1 showed a 64% and 70% reduction of AB40 in
the brain at 4 and 6 hours respectively; and a 80% and 85% reduction of A340 in the
CSF at 4 and 6 hours respectively. Thus compounds of the present ion show
decreased ng efflux relative to previous inventions whilst demonstrating efficacy in the
CNS. The efficacy is thus achieved with lower circulating plasma concentrations.
Method For Determination of Plasma Protein Binding (PPB) and Brain Tissue
Binding (BTB)
Compound Preparation
nds were dissolved in DMSO to give a 1 mg free base/mL solution,
before further dilution to 100 ug/mL in acetonitrile (100 uL of 1 mg/mL into 900 uL
acetonitrile).
Matrix Preparation
On the morning of dialysis, control male Sprague Dawley rat plasma and brain,
previously stored at —80°C were thawed at room temperature. Plasma was checked for
pH and if necessary adjusted to 7.4 with 1M HCl. Plasma was then centrifuged (2000
g for 10 min) and the brains d with 2 mL of ate Buffered Saline (pH 7.4)
per gram of tissue and homogenised using a mechanical homogeniser. An aliquot (10
uL) of the 100 ug/mL acetonitrile compound solution was then added to 1 mL of
plasma and brain homogenate and vortex mixed to give a final compound concentration
of 1 ug/mL in matrix.
RED Plate Preparation
The Rapid Equilibrium Dialysis (RED) plate (Thermo Scientific) was prepared
in accordance with the manufacturers guidelines ie. the base plate was soaked in 20%
(v/v) l for 10 min and then rinsed twice with deionised water before being
allowed to dry. The base plate was then filled with the appropriate number of
disposable inserts (n=3 per compound) o Scientific) and matrix containing 1
ug/mL compound added into the matrix chamber of the inserts (200 uL) and an aliquot
(350 uL) of PBS added to the buffer chamber. The plate was then covered with an
adhesive and incubated in air at 37°C for 6 h with 130 rpm agitation.
Sampling
Following the 6 h incubation the seal was removed and an aliquot (50 uL) taken
from the PBS chambers and dispensed into Micronics tubes. Also, an aliquot (50 uL)
was removed from the matrix chambers and placed into separate Micronics tubes.
Plasma and brain was then matrix matched with 50 pL of drug—free PBS and the PBS
samples with 50 pL of the corresponding drug—free matrix, to give equal final
compositions and volumes (100 nL).
Sample Analysis
s were vortex mixed and an aliquot (300 nL) of acetonitrile ning
0.1% formic acid and 100 ng/mL of an appropriate internal standard added. Samples
were then mixed and centrifuged (2000 g for 15 min) and an aliquot of the supernatant
(100 pL) removed into a p well plate and d with an equal volume of water
ready for analysis by LC~MS/MS. The following data was obtained for the
following compounds in the above assay (Table 5).
Table 5:
Rat PPB(%> Rat Plasma fu RatBTB(%)
Comparative 65 .0 0.350 93 .3 0067
Exam le 4
0.049 0.013
0.104 0.022
Data represents the Mean of n=3 replicates
fu = fraction unbound
From the data presented herein above it will be apparent to those skilled in the
art that the compounds of Examples 1 and 8 achieve a similar reduction of brain AB40
to that of Comparative Example 4, but with a lower plasma tration and free
plasma concentration. This is advantageous and indicates that the compounds of the
invention will have r or better efficacy at lower concentrations than the
compounds of W02009/091016, and consequently will be less likely to cause unwanted
peripherally mediated side effects, such as‘cardiovascular effects, phospholipidosis,
liver toxicity, renal toxicity and gastrointestinal toxicity.
Assessment of effects on QTc interval in guinea pigs
Male -Hartley guinea pigs were weighed and anaesthetised using 4%
isoflurane in carbogen. hesia was maintained at 1.5% isoflurane and the
animals were kept under anaesthesia for the duration of the study. Xylazine at Zing/kg
i.m. was administered into the hind limb as a bradycardic agent to enable detection of
QR: prolongation by the software.
The carotid artery and r vein were cannulated with lines ning
heparinised saline and a 3-lead ECG connected and monitored using LabChart Pro
software. Animals were allowed to stabilise for 30 minutes after the completion of the
surgical procedure, before the initiation of an iv. vehicle (5%DMSO/90% MilliQ/5%
O. IN HCl) infusion from time zero (infusion rate = 0.2 ml/kg/min). At 10 mins, an
arterial blood sample was ted for PK analysis (lSOul; all collection syringes were
heparinised). At 12 mins, drug infusion was started @ 2.0 mg/kg/10min iv. The dose
was increased to 6.0 mg/kg/10min, then 20mg/kg/10min i.v., with a 10 minutes infusion
period and two minutes blood sampling at each dose. After the final dose, a blood
sample was taken and a second vehicle infusion initiated. Eight minutes later a
terminal blood sample was ted for plasma PK analysis and the animal killed by a
Schedule 1 method.
QTC (B azett’s) changes were analysed using rt Pro software. QTc was
ged up to the highest dose/concentration tested, which corresponded to an
unbound plasma concentration of 9503nM for Example 8 and 296nM for Example 1.
ment of effects on QTc interval in beagle dogs
Male beagle dogs were weighed and ed with sodium thiopental for
induction of anesthesia. Anaesthesia was ined with mixture of l-l.5% isoflurane
and oxygen and the animals were kept under artificial respiration and anesthesia using
isoflurane for the duration of the study.
The carotid artery and saphenous vein were cannulated with lines containing
nised saline and a LII ECG connected and monitored using polygraph system.
Animals were allowed to stabilise for 30 minutes before the infusion of compound
solution and the infusion via cannula was started from time zero with l mg/kg/lOmin.
The dose was increased to 3 mg/kg/ 10min, then 10 mg/kg/10min. An arterial blood
sample was collected after every dosing for PK analysis.
QTc was unchanged up to the highest dose/concentration tested, which
corresponded to an unbound plasma concentration of 4128 nM for Example 8 and 1329
3O nM for Example 1.
Next, methods for preparing the compound of the formula (I) or a
pharmaceutically able salt thereof according to the present invention will be
described.
A. General Preparation Method A:
A-(14)
In the formula, X, Y and A are as defined above.
General Preparation Method A is a method for preparing a compound A—(lS)
which corresponds to compound (1) according to the present invention from a
compound A—( l) as a raw material through multiple steps of Step A—(i) to Step A—(xiv).
The compound A-(l) is commercially available.
Step A-gi):
This step is a step of ing a nd A-(Z) by opening the epoxide A—(l)
with a sulfonium ylide to generate an ediate allylic alkoxide which is then
alkylated to give the compound A-(2). Those skilled in the art will appreciate that this
-35_
transformation can be conducted in one pot or as two individual reactions. Those
skilled in the art will appreciate the benefits and drawbacks of a one pot reaction
compared to conducting two separate reactions and choose the best method for their
requirements accordingly.
Specifically, the epoxide A-(l) can be opened by the anion of
lrimethylsulfonium iodide and resultant loss of dimethylsulfide to give the
ponding allylic alkoxide. Trimethylsulfonium iodide can be deprotonated with a
suitable base, for example butyl lithium. The solvent used in the reaction is not
particularly limited insofar as it does not ere with the reaction. es of
suitable ts include THF. Those skilled in the art will iate that the word
solvent in this instance is used to denote the liquid in which the reaction is effected and
that the reagents may not be dissolved. Preferably the reaction should be conducted
below room ature, preferably ~30 — 20°C. Upon on the reaction may be
warmed to room temperature to facilitate reaction. The reaction time is not
particularly limited and is usually 5 minutes to 24 hours, preferably 1 — 6 hours.
Those skilled in the art will appreciate that the alkoxide generated from this
reaction can be reacted with an alkylating agent directly, such as tert—butyl bromoacetate,
and that this reaction may proceed with or without additional solvents. If additional
solvents are required to facilitate reaction, then solvents such as DMF or NMP are
le. The reaction temperature is not particularly limited. Suitable reaction
temperatures e room temperature to 80°C, preferably room temperature. The
reaction time is not particularly limited and is usually 5 s to 1 week, ably 1
- 48 hours.
Those skilled in the art will appreciate that the intermediate alkoxide could be
quenched, isolated and purified then subjected to independent alkylation conditions.
This reaction can be performed under the same conditions as those usually used in O—
alkylation reaction of an alcohol compound (such as the conditions described in
Tetrahedron Lett. 46 (2005) 45, 7751—7755). In this reaction, the compound A—(2) can
be obtained by adding a base such as sodium hydride to a solution of the the
intermediate alcohol in THF to prepare an alkoxide, and then reacting the alkoxide with
the tert~buty1 bromoacetate, for example. The solvent used in the on is not
particularly limited insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain . Examples of the solvent include
solvents such as THE, DMF and dimethyl sulfoxide. The reaction can be performed
by g l to 3 lents of an appropriate base to act in the ce of such a
solvent. Examples of the base used include sodium hydride, potassium hydride and t-
butoxypotassium. The reaction time is not particularly limited and is usually 0.5 to 72
-36~
PCTIEP2012/050833
hours, and preferably 0.5 to 12 hours. The reaction temperature is usually —20°C to
50°C.
A more preferable result such as an improved yield may be achieved by adding a
salt such as tetrabutylammonium iodide in this reaction.
Step A-gii):
This step is a two step sequential reaction to obtain compound A—(3) from
compound A—(2) by deprotecting the ester group then forming a Weinreb amide.
Specifically, the teit-butyl ester of compound A—(2) can be deprotected under the
same conditions as those generally used in deprotection of a tert-butyl ester nd
(such as the conditions described in a document such as T. W. Greene and P. G. M.
Wuts, "Protective Groups in Organic Chemistry, Third Edition", John Wiley & Sons
(1999), p. 404—408). In this reaction, the compound A~(2) can be reacted with an
appropriate acid in a le solvent, such as formic acid, as solvent and acid, for
example. The solvent used in the on is not particularly limited insofar as it does
not inhibit the reaction and allows the starting material to be dissolved therein to a
n extent. The reaction time is not particularly limited and is usually 0.5 to 72 hours,
and preferably 0.5 to 24 hours. The reaction temperature is usually ice—cold
ature to 60°C.
The ediate acid can then be transformed to the [Weinreb amide
(Tetrahedron Lett. 1981, 22, 3815) by reaction of N,O~dimethylhydroxylamine
hydrochloride under standard amide formation conditions, ie by condensing the
intermediate acid with N,O-dimethylhydroxylamine hydrochloride using a sing
agent. Alternatively, this step is a step of obtaining a compound A—(3) by condensing
the intermediate acid with N,O-dimethylhydroxylamine hydrochloride by acylation
reaction.
The condensation reaction of the intermediate acid with NO-
dimethylhydroxylamine hydrochloride using a condensing agent can be performed
under the same conditions as those y used and described in the following
documents. Examples of the known method e those in Rosowsky et al.; J . Med.
Chem, 34 (1), 227—234 (1991), wska et al.; Heterocycles, 32 (10), 1968-1972
(1991), and Romero et al.; J. Med. Chem, 37 (7), 998—1014 (1994).
The N,O—dimethy1hydroxylamine hydrochloride may be a free form or a salt.
The solvent in this on is not particularly limited insofar as it does not
t the reaction. Examples of the solvent e tetrahydrofuran, oxane,
ethyl acetate. methyl acetate, dichloromethane, chloroform, N,N-dimethylformamide,
toluene, acetonitrile and xylene. Examples of the condensing agent include CD1
(N,N‘—carbonyldiimidazole), Bop (1H—1,2,3-benzotriazol— l—
PCT/EP20121050833
yloxy(tri(dimethylamino))phosphonium hexafluorophosphate), WSC (1—ethyl—3—(3-
dimethylaminopropyl)carbodiimide hydrochloride), DCC (N.N-
ohexylcarbodiimide), diethylphosphoryl cyanide, PyBOP (benzotriazol—l-
yloxytris(pyirolidino)phosphonium hexafluorophosphate) and EDC-HCl (1—ethyl-3—(3-
dimethylaminopropyl)carbodiimide hydrochloride). Suitable conditions e an
agent to activate the acid, such as N,N’-carbonyl diimidazole. One equivalent to a
large excess of N,O-dimethylhydroxylamine hloride is used with respect to the
intermediate acid. One equivalent to a large excess of an c base such as
triethylamine may be added where necessary.
The reaction time is not particularly limited and is usually 0.5 to 72 hours, and
preferably 0.5 to 24 hours. The reaction temperature varies according to the raw
material used, the solvent and the like and is not particularly limited. Ice—cold
ature to solvent reflux temperature is acceptable, ice cold to room temperature is
preferable.
Step A-giii}:
This step is a step of obtaining a compound A-(4) by on of an
organometallic (aryllithium reagent or a Grignard reagent) reagent with compound A—
(3) as described in Tetrahedron Lett. 1981, 22, 3815.
The reaction in this step can be med under the same conditions as those
bed in Tetrahedron Lett. 1981, 22, 3815, for example.
The aryllithium reagent (including heterocyclic) or the Grignard t
(including heterocyclic) can be ed by a method known to a person skilled in the
art. Specifically, the corresponding phenyl lithium reagent or phenyl magnesium
(Grignard) reagent can be prepared by halogen—metal exchange between an aryl halide
nd and a commercially available organometallic reagent such as an alkyllithium
reagent such as n—, sec— or tert—butyllithium or a Grignard reagent such as
isopropylmagnesium bromide, or metallic magnesium, for e.
The solvent used in this step varies according to the starting material and the
3O reagent used, and is not particularly limited insofar as it does not inhibit the reaction,
allows the starting al to be ved therein to a certain extent, and is always
inert during the reaction. Preferable examples of the solvent include organic solvents
such as diethyl ether, tetrahydrofuran, 1,4—dioxane, 1,2—dimethoxyethane, e and
toluene, and mixed solvents thereof. The reaction time is not particularly limited and
is usually 0.1 to 48 hours, and preferably 0.1 to 12 hours. The reaction temperature
varies according to the starting material, the reagent used and the like, and is preferably
maintained to be low, for example, at -78 - -60°C.
-38—
Step A—t iv 1:
This step is a step of obtaining a compound A—(5) by oximation of the compound
A-(4).
The reaction in this step can be performed under the same conditions as those
y used in oximation reaction of a carbonyl compound such as the conditions
described in Org. Lett. 9 (2007) 5, 753—756, Tetrahedron: Asymmetry 5 (1994) 6, 1018-
1028 and Tetrahedron 54 (1998) 22, 5868—5882.
Specifically, the compound A—(S) can be obtained by reacting the compound A—
(4) with hydroxylamine or a hydroxylamine salt (such as hydroxylamine hydrochloride
or ylarnine sulfate) in the presence of a base or in the absence of a base, for
example.
The t used in this reaction is not particularly limited insofar as it does not
inhibit the reaction. Preferable examples of the solvent include organic solvents such
as ethanol, methanol, tetrahydrofuran, l,4~di0xane, 1,2—dimethoxyethane and
dichloromethane, and mixtures of these solvents and water. Examples of the base used
include sodium e, ne, sodium ide, cesium hydroxide, barium
hydroxide and 2,6—lutidine. The reaction time is not particularly limited and is usually
minutes to 24 hours, and ably 5 minutes to 12 hours. The reaction temperature
is usually -20°C to solvent reflux temperature, and more preferably 0°C to solvent
reflux temperature.
Step A—tv}:
This step is a step of obtaining a nd A—(6) by a thermal intramolecular
cycloaddition of the alkenyl oxime A-(5).
The reaction is conducted in the presence of an ve, for example
hydroquinone.
The solvent used in this reaction is not particularly limited insofar as it does not
inhibit the reaction. Suitable reaction solvents include high boiling solvents such as
xylenes. The reaction temperature is not particularly limited and is usually 80 — 200°C
3O or t reflux temperature. The reaction time is not particularly limited and is
usually 0.5 to 48 hours, and preferably 0.5 to 24 hours.
Step A~tvi):
This step is a step of obtaining a compound A—(7) by subjecting the compound
A-(6) to reductive ge reaction of the N-O bond.
The reductive ge reaction of the N-O bond can be performed under the
conditions using zinc—acetic acid, a metal catalyst such as hydrogen-platinum oxide, or
lithium aluminum e, for example.
_39-
The reaction using zinc such as zinc—acetic acid can be performed under the same
conditions as those described in J. Org. Chem. 2003, 68, 1207—1215 and Org. Lett. 7
(2005) 25, 742, for example. Examples of the acid used e acetic acid,
formic acid and hydrochloric acid. The solvent used in the reaction is not particularly
limited r as it does not inhibit the reaction and allows the starting al to be
ved therein to a certain extent. Examples of the solvent include methanol,
ethanol, 1,4-dioxane, THF and water. The above acid may also be used as a solvent.
The reaction temperature is usually —20°C to solvent reflux temperature, and preferably
ice—cold temperature to solvent reflux temperature. The reaction time is not
particularly limited and is usually 5 minutes to 48 hours, and preferably 5 minutes to 24
hours.
The reaction using a metal catalyst such as hydrogen-platinum oxide can be
performed under the same conditions as those bed in Tetrahedron: try 5
(1994) 6, 1018—1028 and Tetrahedron, Vol. 53, No. 16, pp 5752-5746, 1997, for
example. The compound A-(7) can be obtained by hydrogenating the compound A—(6)
using platinum oxide as a catalyst in a t such as methanol, for example.
The reaction using lithium um hydride can be performed under the same
conditions as those described in Bull. Chem. Soc. Jpn., 66, 2730—2737 (1993), for
example. The compound A-(7) can be obtained by reducing the compound A-(6)
using lithium aluminum hydride in a solvent such as ether, for example.
Step A—tviig:
This step is a step of ing a compound A—(8) from the compound A-(7).
The thiourea derivative A—(8) can be obtained from the compound A~(7) by a method
known to a person skilled in the art.
The compound A-(8) can be obtained in this step by reacting the compound A-
(7) with benzoyl isothiocyanate in a solvent such as dichloromethane or toluene. This
reaction can be performed under the same conditions as those described in J. Med.
Chem. 1990, 33, 2393-2407, for example. The solvent used in the reaction is not
3O particularly limited insofar as it does not inhibit the reaction and allows the ng
material to be ved n to a certain extent. Examples of the t e
dichloromethane, chloroform, toluene, 1,4-dioxane and THF. The reaction
temperature is usually -20°C to solvent reflux temperature, and preferably ice—cold
temperature to solvent reflux temperature. The reaction time is not particularly limited
and is usually 5 minutes to 48 hours, and preferably 5 minutes to 24 hours.
Step A-gviiig:
PCT/EP20121'050833
This step is a method of obtaining a compound A—(9) by cyclizing the compound
A—(S).
In this reaction, the compound A—(8) can be cyclized under various conditions to
obtain the compound A—(9) by activating the alcohol of compound A-(8).
For example, the nd A—(9) can be obtained in this reaction by heating the
compound A-(8) in a solvent such as methanol in the presence of an acid such as
concentrated hydrochloric acid, for example. The t used in the on is not
particularly limited insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a n extent. es of the solvent include
solvents such as methanol, ethanol, l—propanol and water, mixed solvents thereof, and
acids used as a solvent. The on can be performed by using one equivalent to a
large excess of an riate acid to act in the presence or absence of such a solvent.
Examples of the acid used include concentrated hydrochloric acid, hydrobromic acid,
sulfuric acid, trifluoroacetic acid, methanesulfonic acid, trifluorornethanesulfonic acid
and es thereof. The reaction time is not particularly limited and is usually 0.5 to
72 hours, and preferably 0.5 to 24 hours. The reaction temperature is usually ice-cold
temperature to solvent reflux temperature.
Alternatively, the compound A-(9) can be obtained by reacting the compound A-
(8) with trifluoromethanesulfonic anhydride in a solvent such as dichloromethane in the
presence of a base such as ne. The solvent used in the reaction is not particularly
limited insofar as it does not inhibit the reaction and allows the starting material to be
dissolved therein to a certain extent. Those skilled in the art will appreciate that a
solvent is not always required and the the on may also be conducted in the absence
of a solvent, for example when the base is pyridine. Examples of the solvent include
solvents such as dichloromethane, chloroform, l,2—dichloroethane, THF, 1,2-
dimethoxyethane and toluene, and mixed solvents f. The reaction can be
performed using 1 to 20 equivalents of an appropriate base in such a solvent.
Examples of the base used include pyridine, 2,6—lutidine, sodium carbonate, potassium
carbonate and mixtures thereof. The reaction time is not particularly limited and is
3O y 0.5 to 24 hours, and preferably 0.5 to 12 hours. The reaction temperature is
usually —78°C to room ature.
Step A—[ixgz
This step is a method of ing the compound A-(lO) by deprotecting the
protecting group of the compound A-(9). The compound A-(lO) can be obtained
under deprotection conditions known to a person skilled in the art.
When the protecting group is a benzoyl group, the compound A—(lO) can be
obtained in this reaction by heating the nd A—(9) in a solvent such as methanol
PCT/EP20121’050833
in the presence of a base such as DBU. for e. This reaction can be performed
under the same conditions as those described in Synth. Commun. 32 (2), 265-272
(2002), for example. The solvent used in the reaction is not particularly limited insofar
as it does not inhibit the reaction and allows the starting material to be dissolved therein
to a certain extent. es of the t include ts such as methanol, ethanol
and anol. The reaction can be performed using 1 to 20 equivalents of an
appropriate base in such a solvent. Examples of the base used include DBU. The
reaction time is not particularly limited and is usually 0.5 to 24 hours, and preferably
0.5 to 12 hours. The reaction temperature is usually room temperature to solvent
reflux temperature.
Alternatively, compound A—(lO) can be ed in this reaction by heating
compound A-(9) with an inorganic base such as potassium carbonate, for example.
The solvent used in the reaction is not particularly limited insofar as it does not inhibit
the on and allows the starting material to be dissolved therein to a certain extent.
Examples of the solvent include solvents such as methanol, ethanol and l-propanol.
The reaction can be med using 1 to 20 lents of an appropriate base in such
a solvent, and preferably a slight excess is used. Examples of the base used include
potassium carbonate. The reaction time is not particularly limited and is usually 0.5 to
24 hours, and preferably 0.5 to 12 hours. The reaction temperature is usually room
ature to t reflux temperature, and preferably 50 — 100°C. Those skilled in
the art will appreciate that the the selected solvent will limit the reaction temperature by
its reflux temperature. Examples of le solvents include refluxing methanol.
Step A—gx}:
This step is a step of obtaining the compound A—(l l) by nitration reaction of the
compound A-(lO). In this nitration reaction, the compound A—(l 1) can be obtained
from the compound A—(lO) by a method known to a person skilled in the art.
Examples of the nitrating agent used in the reaction e potassium
nitrate/concentrated sulfuric acid, fuming nitric acid/concentrated sulfuric acid and
fuming nitric acid/acetic anhydride. Suitable solvents for the reaction include
trifluoroacetic acid. The reaction temperature is not particularly limited and is usually
-20°C to room temperature, and preferable reaction temperatures include 0 — 10°C.
Step A—gxi}:
This step is a step of obtaining a compound A—(12) by xycarbonylation of
the amino group of the compound A—(l l).
The reaction can be performed under the same conditions as those generally used
in t—butoxycarbonylation of an amino compound such as the conditions described in a
document such as T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic
Chemistry, Third Edition". John Wiley & Sons (1999), P. 518-525. The compound A—
(12) can be obtained by reacting the compound A-(l l) with di-tert-butyl dicarbonate
using in a solvent such as tetrahydrofuran, for example. Alternative solvents include
acetonitrile and DMF. Those d in the art will appreciate that a base may also be
added to the reaction mixture, although is not essential. le examples of a base
e, but are not limited to triethylamine and diisopropylethylamine. The reaction
temperature is not particularly limited and is usually to room ature to reflux, and
preferably room temperature to 60°C.
Step A-txii):
This step is a step of obtaining a compound A-(13) from the compound A—(12).
The compound A-(13) is synthesized by reducing the nitro compound A-(l2) by
a sis method known to a person skilled in the art. Examples of the method
include reduction by catalytic hydrogenation using a noble metal catalyst such as Raney
nickel, palladium, ium, rhodium or platinum. Other reducing ts include
tin chloride, for example. Examples of the solvent include alcoholic solvents such as
methanol, l and l-propanol, preferably ethanol. The reaction time is not
particularly limited and is usually 0.5 to 24 hours, and preferably 0.5 to 18 hours. The
2O reaction temperature is usually room temperature. ative reduction reaction
ions e reaction with iron with an additive such as ammonium chloride or
hydrochloric acid, in an alcoholic solvent such as ethanol, at an appropriate reaction
temperature, for example 65°C.
Step A—t xiii):
This is a step of obtaining a compound A—(l4) from the compound A—(l3) by
condensing compound A—(l3) with a carboxylic acid and a condensing agent. The
condensation reaction can be performed under the same conditions as those usually used
and described in the following documents. Examples of the known method include
3O those in Rosowsky et al.; J. Med. Chem, 34 (1), 227~234 , Brzostwska et al.;
Heterocycles, 32 (10), 19684972 (1991), and Romero et al.; J. Med. Chem, 37 (7),
998—1014 .
The compound A-(13) may be a free form or a salt.
The solvent in this on is not particularly limited insofar as it does not
inhibit the reaction. Examples of the solvent include tetrahydrofuran, 1,4—dioxane,
ethyl acetate, methyl acetate, dichloromethane, chloroform, N,N-dimethylf01mamide,
toluene, acetonitrile and xylene. Examples of the condensing agent include CDl
(N,N'—carb0nyldiimidazole), Bop (1H— 1 ,2,3—benzotriazol— l—
PCT/EP20121050833
yloxy(tri(dimethylamino))phosphonium orophosphate), WSC ( l—3—(3-
ylaminopropy1)carbodiimide hydrochloride), DCC (N,N-
dicyclohexylcarbodiimide), diethylphosphoryl cyanide, PyBOP (benzotriazol-lyloxytri
(pyrrolidino)phosphonium hexafluorophosphate) and EDC . HCl (1—ethyl(3 -
dimethylaminopropyl)carbodiimide hydrochloride). Suitable conditions include an
agent to activate the acid, such as N,N’~carbonyl diimidazole. One equivalent to a
large excess of the acid may be used with respect to the compound A-(13). One
equivalent to a large excess of an organic base such as triethylamine or N,N—
diisopropylethylamine may be added where necessary.
The reaction time is not ularly limited and is usually 0.5 to 72 hours, and
preferably 0.5 to 24 hours. The reaction temperature varies according to the raw
material used, the solvent and the like and is not particularly limited. Ice-cold
temperature to solvent reflux temperature is acceptable, ice cold to room ature is
preferable.
Alternatively, the compound A—( 14) can be obtained by ting the desired
carboxylic acid to the ponding acid chloride and then ng the acid chloride
with the compound A-( 13). The acid chloride can be synthesized by a means known
to a person skilled in the art. For example the desired carboxylic acid may converted
to the corresponding acid chloride by reaction with thionyl chloride in the presence or
absence of a solvent, for example dichloromethane, N,N’-dimethylimidazolineone,
NMP or DMF. One to two equivalents or a large excess of thionyl chloride may be
used with respect to the desired carboxylic acid. The reaction temperature is ~30°C to
reflux, and preferably ~10°C to room temperature. The acid chloride may also be
formed by treating the acid with oxalyl chloride in a t such as dichloromethane in
the presence of DMF. The reaction temperature is —30°C to room temperature, and
preferably —10°C to room temperature
Alternatively, the compound A—( 14) can be obtained by converting the desired
carboxylic acid to a mixed acid anhydride and then reacting the mixed acid anhydride
with the compound A-(l3). The mixed acid anhydride can be synthesized by a means
3O known to a person skilled in the art. The synthesis is performed by reacting the
desired carboxylic acid with a chloroformate such as ethyl chloroformate in the
presence of a base such as ylamine, for e. One to two lents of the
chloroformate and the base are used with respect to the desired carboxylic acid. The
reaction ature is —30°C to room temperature, and preferably —20°C to room
temperature.
The step of sing the mixed acid anhydride with the compound l-(13) is
performed by reacting the mixed acid anhydride with the compound l-(l3) in a solvent
such as dichloromethane, tetrahydrofuran or N,N—dimethylformamide, for example.
One lent to a large excess of the desired carboxylic acid is used with respect to
the compound A—(l3).
The reaction time is not particularly limited and is usually 0.5 to 48 hours, and
preferably 0.5 to 12 hours. The reaction temperature is -20°C to 50°C, and preferably
~20°C to room temperature.
Alternatively, the compound A-(l4) can be obtained by converting the d
carboxylic acid to an active ester and then reacting the active ester with the compound
A—(l3). The step of obtaining the active ester is performed by reacting the desired
carboxylic acid with an active ester synthesis reagent in a t such as 1,4—dioxane,
tetrahydrofuran or N,N—dimethylformamide in the presence of a condensing agent such
as DCC, for example. Examples of the active ester synthesis reagent e N-
hydroxysuccinimide. One to 1.5 lents of the active ester synthesis reagent and
the condensing agent are used with respect to the compound A-(l3). The reaction time
is not particularly limited and is usually 0.5 to 48 hours, and ably 0.5 to 24 hours.
The reaction temperature is -20°C to 50°C, and preferably -20°C to room
temperature.
The step of sing the active ester with the compound A—(l3) is performed
by reacting the active ester with the compound A—(l3) in a solvent such as
dichloromethane, tetrahydrofuran or N,N-dimethylformamide, for example. One
equivalent to a large excess of the active ester is used with respect to the compound A-
(13). The reaction time is not particularly limited and is y 0.5 to 48 hours, and
preferably 0.5 to 24 hours. The reaction temperature is -20°C to 50°C, and preferably
—20°C to room temperature.
Step A-txiv}:
This step is a step of obtaining the compound A-(15 ) by deprotection of the t—
butoxycarbonyl group of the compound .
The reaction can be performed under the same conditions as those generally used
in deprotection reaction of a t~butoxycarbonyl group such as the conditions described in
a document such as T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic
Chemistry, Third n", John Wiley & Sons (1999), P. 518-525. The nd A-
(15) can be obtained by reacting the compound 1—(14) with a strong acid, for example
trifluoroacetic acid in the presence or absence of a solvent. Suitable solvents include
dichloromethane. Alternative acids include hydrochloric acid in suitable solvents,
such as dichloromethane or dioxane, for example.
The reaction temperature is normally ice cold to 80°C, preferably room
temperature. The reaction time is not particularly limited and is usually 5 minutes to
48 hours, and preferably 5 minutes to 12 hours.
B. General Preparation Method B:
In the formula, X, Y and A are as defined above.
General Preparation Method B is an alternative method for preparing a
compound A—(15) which ponds to nd (1) according to the present
invention from a compound A—(l 1) as a raw material through multiple steps of Step B—
(i) to Step .
The compound A—(l 1) may be prepared as described in General Preparation
Method A or the examples.
X N02
F B-(i)
o NH2 '——"
A—(11)
Step B—(i):
This step is a step of obtaining a compound A—(_16) from the compound A—( 1 1).
The compound A—(16) is synthesized by reducing the nitro compound A-(l l) by
a sis method known to a person skilled in the art. Examples of the method
e ion by catalytic hydrogenation using a noble metal catalyst such as Raney
nickel, palladium, ium, rhodium or platinum. Other reducing reagents include
tin chloride, for example. Examples of the solvent include alcoholic solvents such as
ol, ethanol and l—propanol, preferably ethanol. The reaction time is not
particularly limited and is usually 0.5 to 24 hours, and preferably 0.5 to 18 hours. The
reaction temperature is usually room temperature. Alternative reduction on
conditions include reaction with iron with an additive such as ammonium chloride or
hydrochloric acid, in an alcoholic solvent such as ethanol, at an appropriate reaction
temperature, for example 65°C.
Step B—gii):
This is a step of obtaining a compound A-(lS) from the compound A-(16) by
condensing compound A-(l3) with a carboxylic acid and a condensing agent. The
sation reaction can be performed under the same conditions as those usually used
and described in the following documents. Examples of the known method include
those in Rosowsky et al.; J. Med. Chem, 34 (1), 227-234 , Brzostwska et al.;
Heterocycles, 32 (10), 1968-1972 (1991), and Romero et al.; J. Med. Chem., 37 (7),
998—1014 (1994).
The compound A—(15 ) can be obtained by converting the desired carboxylic acid
to the corresponding acid chloride and then reacting the acid chloride with the
compound . The acid chloride can be synthesized by a means known to a
person skilled in the art. For example the desired carboxylic acid may converted to the
corresponding acid chloride by reaction with thionyl chloride in the presence or absence
of a solvent, for example dichloromethane, N,N’—dimethylimidazoline-2—one, NMP or
DMF. One to two equivalents or a large excess of thionyl chloride may be used with
respect to the d carboxylic acid. Those skilled in the art will appreciate that the
choice of reaction conditions employed may affect the outcome of the reaction, for
example the conditions may affect whether the acid chloride reacts with the aniline or
the isothiourca moieties. Those skilled in the art will iate that the reaction of
thionyl chloride with a carboxylic acid results in the concomitant formation of 1
equivalent of hydrochloric acid in addition to the formation of the desired acid chloride.
Those d in the art will appreciate that the current conditions do not employ a
method of removing the thus formed hydrochloric acid. The hloric acid formed
in this reaction may or may not affect the selectivity of the on which may or may
not result in a ial outcome. The reaction time is not particularly limited and is
usually 0.5 to 48 hours. and preferably 0.5 to 12 hours. The reaction temperature is -
°C to reflux, and preferably -10°C to room temperature. The acid chloride may also
be formed by treating the acid with oxalyl chloride in a solvent such as dichloromethane
in the presence of DMF, The reaction temperature is -30°C to room temperature, and
preferably —10°C to room temperature.
C. General Preparation Method C:
General Preparation Method C is an alternative method for preparing a
compound A—(Z) which is a synthetic ediate of the compound (1) according to the
present invention from a compound A-(l7) as a raw material through Step C-(i).
The nd A-(l7) is cially available.
C—(i)i
W0 —” 070K
A-(17) F
A-(2a)
$.04:
This step is a step of obtaining a compound A—(Za) from A-(l?) by adding a
trifluoromethyl anion to the compound A—(17) to generate an intermediate c
alkoxide or ediate trimethylsilyl ether which is then alkylated to give the
compound A—(Za). Those skilled in the art will appreciate that this transformation can
be ted in one pot or as two individual reactions. Those skilled in the art will
.47~
appreciate the benefits and drawbacks of a one pot reaction compared to ting two
separate reactions and choose the best method for their ements accordingly.
Specifically, acrolein A-(l7) can react with a trifluoromethyl anion which can be
generated by the action of fluoride on reagents such as (trifluoromethyl)trimethylsilane
to generate the corresponding c alkoxide or allylic timethylsilyl ether. The
solvent used in the reaction is not particularly limited r as it does not interfere
with the reaction. Examples of suitable solvents include THF. Acceptable
temperature ranges for the reaction include -10°C to solvent reflux, preferably below
room ature. Those skilled in the art will iate that n chemical
reactions can be exothermic and that control measures should be put in place to control
these exotherms. Those skilled in the art will also appreciate that the reaction
rm may be controlled by allowing the solvent to reflux. Suitable precursors to
generate oromethyl anion e, but are not limited to,
(trifluoromethyl)trimethylsilane (Rupert’s t, Chem Rev 1997, 97, 757) and
le fluoride sources include, but are not limited to, tetrabutylammonium fluoride
(TBAF), tetrabutylammonium difluorotriphenylsilicate (TBAT) and caesium fluoride.
Although the initial reaction temperature may be below room temperature it is
acceptable to allow the reaction temperature to reach solvent reflux during the course of
the reaction to facilitate reaction. The reaction time is not particularly d and is
usually 5 minutes to 24 hours, preferably 1 — 6 hours.
Those skilled in the art will appreciate that the alkoxide generated from this
reaction can be reacted with an alkylating agent directly, such as tert—butyl bromoacetate,
and that this reaction may proceed with or without additional solvents. If additional
solvents are required to facilitate reaction, then ts such as DMF or NMP are
suitable. The reaction temperature is not particularly limited. Suitable reaction
temperatures include room temperature to 80°C, preferably room temperature. The
reaction time is not particularly limited and is usually 5 minutes to 1 week, preferably 1
~ 48 hours. Alternatively, the alkylation reaction can be conducted under phase
transfer conditions, for example by adding an aqueous base, for e aqueous
3O sodium hydroxide. Those skilled in the art will appreciate that when these conditions
are d the use of a phase transfer st is ed. Suitable phase transfer
catalysts include, but are not limited to, tetrabutylammonium hydrogen sulfate.
Those skilled in the art will appreciate that the intermediate alkoxide could be
quenched, isolated and purified then subjected to independent alkylation conditions.
This reaction can be performed under the same conditions as those usually used in O—
alkylation reaction of an alcohol compound (such as the conditions bed in
Tetrahedron Lett. 46 (2005) 45, 7751-7755). In this reaction, the compound A—(Za)
can be obtained by adding a base such as sodium hydride to a solution of the the
~48-
intermediate l in THF to prepare an alkoxide, and then reacting the alkoxide with
the tert—butyl bromoacetate, for e. The solvent used in the reaction is not
particularly limited insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a n . Examples of the solvent include
ts such as THE DMF and dimethyl sulfoxide. The reaction can be performed
by g l to 3 equivalents of an appropriate base to act in the presence of such a
solvent. Examples of the base used include sodium hydride, potassium hydride and t—
butoxypotassium. The reaction time is not particularly limited and is usually 0.5 to 72
hours, and preferably 0.5 to 12 hours. The reaction temperature is usually —20°C to
50°C.
A more preferable result such as an improved yield may be achieved by adding a
salt such as tetrabutylammonium iodide in this reaction.
Those d in the art will appreciate that this reaction generates a new chiral
centre in the compound A-(Za) and that compound A—(Za) is the same as compound A-
(2) except that compound A-(Z) is enatiomerically pure s compound A—(Za) is
racemic. It will be appreciated by those skilled in the art the enantiomerically pure
compound A—(Z) and the racemic compound A—(Za) are indistinguishable by analytical
techniques such as NMR and liquid chromatography, however they are distinguishable
by chiral HPLC. Those skilled in the art will appreciate that the most appropriate
methods to obtain the desired mer from the compound A-(Za) or a more advanced
synthetic intermediate or final compound. Appropriate methods and appropriate stages
of enantiomeric purification include those as detailed in the examples.
In a further aspect, the present invention provides a process of preparing a
compound of formula (I), which comprises ng a nd of formula A—(lé),
n X is defined in formula (I), with a compound of formula (II) wherein A and Y
are as defined in formula (I), or a C 1-6 alkyl ester, acid anhydride or acid halide thereof,
to yield a compound of formula (I), and optionally converting the compound to a further
compound of formula (I) or forming a pharmaceutically acceptable salt thereof.
A Y A Y
X NH2 ;I/ X NWfJ;N:I/
0 (II) o
F F
N NHz N NH
\ 2
o I 0 \Y
FSC H A-ue) H
The reaction of A-(l 6) and (H) may conveniently be conducted in a solvent (such
as tetrahydrofuran, 1,4—dioxane, ethyl acetate, methyl acetate, dichloromethane,
chloroform, N,N~dimethylformamide, toluene, itrile or xylene) at a temperature
_49_
in the range of —30 °C to 100 °C. In one embodiment of the invention, compound (11)
may conveniently take the form of an acid halide (e.g. chloride) as may be prepared by
reacting the acid with a suitable reagent (e.g. thionyl chloride)
It will be iated by those skilled in the art that in the process of the present
invention certain functional groups such as hydroxyl, carboxyl or amino groups in the
starting reagents may need to be protected by protecting . Thus the preparation of
the compounds of formula (I) may additionally involve incorporation and removal of
one or more protecting groups. The protection and deprotection of functional groups is
for example described in T. W. Greene and P. G. M. Wuts, "Protective Groups in
Organic Chemistry, Third Edition", John Wiley & Sons (1999).
The present invention will be described more specifically below with reference
to Examples, Preparation Examples and Test Example. However, the present
ion is not d thereto. The abbreviations used in Examples are conventional
abbreviations known to a person d in the art. Some abbreviations are shown
below:
LCMS, LC/MS & LC—MS (liquid chromatography/mass spectrometry); MS (mass
spectrometry); MDAP (mass directed auto purification); NMR (nuclear magnetic
resonance); 3, d, t, dd. m. br (singlet, doublet, triplet, doublet of doublets, multiplet,
broad); Ph, Me, Et, Pr, Bu, Bn (phenyl, , ethyl, propyl, butyl, benzyl); THF
(tetrahydrofuran); DCM (dichloromethane); DMF (N,N-dimethylformamide); h, hr, hrs
(hours); EDC & EDAC (N-3—(dimethylaminopropyl)—N’ethylcarbodiimide
hydrochloride); DMAP (4—N,N—dimethylaminopyridine); DMSO (dimethylsulfoxide);
UV (ultraviolet); RT & rt (room ature); Rt (retention time); min & mins
(minutes); EtOAc (ethyl acetate); EtZO (diethyl ether); MeCN (acetonitrile); EtOH
(ethanol); MeOH (methanol); PhCH3 & PhMe (toluene); tlc (thin layer
tography); TFA (trifluoroactic acid); NaOH (sodium hydroxide); HCl
(hydrochloric acid); NMP (N-rnethylpyrrolidinone or l-methyl—Z-pyrrolidinone); HPLC
(high performance liquid chromatography); TBAF butylammonium e);
BuLi (n—butyl lithium); PyBOP: benzotriazol—l~yloxytris(pyrrolidino)phosphonium
hexafluorophosphate; Pdgdb‘cl}: tris(dibenzylideneacetone)dipalladium; Pd(t-Bu3P)2:
bis(tri-t—butylphosphine)palladium; TEA: trifluoroacetic acid; pTLC: preparative thin—
layer chromatography; HRMS (high resolution mass spectrometry); Tr or Trt (trityl or
triphenylmethyl).
1H NMR spectra were recorded on a Bruker AM series spectrometer operating at
a (reported) frequency of 400 MHz. Chemical shifts in proton r magnetic
resonance spectra are recorded in 5 units (ppm) relative to tetramethylsilane and
coupling constants (J) are ed in Hertz (Hz). Patterns are designated as s: t,
d: doublet, t; triplet, br; broad.
The "room ature" in the following Examples and Preparation Examples
lly refers to about 10°C to about 35°C. "%" indicates wt% unless otherwise
Chemical names were generated from chemical structures using ChemBioDraw
Ultra 11.0 and 12.0.
Description of Figures:
Figure 1 is a Typical Chromatogram from a Chiral HPLC Isolation of Compound l—(20).
Preparation e 1
Inthesis of tert—but l 4aS.SS.7aS -7a— 5—amino~2—fluoro hen 1 -5— trifluorometh 1 -
4a,5.7 7a—tetrah dro-4H—furo 3.4—d l 3 n-2~ 1 carbamate 1— 1‘3
1-(2) S Inthesis of Kerr-but 1 ZS -1 1.1-trifluorobut—3-en—2— 1 ox acetate
To a suspension of trimethylsulfonium iodide (110 g) in THE (500 mL) at -30°C was
added lithium hexamethyldisilazide (530 mL, 1N in THF) portionwise over 45 mins.
After stirring at —20°C for 20 mins, (S)—2—trifluoromethyloxirane (37.97 g) was added at
the same temperature over 15 mins, and the mixture was allowed to warm to RT and
stirred for 3 h. The slurry was then added portionwise to an ice-cold solution of ten-
butyl bromoacetate (10568 g) in NMP (200 mL). The resulting mixture was allowed
to warm to RT and stir for 2 days, before dilution with EtOAC (1 L). The organic layer
was washed with sodium onate (sat, aq., 4 x 400 mL), dried over MgSO4 and
evaporated. The residue was purified by silica gel column chromatography (5%
EtOAc in hexanes) to obtain the title compound (70.1 g) which was used in the
subsequent step without purification. 1H—NMR (400 MHZ, CDC13) 5 (ppm): 1.30 (s, 9
H) 3.83 — 3.96 (m, 2 H) 4.14 - 4.21 (m, l H) 5.34 - 5.48 (m, 2 H) 5.56 — 5.71 (m, l H)
PCTIEP2012/050833
vl )oxy )acetamide
zert—Butyl {[(ZS)-l,1,1-trifluorobut—3~en~2~ylloxy}acetate (70.1 g, crude) was dissolved
in ice—cold formic acid (200 mL). The mixture was allowed to warm to RT and stir
overnight. The reaction mixture was then concentrated under reduced pressure,
toluene (200 mL) was added, the mixture concentrated, before a second addition of
toluene (200 mL) and concentration to an oil. The e was dissolved in DCM (600
mL), cooled in an ice-bath, and N,N "carbonyl azolc (35 g) was added
portionwise over 20 mins. After stirring for 45 mins, N, O-dimethyl hydroxylamine
hloride (22 g) was added, and the reaction mixture was allowed to warm to RT
and stir overnight. Saturated NaHC03 (500 mL) and brine (250 mL) were then added,
and the mixture extracted with EtOAc (3 x 750 mL). The combined organic ns
were dried over MgSO4 and evaporated. The residue was purified by silica gel column
chromatography (1% to 30% EtOAc in hexanes) to obtain the title compound (25.17 g).
1H—NMR (400 MHZ,CDC13) 5 (ppm) 3.21 (s, 3 H), 3.71 (m, 3 H), 4.36 - 4.51 (m, 3 H),
.54 — 5.69 (m, 2 H), 5.84 (ddd, J=l7.7, 10.4, 7.3 Hz, 1 H)
l-(4) S nthesis of S '2-fluoro hen 1 ' 1.1 l—trifluorobut-3—en-2— 1 ox ethanone
A on of n-butyllithium in hexane (2.50 M; 90 mL) was added dropwise over 25
mins to a solution of 2-bromofluorobenzene (40.35 g) in THF (250 mL) under a N3
atmosphere at -78°C. The reaction solution was allowed to warm to -60°C and stir for
60 min. (S)—N-Methoxy-N—methyl~2—((l,1,1-trifluorobut—3-en~2—yl)oxy)acelamide (40 g)
in THF (25 mL) was added dropwise to the reaction on, and after stirring at -60°C
for 2 h, aqueous NH4Cl (100 mL) was added to the reaction solution, followed by
warming to RT. Brine (200 mL) was added to the reaction solution, and the mixture
was extracted with EtOAc (3 x 400 mL). The ed organic portions were dried
over MgSO4, ated, and the residue was purified by silica gel column
chromatography (1% to 10% EtOAc in hexanes) to obtain the title compound (33.59 g).
1H—NMR (400 MHz, CDC13) 5 (ppm): 4.40 (pentet, J 6.3 Hz, 1 H) 4.81 — 4.87 (m, 2 H),
.54 — 5.69 (m, 2 H), 5.86 (ddd, J 4, 7.3 Hz, 1 H) 7.12 — 7.22 (m, 1 H) 7.24 ~
7.34 (m, l H) 7.54 - 7.63 (m, l H) 7.94 - 8.02 (m, l H).
1—(5) S s of S —l— 2-fluoro hen l -2— l.l.l—trifluorobut—3—en—2- lox , ethanone
oxime
(S)-l-(2-Fluorophenyl)—2-((1,1,l—trifluorobuten-2—y1)oxy)ethanone (41.22 g) was
dissolved in anhydrous methanol (400 mL) and hydroxylamine hydrochloride (14.0 g)
and sodium acetate (19.0 g) were added. The reaction mixture was heated to 50C for
90 min, then cooled to RT, concentrated in vacuo and the residue d by silica gel
chromatography (2% to 15% EtOAC in hexanes) to afford the title compound as a
mixture of geometric isomers (40.54 g). 1H—NMR (400 MHZ, CDC13) 5 (ppm): 4.04 —
4.15 (m, 0.8 H), 4.18 — 4.26 (m, 0.2 H), 4.44 - 4.57 (m, 0.4 H) 4.79 - 4.90 (m, 1.6 H)
.37 — 5.56 (m, 2 H) 5.64—5.78 (m, 1 H) 7.03 - 7.54 (m, 2 H), 7.90
— 7.26 (m, 2 H) 7.33
(br s, 0.2 H), 8.51 (br s, 0.8 H).
1—(6) Synthesis of g3aR.4S.6aS)-6a-g2-fluorophenyl )~4—
3O 1trifluoromethyl)hexahydrofuro]3 ,4—c lisoxazole
(S)-l—(2-fluorophenyl)—2—((1,1,l—trifluorobuten-2—yl)oxy)ethanone oxime (40.54 g)
was dissolved in xylenes (400 mL) and hydroquinone (4.0 g) was added. The reaction
mixture was heated to reflux (heating block temperature 140°C) for 22 h, then cooled
and evaporated. The residue was purified by silica gel column chromatography (1% to
30% EtOAc in hexanes) to obtain the title nd (28.76 g). 1H-NMR (400 MHZ,
CDClg) 8 (ppm): 3.71-3.81 (m, l H), 4.04 — 4.35 (m, 4 H), 4.51-4.62 (m, 1 H), 5.38-5.54
(in, l H), 7.07 - 7.26 (m, 2 H), 7.32 - 7.42 (m, 1 H), 7.54-7.67 (in, 1 H).
1—(7) 2S.3R 4S —4-amino-4— 2—fluoro hen 1 —2— orometh l tetrah drofuran—3—
(3aR,4S,6aS)-6a-(2-fluorophenyl)(trifluoromethyl)hexahydrofuro[3,4—c]isoxazole
(28.76 g) was dissolved in acetic acid (200 mL) and the solution was cooled to 0°C.
Zinc (50 g) was added, and the on mixture was allowed to warm and stir at RT for
16h. The reaction mixture was then diluted with EtOAc (500 mL) and filtered h
celite, washing with a further 500 mL of EtOAc. The combined c portions were
ated, ved in chloroform (200 mL), and ammonia (28% aq., 250 mL) was
added slowly. The layers were separated, and the aqueous n was further
extracted with chloroform (2 x 250 mL). The combined organic extracts were dried
over anhydrous MgSO4 and evaporated to afford the title compound (31.12 g) which
was used in the subsequent step without further cation. 1H-NMR (400 MHz,
CDClg) 5 (ppm): 2.93 (ddd, J=7.7, 4.9, 2.5 Hz, 1 H), 3.84 (dd, J=12.4, 4.8 Hz, 1 H),
4.05 (dd, J=9.2, 3.2 Hz, 1 H), 4.17 (dd, J=12.4, 2.3 Hz, 1 H), 4.31 (d, J=9.3 Hz, 1 H),
4.72 (quin, J=7.3 Hz, 1 H), 7.13 (ddd, J=13.1, 8.8, 1.3 Hz, 1 H), 7.22 (td, J=7.6, 1.3 Hz,
1 H), 7.31 - 7.40 (m, 1 H), 7.51 (Cd, J=8.0, 1.6 Hz, 1 H)
l~(8) S s of N- ’ ’(3S 4R SS ’2—fluoro hen 1 —4- h drox meth l —5—
(trifluoromethyl 1tetrahydrofuranyl Zearbamothioyl zbenzamide
Benzoyl isothiocyanate (19.0 mL) was added to a solution containing ((2S,3R,4S)
amino(2—fluorophenyl)—2—(trifluoromethyl)tetrahydrofuran—3—y1)methanol (28.72 g)
in DCM (150 mL), and the mixture was stirred at RT for 18 h. Sodium bicarbonate
(sat, aq., 200 mL) was then added, the mixture extracted with EtOAc (3 x 300 mL),
dried over MgSO4 and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (5% to 30% EtOAc in hexanes) to obtain the title
compound (37.07 g). 1H-NMR (400 MHZ, CDC13) 8 (ppm): 3.22 (dd, J=8.l, 4.5 Hz, 1
H), 3.31 (td, J=8.0, 3.0 Hz, 1 H), 3.94 — 4.07 (m, l H), 4.31 - 4.46 (m, 1 H), 4.53 (d,
J=9.9 Hz, 1 H), 4.83 (d, J=9.9 Hz, 1 H), 6.97 ~ 7.14 (m, 1 H), 7.22 (td, J=7.7, 1.3 Hz, 1
H), 7.31 — 7.45 (m, 1 H), 7.49 — 7.61 (m, 2 H), 7.61 — 7.70 (m, 1H), 7.75 (td, 128.1, 1.5
Hz, 1 H), 7.79 — 7.93 (m, 2 H), 8.90 (s, l H), 11.85 (s, 1 H)
1—(9) S nthesis of N- 4aS.SS,7aS)-7a~ 2—fluoro hen 1 —5— trifluorometh 1 -4a.5.7.7a-
tetrahvdro—4H—furol 3.4—d l 1,3 [thiazin—Z-yl )benzamide
N—(((3S,4R,SS)-3~(2-Fluorophenyl)-4—(hydroxymethyl)
(trifluoromethylfietrahydrofuranyl)carbamothioyl)benz.amide (31.1 g) was dissolved
in pyridine (150 mL), and the mixture cooled to -20°C. Trifluoromethanesulfonic
anhydride (14.0 mL) was added dropwise over 30 min and the reaction was allowed to
warm to 0°C. After stirring for 2 h, the reaction was quenched by the addition of
PCT/EP20121'050833
ammonium chloride (sat, aq., 400 mL) and ted with EtOAc (3 x 500 mL). The
combined organic ts were dried over MgSO4, concentrated in vacuo and purified
by silica gel column chromatography (2% to 30% EtOAc/hex) to obtain the title
compound (18.50 g). 1H NMR (400 MHz, CDC13) 5 ppm 2.86 (dd, J=13.9, 3.5 Hz,
1H), 3.25 (d, J=13.6 Hz, 1 H), 3.61 (br. s., 1 H), 4.00 ~ 4.10 (m, l H), 4.66 (d, J=8.8 Hz,
1 H), 4.78 — 4.87 (m, 1 H), 7.12 - 7.60 (m, 6 H), 7.68 — 7.73 (m, 1 H), 7.99 — 8.16 (br. s.,
2 H), 8.62 — 8.66 (m, 1 H)
1—(10) S nthesis of N— 4aS.SS.7aS —7a— 2—fluoro henvl —5- trifluorometh l 421 5.7,7a—
tetrahvdro—4H—furol 3.4-d l 1,3 lthiazin—2-y11benzamide
N—((4aS,SS,7aS)-7a-(2—F1uorophenyl)~5-(trifluoromethy1)~4a,5.7,7a—tetrahydro-4H—
furo[3,4—d][1,3]thiazin-Z-yl)benzamide (21.5 g) was dissolved in ol (160 mL),
1,8~diazabicyclo[5.4.0]undec—7-ene (16.29g) was added, and the solution was heated to
reflux (heating block temperature 80°C). After 16 h, the reaction mixture was
trated under reduced pressure, and the residue purified by silica gel column
chromatography (10% to 60% EtOAc in hexanes) to afford the title compound (13.82 g).
1H NMR (400 MHZ, CDC13) 5 ppm 2.85 (dd, J=l3.6, 3.8 Hz, 1 H), 3.14 (dd, ,
3.2 Hz. 1 H). 3.33 — 3.45 (m. 1 H), 3.92 (dd, J=8.1, 2.0 Hz, 1 H), 4.49 (br. s., 2 H). 4.63
- 7.22 (m,
- 4.76 (m, 2 H), 7.08 (ddd, J=12.6, 8.1, 1.0 Hz, 1H), 7.13 1 H), 7.25 - 7.36
(m, 1 H), 7.44 (td, J=8.0, 1.9 Hz, 1 H)
l-(l l) S nthesis of .7aS —7a— 2—fluoro—5-nitro hen 1 -5— trifluorometh l -
.7.7a—tetrah —furo 3.4—d 1.3 thiazin—2-arnine
N-((4aS,SS,7aS)—7a—(2—Fluorophenyl)~5~(trifluorornethyl)—4a,5,7,7a—tetrahydr0—4H-
furo[3,4—d][l,3]thiazin—2-yl)benzamide (5.15 g) was dissolved in TFA (75 mL), and the
solution was cooled to 0°C. Sulfuric acid (cone, 20 mL) was added, followed by
fuming nitric acid (2 mL) dropwise over 20 mins. After stirring at 0°C for 90 mins, the
on mixture was poured onto ice (200 g) and basified to pH 12 with 6N NaOH (aq.).
After allowing the ice to melt, the mixture was extracted with EtOAc (3 x 500 mL), and
the combined organic portions dried over MgSO4 and evaporated to afford the title
compound (22.1 g, purity approx. 71%) which was used in the subsequent step without
purification. 1H NMR (400 MHZ, CDC13) 8 ppm 2.89 (d, J=3.8 Hz, 1 H), 3.09 (br. s., 1
H), 3.28 - 3.54 (in, l H), 3.80 — 4.03 (m, l H), 4.50 — 4.70 (m, 3 H), 4.71 — 4.86 (m. l H),
7.21 — 7.30 (m. 1 H), 8.18 — 8.28 (m, 1 H), 8.45 (dd, J=6.8. 2.8 Hz, 1 H)
1-(12) Synthesis of tart-but l 4aS.SS.7aS ~7a- 2-fluoronitro hen 1 —5-
trifluorometh 1 -4a 5.7.7a-tetrah dro-4H-furo 3.4—d 1 3 thiazin l carbamate
(4aS,SS,7aS)-7a-(2—Fluoronitrophenyl)—5-(trifluoromethyl)-4a,5,7,7a—tetrahydro—4H—
furo[3,4—d][1.3]thiazin—2—amine (20.6 g, crude) was dissolved in THE (300 mL), di—tert—
butyl dicarbonate (12 g) was added portionwise over 20 mins and the reaction mixture
was heated to 60°C. Further portions of di-tert-butyl dicarbonate (10 g) were added
until starting material was consumed by TLC. The reaction mixture was cooled and
sodium bicarbonate (sat., aq.. 200 mL) and brine (200 mL) were added. The mixture
was then extracted with EtOAc (3 x 500 mL) and the combined organic portions were
dried over MgSO4 and evaporated. The residue was purified by silica gel column
tography ( 10% to 25% EtOAc in hexanes) to afford the title compound (16.62g).
1H NMR (400 MHZ, CDCig) 5 ppm 1.55 (s. 9 H). 2.73 — 2.84 (m, l H), 2.92 e 3.05 (m, 1
H). 3.43 — 3.55 (m, 1 H), 3.81 — 3.94 (m, 1 H). 4.57 (d, J=8.3 Hz, 1 H), 4.73 ~4.83 (m. 1
H), 7.19 - 7.39 (m, 2 H), 8.20 — 8.29 (m, 1 H), 8.32 (d, J=6.8 Hz, 1 H)
l—(13) S nthesis of tert-but 1 4aS,SS 7218 —7a— 5—amino—2—fluoro hen 1 —5-
trifluorometh 1 -4a.5 7.7a—tetrah dro-4H—furo 3,4-d 1.3 n—2— 1 carbamate
lert—B utyl ((4aS ,SS,7aS)-7a-(2—fluoronitrophenyl)—5—(trifluoromethyl)—4a,5,7,7a-
tetrahydro—4H—furo[3,4~d][l,3]thiazin—2—y1)carbamate (16.61 g) was ved in ethanol
(250 mL) and tin chloride dihydrate (25.0 g) was added. After stirring at RT for 18 h.
the on was poured onto NaOH (2N aq., 300 mL) and celite® (~50 g) was added.
The resulting mixture was filtered through more celite® and extracted with EtOAc (2 x
500 mL). The combined c ns were dried over MgSO4 and evaporated to
afford the title compound (15.52 g). This material could be used crude but a portion
was purified by silica gel column chromatography (20% to 50% EtOAc in hexanes) to
afford pure material (recovery 79%). 1H NMR (400 MHZ, CDC13) 5 ppm 1.53 (s, 9H),
2.77 (d, 1:144 Hz, 1H), 3.09 (br. s., 1H), 3.46 (br. s., 1H), 3.62 (br. s., 2H), 3.87 (br. 3.,
1H), 4.61 (d, J=8.6 Hz. 1H), 4.71 (br. 3., 1H), 6.61 (br. s., 2H), 6.85 — 6.95 (m, 1H)
ation Example 2
S nthesis of ten—but l 4aS.SS.7aS ~7a- 5~amino-2—fluoro hen 1 trifluorometh l -
4a 5.7.7a-tetrah dro-4H—furo 3.4—d 1.3 thiazin—2— 1 carbamate 2— 10
—56—
W0 20121098213 PCTIEP2012/050833
l ‘9“
" F " F
o O O
FFW FW W
Frm F F
2-(2)
F F
249)
2—(1) S nthesis of S —1— 2.3—difluoro hen l 1. l . l ~trifluorobut-3—en—2—
l)ox ethanone
A solution of llithium in hexane (2.50 M, 13.5 mL) was added dropwise over 20
mins to a solution ning l—bromo-2,3—diflu0robenzene (6.50 g) in Eth (50 mL)
under a N2 atmosphere at -78°C. The reaction solution was allowed to stir for 60 mins.
(S)—N-Methoxy-N-methyl-2—((1,l,l—trifluorobut—3—en~2~yl)oxy)acetamide) (5 .20 g) in
EtZO (10 mL) was then added dropwise to the reaction solution, and after stirring at -
78°C for l h, aqueous NH4Cl (50 mL) was added to the on solution, followed by
warming to RT. NaHC03 (sat. aq., 100 mL) was added to the reaction solution, and
the mixture was extracted with EtOAc (3 x 100 mL). The combined organic portions
were dried over MgSO4, evaporated, and the residue was purified by silica gel column
chromatography (1% to 10% EtOAc in hexanes) to obtain the title nd (3.91 g).
1H NMR (400 MHz, CDC13) 5 ppm: 4.33 - 4.43 (m, 1 H), 4.80 — 4.84 (m, 2 H), 5.55 —
.67 (m, 2 H), 5.76 - 5.94 (m, l H), 7.18 — 7.28 (m, 1 H), 7.37 — 7.47 (m, l H), 7.70 (ddt,
J=7.9, 6.0. 1.7 Hz, 1 H)
2—(2) S nthesis of S —l— 2.3—difluoro hen 1 1.1,l-trifluorobut—3—en—2—
Vl )oxyjethanone oxime
WO 98213
(S)~1—(2,3—difluorophenyl)—2-((1,1,l-trifluorobut—3—en—2—yl)oxy)ethanone (3.91 g) was
dissolved in anhydrous ol (40 mL) and hydroxylamine hydrochloride (1.25 g)
and sodium acetate (1.68 g) were added. The reaction mixture was heated to 50°C for
90 min, then cooled to RT, concentrated in vacuo and the residue purified by silica gel
chromatography (2% to 20% EtOAc in hexanes) to afford the title compound as a
mixture of ric isomers (4.10 g). 1H—NMR (400 MHz, CDCI3) 5 (ppm): 4.04 -
4.26 (m 1 H), 4.43 — 4.55 (m, 0.4 H) 4.80 — 4.89 (m, 1.6 H) 5.39 - 5.55 (m, 2 H) 5.64—
.80 (m, 1 H) 7.05 — 7.30 (m, 3 H), 7.76 (br s, 0.2 H), 8.30 (br s, 0.8 H).
2—(3) S nthesis of 48 —6a- 2.3-difluoro hen l —4- 'trifluorometh l hexah drofuro 3 4-
clisoxazole
(S)(2,3-difluorophenyl)—2-((1,1,1—trifluorobuten-2—yl)oxy)ethanone oxime (4.10 g)
was dissolved in xylenes (40 mL) and hydroquinone (380 mg) was added. The
on mixture was heated to reflux (heating block temperature 140°C) for 20 h, then
cooled and evaporated. The residue was purified by silica gel column chromatography
(1% to 25% EtOAc in hexanes) to obtain the title compound (3.16 g). 1H NMR (400
MHZ, CDC13) 6 ppm 3.77 (br. s., 1H), 3.99 - 4.16 (m, 1H), 4.16 - 4.22 (m, 1H), 4.22 —
4.44 (m, 2H), 4.51 (d. J=9.9 Hz, 1H). 5.44 (s, 1H), 7.07 — 7.24 (m, 2H). 7.38 (br. s.. 1H)
2-(4) Synthesis of {128.3 R,4S 2aminog 2,3-difluorophenyl 3
gtrifluoromethyl )tetrahydrofuran—3—yl )inethanol
(4S)-6a—(2,3-diflu0rophenyl)—4—(trifluoromethyl)hexahydrofuro[3,4—c]isoxazole (3.16 g)
was dissolved in acetic acid (20 mL) and the reaction mixture cooled to 0°C. Zinc (5.0
g) was added, and the reaction was allowed to warm and stir at RT for 20 h. The
reaction mixture was then diluted with EtOAc (50 mL) and filtered through celite®,
washing with a further 100 mL of EtOAc. The combined organic portions were
ated, dissolved in CHC13 (20 mL), and ammonia (28% aq., 25 mL) was added
slowly. The layers were separated, and the aqueous portion was further extracted with
CHC13 (2 x 25 mL). The combined organic ts were dried over anhydrous
MgSO4 and evaporated to afford the title compound (3.12 g) which was used in the
subsequent step without further purification. 1H NMR (400 MHZ, CDClg) 5 ppm 2.93
(ddd, J=7.8, 5.1, 2.8 Hz, 1 H), 3.85 (dd, J=l2.4, 5.1 Hz, 1 H), 4.03 (dd, J=9.1, 2.8 Hz, 1
H), 4.14 (dd, J=12.3, 2.7 Hz, 1 H), 4.35 (d, J=9.1 Hz. 1 H), 4.68 (quin, J=7.3 Hz, 1 H),
7.09 - 7.25 (m, 2 H), 7.25 - 7.34 (m, 1 H)
2—(5) S s of N- . .
gtrifluoromethyl )tetrahvdrofuran-3—yl mothioyl )benzamide
Benzoyl isothiocyanate (2.0 mL) was added to a solution containing ((23,3R,4S)—4~
amino—4-(2,3-difluorophenyl)-2—(trifluoromethyl)tetrahydrofuran-3 -yl)methanol (3 .12
g) in DCM (20 mL), and the mixture was d at RT for 18 h. Sodium bicarbonate
(sat, aq., 50 mL) was then added, the mixture extracted with EtOAc (3 x 75 mL), dried
over MgSO4 and concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (5% to 40% EtOAc in hexanes) to obtain the title
nd (4.18 g). 1H NMR (400 MHZ, CDC13) 5 ppm 3.12 (dd, 1:7.6, 4.3 Hz, 1 H),
3.18 - 3.29 (m, l H), 4.03 (ddd, J=12.3, 7.2, 4.5 Hz, 1 H), 4.35 - 4.49 (m, 1 H), 4.59 (d,
J=9.9 Hz, 1 H), 4.81 (d, J=9.6 Hz, 1 H), 7.07 — 7.23 (m, 2 H), 7.49 (t, J=7.2 Hz, 1 H),
7.56 (t, J=7.7 Hz, 2 H), 7.67 (t, J=7.5 Hz, 1 H), 7.88 (d, J=7.l Hz, 2 H), 8.92 (s, 1 H),
11.89 (s, 1 H)
2-(6) S nthesis of N—( 4aS,SS 7aS)-7a- 2,3-difluoro hen l trifluorometh l -
4a 5.7,7a—tetrah dro-4H-furo 3.4-d 1.3 thiazin—Z— l benzamide
N—(((3S,4R,58)(2,3-Dif1uorophenyl)—4—(hydroxymethyl)
(trifluoromethyl)tetrahydrofuran—3—yl)carbamothioyl)benzamide (2.99 g) was dissolved
in ne ( 14 mL), and the mixture cooled to —20°C. Trifluoromethanesulfonic
anhydride (1.55 mL) was added dropwise over 10 min and the reaction mixture was
allowed to warm to -10°C. After stirring for 2 h, a further portion of
trifluoromethanesulfonic anhydride (1.0 mL) was added dropwise over 10 min, the
reaction was stirred for a further 2 h, and was then ed by the on of
ammonium chloride (sat., aq., 50 mL) and extracted with EtOAc (3 x 100 mL). The
combined organic extracts were dried over MgSO4, concentrated in vacuo and purified
by silica gel column tography (5% to 20% EtOAc/hex) to obtain the title
compound (1.20 g). 1H NMR (400 MHZ, CDC13) 8 ppm 2.86 (d, J=10.6 Hz, l H),
3.20 (br. 3., 1H), 3.55 (br. s.. l H), 4.04 (br. s., l H), 4.65 (d, J=8.8 Hz, 1 H), 4.81 (br.
s., 1H), 7.06 — 7.24 (m, 3 H), 7.40 - 7.64 (m, 3 H), 7.82 — 8.21 (m, 2 H)
2—(7) S nthesis of 4aS.5S.7aS ~7a~ 2.3-difluoro hen l) trifluorometh l —4a.5 ,7,7a-
vdro-4H-fnrol 3.4-d [ 1,3 lthiazin—2—arnine
N—((4aS,SS,7aS)-7a—(2,3—Difluorophenyl)(trifluoromethyl)~4a,5,7,7a-tetrahydro-4H—
furo[3,4—d][1,3]thiazinyl)benzamide (2.00 g) was dissolved in methanol (250 mL),
l,8—diazabicyclo[5.4.0]undec—7—ene (1.53g) was added, and the solution was heated to
reflux (heating block temperature 80°C). After 3 h, the reaction mixture was
concentrated under reduced pressure, d with water (100 mL) and extracted with
EtOAc (3 x 100 mL). The combined organic portions were dried over MgSO4,
ated, and the residue purified by silica gel column chromatography (0% to 50%
EtOAc in hexanes) to afford the title compound (1.42 g). 1H NMR (400 MHz, CDClg)
WO 98213
8ppm 2.86 (dd, J=13.6, 3.8 Hz, 1 H), 3.15 (dd, J=13.8, 3.2 Hz, 1 H), 3.27 - 3.42 (m, 1
H). 3.93 (dd, J=8.2. 1.9 Hz, 1 H), 4.39 - 4.78 (m, 4 H), 6.96 — 7.25 (m. 3 H)
2—(8) S nthesis of 4aS.SS.7aS —7a— 2 3-difluoronitro hen l trifluorometh l)-
4a.5.7 7a—tetrah dro-4H—furo 3 4—d 1.3 thiazin—2—amine
(4aS,SS,7aS)-7a—(2,3—Dilluoropheny1)—5—(trifluoromethyl)—4a,5,7,7a~tetrahydro—4H-
furo[3,4-d][1,3]thiazin—2—amine (1.42 g) was dissolved in TFA (6 mL), and the solution
was cooled to 0°C. Sulfuric acid (cone, 1 mL) was added, followed by fuming nitric
acid (0.30 mL) dropwise over 20 mins. After stirring at 0°C for 1 h, the reaction
e was poured onto ice (50 g) and basified to pH 12 with 2 N NaOH (aq.). After
allowing the ice to melt, the mixture was extracted with EtOAc (3 x 75 mL), and the
combined organic portions dried over MgSO4 and evaporated to afford the title
compound (1.91 g, purity . 80%) which was used in the subsequent step without
cation. 1H NMR (400 MHZ, CDCl3) 5 ppm 2.88 (dd, J=13.8, 3.9 Hz, 1 H), 3.11
(dd, J=13.6, 2.8 Hz, 1 H), 3.37 (dt, J=7.4, 3.5 Hz, 1H), 3.93 (d, J=7.8 Hz, 1 H), 4.53 -
4.83 (m, 4 H), 8.09 (ddd, J=9.0, 6.3, 2.9 Hz, 1 H), 8.27 (dt, J=5.2, 2.6 Hz, 1 H)
2—(9) Synthesis of ut l "4aS 58.7aS —7a— 2.3—difluoro~5-nitro hen l -5—
trifluorometh l-4a.5.7.7a~tetrah dro-4H-furo 3.4—d 1.3 thiazin—2- lcarbamate
(4aS,SS,7aS)-7a-(2,3-Difluoronitrophenyl)(trifluoromethyl)—4a,5,7,7a—tetrahydro-
4H—furo[3,4—d][1,3]thiazin—2—amine (1.91 g, crude) was ved in THF (10 mL), di—
tert—butyl dicarbonate (1.3 g) was added portionwise over 20 mins and the reaction
mixture was heated to 65°C. After 3 h, the reaction mixture was cooled and sodium
bicarbonate (sat, aq., 50 mL) was added. The mixture was then extracted with EtOAc
(3 x 750 mL) and the combined c portions were dried over MgSO4 and
evaporated. The e was purified by silica gel column chromatography (0% to
% EtOAc in hexanes) to afford the title compound (1.43g crude, in a mixture with the
bis-boc version).
2—(10) S nthesis of [err—but 1 42.8 SS 7213 -7a- .
(t1fi1uoromethy1)-4a,5 27,7a—tetrahydro—4H~furo[ 3 ,4-d H 1,3 lthiazin—2—y1 )carbamate
The crude mixture obtained in preparation example 2—(9) containing Iert—Butyl
((4aS,SS,7aS)—7a-(2,3—difluoro—5~nitrophenyl)(trifluoromethyl)—4a,5,7,7a—tetrahydro—
o[3,4—d][1,3]thiazin—2—yl)carbamate) (1.43 g) was dissolved in ethanol (25 mL)
and tin chloride dihydrate (2.50 g) was added. After stirring for 18 h, the solution was
poured onto NaOH (2N aq., 100 mL) and extracted with EtOAc (3 x 100 mL). The
combined organic portions were dried over MgSO4, evaporated and purified by silica
gel column cinematography (0% to 30% EtOAc in hexanes) to afford firstly the bis—boc
~60~
PCT/EP20121050833
product (730 mg), and secondly the title nd (300mg). 1H NMR (400 MHz,
CDC13) 25me 1.53 (5,9 H), 2.76 (dd. 1:139, 3.8 Hz, 1H), 3.08 (d. J=13.6 Hz. 1 H).
3.36 - 3.45 (m, 1 H), 3.71 (br. s., 2 H), 3.90 (d, J=8.3 Hz, 1 H), 4.57 (d, J=8.6 Hz, 1 H),
4.68 - 4.79 (m, 1 H), 6.30 - 6.37 (m, 1 H), 6.42 - 6.49 (m, 1 H)
Pre n exam 1e 3: S nthesis of 5—ethox razine—2-carboxv1ic acid 3- 2
/N Cl r
/0\w):\N]/ N O
O VOYENJ/ HOWE:j/O
O O
3-(1) 3(2)
S nthesis of eth 15-ethox razine-2—carbox late 3— 1
A stirred solution of methyl 5~chloropyrazine—Z—carboxylate (0.50 g) in ethanol (10 mL)
was cooled to 0°C. and sodium ethoxide (21% w/w solution in ethanol, 1 mL) was
added over 10 mins. After allowing to warm to RT and stir for 2 h, water (100 mL)
was added and the mixture extracted with EtOAc (2 x 150 mL). The combined
organic portions were dried over MgSO4 and evaporated to afford the title compound.
(0.65 g, purity approx. 85%). 1H NMR (400 MHz, CDClg) 8 ppm 1.45 (t, J=7.1 Hz, 3
H), 1.46 (t, .1271 Hz, 3 H), 4.48 (q, J=7.1 Hz, 2 H), 4.49 (q, 1271 Hz, 2 H), 8.28 (d,
J=1.3 Hz, 1 H), 8.88 (d, J=1.3 Hz, 1 H)
Synthesis of 5—ethoxypyrazine—2—carboxylic acid 3—(2)
Ethyl xypyrazinc—Z—carboxylatc (0.65g, approx. purity 85%) was dissolved in
dioxan (3 mL) and water (3 mL) was added, followed by lithium hydroxide
drate (255 mg, portionwise over 10 mins). After stirring at RT for 24h, 13th
(25 mL) and NaHC03 (sat, aq., 25 mL) were added. The layers were separated and
the c layer was extracted with NaOH (1 N, aq., 25 mL). The combined aqueous
portions were ied with 6N HCl to pH 2, and the mixture extracted with EtOAc (3
x 40 mL). The combined EtOAc extracts were dried over MgSO4 and evaporated to
afford the title compound as an off—white powder. 1H NMR (400 MHz. CDC13) 5 ppm
1.47 (t, J=7.1 Hz, 3 H), 4.53 (q, J=7.1 112,2 H), 8.16 (d, J=1.2 Hz, 1H), 8.98 (d, 121.2
Hz, 1 H)
Pre aration exam 1e 4: S nthesis of 5—ethox razine-2—carboxvlic acid ’4— 3
O O F F F F
HZNYLN[ka /N])K / EX
_., :\N —-—-—>
\N/N]X /O HO \N
0 o O 0
4(1) 4-(2) 4-(3)
Meth t l razinecarbox late 4- 1
S—Acetylpyrazine-Z—carboxamide (3.275 g) was dissolved in methanolic HCl (1.25 N,
150 mL) and the reaction mixture was heated to reflux and d overnight. After
cooling, sodium bicarbonate was added and the mixture was extracted with EtOAc.
The EtOAc layer was dried over MgSO4 and evaporated to afford the title compound
(3.79 g, approx purity 90%). 1H NMR (400 MHZ, CDCl3) 5 ppm 2.78 (s, 3 H), 4.10 (s,
3 H), 9.33 (d, J=15 Hz, 1 H), 9.36 (d, J21.5 Hz, 1 H)
Methyl 5—1 1,1—difluoroethvl )pyrazinecarboxylate 4-12 1
Methyl 5-acetylpyrazine-Z-carboxylate (300 mg, approx purity 90%) was ved in
DCM (15 mL) and cooled to 0°C under nitrogen. Bis(2-methoxyethyl)aminosulfur
trifluoride (0.61 mL) was added dropwise and the reaction mixture allowed to warm to
RT and stir overnight. Sodium bicarbonate (sat, aq.) was added cautiously and the
mixture extracted with DCM. The organic portions were dried over MgSO4. evaporated
and purified by silica gel chromatography (35% EtOAc in hexane) to afford the title
compound (155 mg) as a white solid. 1H NMR (400 MHZ, CDClg) 5 ppm 2.00 (t,
J=18.8 Hz, 3 H), 4.01 (s, 3 H), 8.98 (d, J=1.5 Hz, 1 H), 9.24 ((1, 1:1.5 Hz, 1 H)
5—; 1,1—Difluoroethyl )pyrazine—2-carboxy1ic acid 4—1 3 1
Methyl 5-(1,l-difluoroethyl)pyrazine~2~carboxylate (0.65 g, approx. purity 85%) was
dissolved in dioxan (2 mL) and water (:2 mL) was added, followed by lithium hydroxide
monohydrate (54 mg, portionwisc). After stirring at RT for 90mins, the e was
concentrated to 2 mL and Eth (20 mL) added. The mixture was then extracted with
NaOH (1 N, aq., 20 mL), and the aqueous portions ed with 6N HCl to pH 2.
The aqueous portion was then extracted with EtOAc, dried over MgSO4 and evaporated
to afford the title nd as a white solid (119 mg). IH NMR (400 MHZ, CDClg) 5
ppm 2.11 (t, J=18.8 Hz, 3 H), 9.01 (d, J=1.3 Hz, 1 H), 9.47 (d, J=1.3 Hz, 1 H)
Preparation example 5: Synthesis of S—(‘fluoromethyl)pyrazine—2—carboxylic acid 15—13))
O ‘0
)1) [N
”YEN”)2 ”fig“ F
—> |
I _’
o \ HO \
/ \(ENEAFfiN N
O O 0
(1) 5-(2) 5-(3)
Meth 15— h drox meth 1 razine—Z—carbox late 5- l
To a solution of methyl 5—formylpyrazine—2—carboxylate (2.47 g) in THF (20 mL) was
added sodium borohydride (170 mg) portionwise over 10 mins. After stirring for 1 11,
methanol (10 mL) was added. The reaction mixture was stirred for a further 20 mins,
and then HCl (1 N, aq., 20 mL) and brine (20 mL) were added. The mixture was
extracted with EtOAc (3 x 40 mL) and the combined organic portions dried over
MgSO4 and evaporated to afford the title compound (1.31 g). 1H NMR (400 MHz,
5ppm 4.07 (s, 3 H), 4.98 (br. s., 2 H), 8.80 (s, l H), 9.27 (s, 1 H)
Methyl 5—(fluoromethVl)pvrazine—2-carboxylate 5—g 2)
To a solution of methyl roxymethyl)pyrazine—2-carboxylate (0.64 g) in THF (20
mL) was added triethylamine (2.30 g) and the solution was cooled to 0°C.
Triethylarnine trihydrofluoride (1.22 g) was then added followed by
orobutanesulfonyl fluoride (2.28 g) di‘opwise over 5 mins. After warming to
RT and stirring for 2 h, NaHC03 (sat, aq., 100 mL) was added, and the mixture was
extracted with EtOAc (2 x 50 mL). The combined organic portions were dried over
MgSO4, evaporated, and purified by silica gel chromatography (5% to 50% EtOAc in
hexane) to afford the title compound (94 mg). 1H NMR (400 MHZ, CDCl3) 5 ppm
4.07 (s, 3 H), 5.67 (d, J=46.5 Hz. 2 H), 8.89 (s. 1 H), 9.28 (s, 1 H)
5- Fluorometh 1) razine-Z-carbox lic acid 5- 3
Methyl 5—(f1uoromethyl)pyrazine—Z-carboxylate (94 mg) was dissolved in dioxan (1
mL) and water (1 mL) was added, followed by lithium hydroxide monohydrate (60 mg).
After stirring at RT for 18 h, EtZO (20 mL) was added and the mixture was then
ted with NaOH (1 N, aq., 2 x 20 mL). The aqueous portions were acidified with
6N HCl to pH 1, extracted with EtOAc (2 x 40 mL), the combined organic portions
dried over MgSO4 and evaporated to afford the title nd as a white solid (71 mg).
1H NMR (400 MHZ, CDCig) 5 ppm 5.70 (d, J=46.2 Hz. 2 H), 8.85 (s, 1 H), 9.40 (s, 1 H)
Pre aration exam 1e 6: S nthesis of 5—difluorometh l razine-Z—carbox lic acid '6-‘5
~63-
PCT/EP20121050833
”MINTN/ ,
O XYLD//O rv/ O
6-(1 ) 5(2)
F F
,Nf0
fixm—waiemmflj/kF /N]/KF
O O
543) -(4) 6—(5)
S nthesis of t-but lS—meth l Irazinecarbox late 6- l
A boron trifluoride-diethyl ether x (91.7 tLL) was added dropwise to a
suspension of 2-methylpyrazine—5-carb0xylic acid (1 g) and tert-butyl 2,2,2—
trichloroacetimidate (4.75 g) in THF (20 mL) under ice~cooling. The reaction on
was warmed to RT, followed by stirring for 2 h. A saturated NaCl solution and EtOAc
were added to the reaction solution, and the organic layer was separated. The organic
layer was dried over anhydrous MgSO4. and the insoluble matter was separated by
filtration. The filtrate was trated and purified by silica gel column
chromatography to obtain the title compound (1.4 g). 1H—NMR (CDC13) 8 (ppm):
1.65 (s, 9H), 2.65 (s, 3H), 8.57 (d, J: 1.2 Hz, 1H), 9.10 (d, J = 1.6 Hz, 1H).
S nthesis of t-but 15- E dimeth lamino-vin l -
A mixture of t—butyl ylpyrazine—Z—carboxylate (1.35 g), DMF (25 mL) and N,N—
dimethylformamide dimethylacetal (25 mL) was stirred at 130°C for 5 h. The reaction
solution was cooled to RT and diluted with EtOAc. The mixture was washed with a
saturated NaCl solution three times. The organic layer was dried over anhydrous
MgSO4, and the insoluble matter was separated by filtration. The filtrate was
trated and the residue was purified by silica gel column chromatography to
obtain the title compound (648 mg). lH—NMR (CDC13) 8 (ppm): 1.63 (s, 9H), 3.00 (s,
6H), 5.16 (d, J = 12.8 Hz, 1H). 7.72 (d, J = 12.8 Hz, 1H), 8.16 (d, J = 1.2 Hz, 1H), 8.81
(d, J :16 Hz, 1H).
Synthesis of t—butyl ylpyrazine-Z-carboxylate 6—131
Sodium periodate (1.67 g) was added to a solution of t-butyl 5-((E)-2—dimethylamino-
Vinyl)—pyrazine—2—carboxylate (645 mg) in 50% THF-water (26 mL), and the mixture
was stirred at RT for 4 h. A saturated NaHC03 solution and EtOAc were added to the
reaction solution, and the organic layer was separated. The organic layer was washed
with a saturated NaCl solution and dried over anhydrous MgSO4. The insoluble matter
was separated by filtration and the filtrate was concentrated. The residue was purified
by silica gel column tography to obtain the title compound (249 mg). 1H-
~64—
NMR (CDC13) 8 (ppm): 1.68 (s, 9H), 9.25 (d, J = 1.2 Hz, 1H), 9.36 (d, J = 1.6 HZ, 1H),
.2 (s. 1H).
Synthesis of t-butyl 5-difluoromethylpyrazine—Z-carboxylate 6—141
[Bis(2—methoxyethyl)amino]sulfur trifluoride (662 uL) was added dropwise to a
solution of l 5-formylpyraaine-Z-carboxylate (249 mg) in CH2C13 (12 mL) under a
N2 atmosphere under ice-cooling. The reaction solution was stirred for 2 h while
gradually returning to RT. A saturated Nal-IC03 solution and EtOAc were added to
the reaction solution, and the organic layer was separated. The c layer was
washed with a saturated NaCl solution and dried over anhydrous MgSO4. The
insoluble matter was separated by ion and the filtrate was concentrated. The
residue was purified by silica gel column chromatography to obtain the title compound
(175 mg). 1H-NMR (CDC13) 5 (ppm): 1.67 (s, 9H), 6.75 (t, J =: 54.4 Hz, 1H), 9.02 (d,
J = 0.8 Hz, 1H), 9.25 (d, J = 0.8 Hz, 1H).
Synthesis of 5~difluoromethy1pyrazine—2-carboxylic acid 6-(5)
Trifluoroacetic acid (1 mL) was added to a solution of t—butyl 5-
difluoromethylpyrazine-Z-carboxylate (175 mg) in dichloromethane (1 mL), and the
mixture was stirred at RT for 5 h. Ether and 5 N NaOH were added to the reaction
on. The aqueous layer was separated and made acidic with 5 N hloric acid.
EtOAc was added to the s layer, and the organic layer was separated. The
organic layer was dried over anhydrous Mg8 04, and the insoluble matter was separated
by filtration. The filtrate was concentrated to obtain the title compound (100 mg).
H—NMR (CDC13) 5 (ppm): 6.80 (t, J = 54.4 Hz, 1H), 9.02 (s, 1H), 9.47 (s, 1H).
Pre aration exam le 7: S nthesis of 5-c ano ridine—2-carbox lic acid 7—2
/ CN /
\.fl /
——* 1 ’Ho i
/ /O \N N
N 1
O O
7~(1) 7-(2)
S nthesis of meth l 5—c ano idine—2—carbox late 7 l
A mixture of methyl opyridine~2~carboxy1ate (2.8 g) and copper cyanide (3.6 g)
in NMP (30 mL) was heated with ng at 170°C for 1.5 h. Water was added to the
reaction solution at RT, and the insoluble matter was removed by filtration. The
filtrate was extracted with EtOAc. The extract was washed with a saturated NaCl
solution and then dried over anhydrous MgSO4. The drying agent was removed by
filtration and the filtrate was concentrated under reduced pres sure. The resulting crude
t was purified by silica gel column chromatography (EtOAc—heptane system) to
obtain the title compound (920 mg). 1H-NMR (400 MHZ, CDC13) 5 (ppm): 4.06 (s,
3H), 8.16 (dd, J = 2.0, 8.0 HZ. 1H), 8.27 (d, J = 8.0 HZ. 1H), 9.01 (d, J = 2.0 Hz. 1H).
Synthesis of 5-cyanopyridine-2—carboxylic acid 7-12)
A solution of the compound of Preparation Example 13~(1) (920 mg) and a 5 N NaOH
on (2.26 mL) in ethanol (30 mL) was stirred at RT for 10 min. 5 N hydrochloric
acid (5.2 mL) was added to the reaction solution at RT, followed by extraction with
EtOAc. The extract was dried over ous MgSO4. The drying agent was
removed by filtration and the filtrate was concentrated under reduced pressure to obtain
the title compound (800 mg). 1H—NMR (400 MHZ, DMSOd6) 5 (ppm): 8.18 (d. J = 8.0
HZ, 1H), 8.51 (dd, J = 2.0, 8.0 HZ, 1H), 9.12918 (m, 1H).
Pre aration exam 1e 8: S nthesis of 5- methox methvl razine—2-carbox lic acid 8—
(2))
N N
/N / fOMe / for/1e
(Kn/E I /O \N HO \N
/ N
o 0
(1) 8-(1) 8—(2)
S s of meth 15- methox meth 1 razine—2—carboxvlate 8- 1
The compound obtained in preparation example 5—( 1) (279 mg) was dissolved in DMF
and the solution was cooled to 0°C. Sodium hydride (60% in mineral oil, 70 mg) was
added, followcd by thanc (250 mg). After 2 days, water (25 mL) was added,
and the solution extracted with EtOAc (100 mL). The aqueous layer was saturated
with NaCl, and r ted with EtOAc (2 x 50 mL). The combined organic
portions were dried over MgS O4, evaporated, and purified by silica gel chromatography
(30% to 50% EtOAc in hexanes) to afford the title compound (55 mg, approx. purity
65%). 1H NMR (400 MHZ, CDClg) 8 ppm 3.55 (s, 3 H), 4.05 (s, 3 H), 4.72 (s, 2 H),
8.84 (d, J=1.0 HZ, 1 H), 9.25 (d, J=1.0 Hz, 1 H)
S nthesis of 5— methox meth l razine—2—carbox lic acid 8— 2
Methyl 5—(methoxymethyl)pyraZine—2—carboxylate, 8(1), (55 mg, crude) was ved
in 1,4—dioxane (1 mL) and water (1 mL) was added followed by lithium hydroxide
monohydrate (50 mg). After stirring at RT for 1 h, water (20 mL) was added and the
mixture was extracted with ether (20 mL). The aqueous portion was acidified to pH 2
and extracted with EtOAc (2 x 25 mL). The combined EtOAc layers were dried over
MgSO4 and evaporated to afford the title compound (19 mg). 1H NMR (400 MHZ,
CDC13) Sppm 3.58 (s. 3 H), 4.77 (s, 2 H), 8.80 (br. s., 1 H), 9.38 (br. 3., 1 H)
-66—
Pre aration exam 1e 9: S—Methox razine-2—carbox lie acid
'1. MeOH, H2804
2. NaOMe N OMe
2. NaOH
I Nj/C' |
HO HO /j/
N/ N
O O
-Chloropyrazineearboxylic acid (5.0 g, 0.032 mol) was charged to a round-bottom
flask equipped with a thermocouple, overhead stirrer and reflux ser. Methanol
(37.5 mL, 0.926 mol) was charged followed by cone. sulfuric acid (0.2 mL, 0.004 mol).
The 3—neck flask was equipped with a heating mantle, and then the reaction mixture was
heated to ca. 65.0 °C (T al). The reaction e continued to stir at ca. 65.0 “C
(T internal) for ca. 4 h. The reaction mixture cooled to ca. 25.8 °C (T internal).
Methanol (12 mL, 0.31 mol) was charged and the slurry continued to stir at ca. 22.3 °C
(T internal) for ca. 15 min then cooled to ca. 10.0 0C (T internal) under an atmosphere
of nitrogen. 25% Sodium methoxide in methanol (1 :3, Sodium methoxidezMethanol,
7.7 mL) was charged to flask while temperature remained below 30.0 °C (T al).
The reaction e was adjusted to 20.4 0C (T internal). After 30 min, sodium
hydroxide (2.0 g, 0.04 mol) and water (37.5 mL, 2.08 mol) were combined to form a
on, and then the solution was charged to the reaction mixture. Water (50.0 mL,
2.78 mol) was charged and then the reaction mixture was heated to 40.0 °C (T internal)
for ca. 60 mins. The heating mantle was removed, and then the reaction mixture
cooled to ca. 25.4 °C (T internal). 38% aq. HCl Solution (38:62, hydrogen
chloridezwater, 4.0 mL) was added at a rate (ca. 5 min.) such that the temperature
remained below 30.0 °C (T internal). The thick slurry was stirrred for l h at ca.
21.4 °C (T internal), and then filtered over a sintered . The solids were rinsed
with water (10.0 mL, 0.555 mol) and dried under vacuum overnight to afford 5—
methoxypyrazine-2—carboxy1ic acid ). 1H NMR (500 MHz, DMSO) 5 13.24 (1H,
br s), 8.79 (1H, d, J = 1.2 Hz), 8.37 (1H, d, J: 1.2 Hz), 3.98 (s, 3H); 13c NMR (125
MHZ, DMSO) 5 165.36, 161.88, 143.88, 136.82, , 54.69.
General procedure for the coupling of anilines prepared in ation Examples 1-113)
and 2— 10 with ar learbox lic acids: Pre aration of N— 3— 421853.733 —2—amino—5—
trifluorometh 1 ~4a.5.7 7a-tetrah dro—4H—furo 3 4—d 1,3 thiazin—7a—
fluorophenyl1—5-methoxypvrazinecarboxarnide (Example 1 1
~67-
N¢\Iro\
O \ N
N NH2
O ‘Y
te rt-Butyl ((4aS ,SS,7aS)—7a—(5—aminofluorophenyl)-5—(trifluoromethyl)-4a,5,7,7a—
ydro—4H—furo[3,4-d][1,3]thiazin-2—yl)carbamate (Preparation Example 1, 56 mg)
was dissolved in DCM (2 mL) and 5—methoxypyrazine—2-carboxylic acid (40 mg), N,N-
diisopropylethylamine (80 mg) and (1H~benzotriazolyloxy)tripyrrolidin- l-
yl)phosphonium hexafluorophosphate (135 mg) were added. The on e was
stirred at RT for 18 h, and sodium bicarbonate (sat, aq., 25 mL) was added. The
mixture was extracted with EtOAc (2 x 40 mL), the combined c portions were
dried over MgS O4, evaporated and purified by silica gel chromatography
(EtOAc/hexanes gradient) to afford the amide (40 mg) as a white solid. The amide
was dissolved in DCM (2 mL) and TFA (1 mL) was added. After stirring at RT for 2
h, the reaction mixture was evaporated and sodium bicarbonate (sat, aq., 25 mL) was
added. The mixture was extracted with EtOAc (2 x 25 mL), and the combined organic
portions dried over MgSO4 and evaporated to afford the title compound as a white solid
(34 mg). 1H NMR (400 MHZ, CDC13) 5 ppm 2.78 — 2.87 (In, 1 H), 3.11 — 3.21 (m, 1
H), 3.38 — 3.48 (m, 1 H), 3.82 - 4.06 (m, 4 H), 4.48 — 4.72 (m, 2 H), 6.96 — 7.10 (m, l H),
7.52 (d, J=4.8 Hz, 1 H), 7.87 (d, J=8.8 Hz, 1 H), 8.09 (s, 1 H), 8.95 (s, 1 H), 9.46 (br. s.,
1 H)
Exam 1e 2: N— 3— 4218 SS 7aS amino-5— trifluorometh 1 ~4a.5 7,7a—tetrah dm—4H-
furo 3 4~d 1.3 thiazin—7a—vl)—4-fluoro hen l c ano icolinamide
0 ‘\
N NH2
0 E
F FFH
Synthesized from l'ert—butyl [(4aS,5S,7aS)—7a-(_5—aminofluorophenyl)—5-
trifluoromethyl-4a,5 ,7,7a-tetrahydro—4H—furo[3 ,4-d] [1,3 ] n-Z-yl]carbamate and 5-
cyanopyrazine-Z-carboxylic acid according to the general procedure. 1H NMR (400
MHz,CDC13)6 ppm 2.82 (dd, 1213.6, 3.5 Hz, 1 H), 3.14 — 3.21 (m, 1 H), 3.37 — 3.45
~68~
(m, 1 H), 3.91 (d, J=9.1 Hz, 1 H), 4.50 — 4.71 (m, 2 H), 7.08 (dd, J=11.9, 8.8 Hz, 1 H),
7.46 — 7.57 (m, 1 H). 7.92 (dt. J=8.8, 3.4 HZ, 1 H), 8.17 (dd, J=8.3, 2.0 Hz, 1 H). 8.34 (d.
J=8.1Hz, 1H), 8.81 - 8.92 (m, 1 H)
Exam 1e 3: N— 3— 43853735 ~2—amino-5— orometh 1 —4a.5.7.7a-tetrah Ciro—4H—
carboxamide
N NH2
O \Y
Synthesized from rert—butyl [(4aS,SS,7aS)—7a— (5-amino-2—fluoropheny1)—5-
romethyl-4a,5 ,7,7a-tetrahydro—4H—furo[3 ,4—d] [1 ,3]thiazin—2-y1]carbamate and 5—
difluoromethyl—pyrazine—Z—carboxylic acid according to the general procedure. 1H
NMR (400 C13)5 ppm 2.81) (dd, J=13.8, 3.7 Hz, 1 1-1), 3.11 (dd, J=13.6, 2.8
Hz, 1 H), 3.31 — 3.41 (m, 1 H), 3.86 (d, J=8.3 Hz, 1 H), 4.57 (d, J=8.3 Hz, 1 H), 4.64 (dt,
1:147, 7.1 Hz, 1 H), 4.75 (br s, 2 H), 6.69 (t, J=56.3 Hz, 1 H), 7.07 (dd, J=11.6, 8.8 Hz,
1 H), 7.57 (dd, J:7.1, 2.8 Hz, 1 H), 7.87 (dt, J=8.5, 3.6 Hz, 1 H), 8.85 (s, 1 H), 9.45 (s,
1 H), 9.58 (br. 3., 1 H)
Example 4: N—g 3;((4as,SS.7aS)-2—amino-5—(tn'f1uoromethy1)-4a,5,7.7a—tetrahydro—4H-
furof3,4—d1[1.3]thiazin—7a—V1)—4—fluoropheny1)~5—(‘trifluoromethyl)picolinamide
N/l F
O \
F F
Synthesized from tert—butyl [(4aS,SS,7aS)-7a— (5—amino—2—fluorophenyl)—5-
trifluoromethyl~4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin—2-y1]carbamate and 5-
trifluoromethyl—pyridine—2—carboxylic acid according to the general procedure. 1H
NMR (400 MHz, CDC13) 8 ppm 2.88 (dd, J=13.6, 3.8 Hz, 1 H), 3.20 (dd, J=13.6, 3.0
Hz, 1 H), 3.37 - 3.53 (m, 1H), 3.94 (dd, J:8.3. 2.3 Hz, 1 H), 4.40 - 4.89 (m, 4 H), 7.14
(dd, J=11.9, 8.8 Hz, 1 H), 7.66 (dd, J=6.8, 2.8 Hz, 1 H), 7.98 (ddd, 1:8.8, 4.0, 3.0 Hz, 1
H). 8.20 (dd, J=8.2, 1.6 Hz, 1 H), 8.45 (d, J=8.3 Hz, 1 H), 8.90 (s, 1 H). 9.95 (s. 1 H)
Exam 1e 5: N— 3- 4aS.SS 7aS -2—amino trifluorometh 1 -4a.5 7.7a-tetrah dro—4H—
Synthesized from utyl [(4aS,SS,7aS)-7a- (5-amino-2—fluoropheny1)—5—
trifluoromethyl—4a,5 ,7,7a-tetrahydr0-4H-fur0[3,4—d] [1,3]thiazin-2—y1]carbamate and 5-
methyl-pyrazine-Z—carboxylic acid according to the general procedure. 1H NMR (400
MHz, CDC13) 5 ppm 2.72 (s, 3 H), 2.88 (dd, J=13.6, 3.8 Hz, 1 H), 3.21 (dd, 1:136, 3.0
Hz, 1 H), 3.42 — 3.49 (m, 1 H), 3.94 (d, J=8.3 Hz, 1 H), 4.39 - 4.80 (m, 4 H), 7.14 (dd,
J=11.9, 8.8 HZ, 1 H), 7.62 (dd, J=7.1, 2.8 Hz, 1H), 7.93 - 7.99 (m, 1 H), 8.46 (d, J=1.0
Hz, 1 H), 9.39 (d, J=1.3 Hz, 1 H), 9.65 (s, 1 H)
Exam 1e 6: N— 3- 4aS.SS.7aS no-5— trifluorometh 1 —4a 5.7.7a—tetrah dro-4H—
furo 3,4-d 1.3 thiazin—7a— ' ' '
Synthesized from terz—butyl [(4aS,SS,7aS)-7a— (5~mnino—2—fluor0phenyl)—5-
trifluoromethy1-4a,5 ,7,7a-tetrahydr0-4H—fu1‘0[3,4—d] [1,3]thiazin—2-yl]carba1nate and 5-
2 O methyl-pyridine-Z-carboxy1ic acid according to the l procedure. 1H NMR (400
MHZ, CDC13) 5 ppm 2.37 (s, 3H), 2.78 (dd, J:13.6, 3.8 Hz, 1H), 3.12 (dd, 1:136, 2.8
Hz, 1H), 3.28 — 3.40 (m, 1H), 3.87 (d, J=8.1 Hz, 1H), 4.28 — 5.02 (m, 4H), 7.02 (dd,
, 8.8 Hz, 1H), 7.55 (dd, J=7.1, 2.8 Hz, 1H), 7.63 (dd, J=8.0, 1.4 Hz, 1H), 7.88
(ddd, J=8.8, 4.0, 2.9 Hz. 1H), 8.10 (d, J=8.1 Hz, 1H). 8.31 — 8.40 (m, 1H). 9.90 (s, 1H)
Exam le 7: N- 3— 4aS 58.7aS ~2—amino trifluorometh 1 -4a.5.7.7a-tetrah dro-4H-
furo 3 4-d 1.3 thiazin«7a—
PCTI’EP2012/050833
O \
N\ NH2
0 I
F FFH
Synthesized from terr—butyl [(4aS,SS,7aS)—7a- (5-amin0-2—fluor0pheny1)—5—
trifluoromethyl—4a,5 ,7,7a~tetrahydro~4H—furo[3 ,4~d] [1,3]thiazin—2-y1]carbamate and 5-
ethyl—pyridine—Z-carboxylie acid according to the general ure. 1H NMR (400
MHZ, CDC13) 8 ppm 1.33 (t, J=7.6 Hz, 3 H), 2.78 (q, J=7.6 Hz, 2 H), 2.88 (dd, J=13.5,
3.7 Hz. 1 H), 3.22 (dd. J=13.6. 2.8 Hz, 1 H), 3.42 — 3.48 (m. 1 H), 3.96 (d, J=7.3 Hz, 1
H), 4.44 — 4.95 (m, 4 H), 7.12 (dd, J=11.6, 8.8 HZ, 1 H), 7.62 (dd, J=6.9, 2.7 Hz, 1 H),
7.74 (dd, 128.1, 1.8 Hz, 1 H), 7.98 (dt, 1:8.7, 3.5 Hz, 1 H), 8.21 (d, J=8.1 Hz, 1 H),
8.44 - 8.48 (m, 1 H), 10.00 (s, 1 H)
Exam 1e 8: N— 3— 4aS.5S.7aS no—5— trifluorometh 1 —4a 5.7.7a-tetrah dro—4H-
furo 3 4-d 1.3 thiazin-7a—v1)-4—fluoro hen 1 —5— fluorometh 1 razine—2-carboxamide
Synthesized from tert—butyl [(4aS,SS,7aS)~7a— (5—amino—2—f1uoropheny1)—5—
trifluoromethyl—4a,5 ,7,7a—tetrahydro—4H—furo[3 ,4—d] [1,3]thiazin-2—yl]carbamate and 5—
fluoromethyl-pyrazine—2—carboxylic acid ing to the general procedure. Details of
an actual preparation are as fel1ows:~tert—Buty1 ((4aS,SS,7aS)-7a—(5—amin0—2—
fluorophenyl)—5—(triflu0romethy1)-4a,5,7,7a—tetrahydro-4H-furo[3,4—d][1,3]thiazin-2—
yl)carbamate (500 mg) was dissolved in DCM (10 ml.) and 5—fluoromethy1-pyraz.ine—2—
carboxylic acid (223 mg), N,N~diisopropylethylamine (521 mg) and (1H—benzolriazel-
1—yloxy)tripyrrolidin—1-y1)phosphonium hexafluorophophate (750 mg) were added. The
reaction mixture was stirred at RT for l h, and sodium bicarbonate (sat., aq., 50 mL)
was added. The mixture was extracted with EtOAc (2 x 75 mL), the combined c
portions were dried over MgS 04. evaporated and ed by silica gel chromatography
(0% to 30% EtOAc/hcxanes gradient) to afford the amide (613 mg) as a white solid.
The amide was dissolved in DCM (2 mL) and TFA (1 mL) was added. After stirring at
RT for 2 h, the reaction e was evaporated and sodium bicarbonate (sat, aq., 25
mL) was added. The mixture was extracted with EtOAc (3 x 25 mL), and the ed
organic portions dried over MgSO4 and evaporated to afford the title compound as a
white solid
1H NMR (400 MHz, CDC13) 5 ppm 2.89 (dd, J=13.8, 3.7 Hz, 1 H), 3.21 (dd, J=13.9, 2.5
Hz, 1 H), 3.40 - 3.51 (m, 1 H), 3.96 (d, J=7.3 Hz, 1 H), 4.42 — 4.85 (111,4 H), 5.69 (d, J:
46.5 Hz, 2 H), 7.15 (dd, J=11.9, 8.8 Hz, 1 H), 7.64 (dd, 127.1, 2.8 Hz, 1 H), 7.94 - 8.00
(m, 1 H), 8.77 (s, 1 H), 9.47 (s, 1 H), 9.68 (s, 1 H)
Exam 1e 9: N— 3- 4318.53 7213 —2—amino-5— trifluorometh 1 —4a.5.7.7a—tetrah dro—4H—
furo 3 4—d 1.3 thiazin-7a-V1)—4—f1uoro hen l —5-rnethox icolinamide
N/ O\
O \
N NH2
O Y
sized from tert-bulyl [(4aS,SS,7aS)-7a- (5—amino—2—fluorophenyl)—5—
trifluoromethyl-4a,5 ,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiaziny1]carbamate and 5-
methoxypyridme-Z—carboxylic acid according to the general procedure. 1H NMR (400
MHz, CDC13) 8 ppm 2.88 (dd, J=13.8, 3.7 Hz, 1 H), 3.23 (dd, J=13.8, 2.4 Hz, 1 H),
3.46 (d, J=7.3 Hz, 1 H), 3.89 - 4.02 (m, 4 H), 4.54 — 5.00 (m, 4 H), 7.11 (dd, , 8.8
Hz, 1 H), 7.36 (dd, J=8.8, 2.8 Hz, 1 H), 7.61 (dd, J=7.1, 2.8 Hz, 1 H), 7.97 (dt, J=8.5,
3.6 Hz, 1 H), 8.23 — 8.30 (m, 2 H), 9.86 (s, 1 H)
Exam 1e 10: N— 3- 4218 58.7213 ~2~amino—5~ trifluoromelh 1 ~4a.5 7.7a—telrah ~
furo 3.4—d 1.3 thiazin-7a4-fluoro hen 1 ~5-ethox razine—2-carboxarnide
Synthesized from tert—butyl [(4aS,SS,7aS)-7a- (5 —amino-2—fluorophenyl)—5-
trifluoromethyl—4a,5 ,7,7a~tetrahydro-4H—furo[3,4-d] hiazin—2-y1]carbamate and 5-
ethoxypyrimidine-Z-carboxylic acid according to the general procedure. 1H NMR
(400 MHz, CDC13) 5 ppm 1.47 (t, J=7.1 Hz, 3 H), 2.87 (dd, 1:136, 3.5 Hz, 1 H), 3.20
(d, J=13.6 Hz, 1 H), 3.40 ~ 3.50 (m, 1 H), 3.94 (d, J=7.8 HZ, 1 H), 4.46 — 4.95 (In, 6 H),
7.11 (dd. J=11.5. 9.0 Hz, 1 H), 7.54 - 7.63 (m, 1 H), 7.90 - 8.01 (m, 1 H). 8.13 (s, 1 H).
9.00 (s, 1 H), 9.52 (br. 3., 1 H)
Exam 1e 11: N— 3- 421853.738 ~2—amino—5— trifluoromethvl)-4a.5.7.7a—tetrah (ho-4H—
furo 3.4—d 1.3 lhiazin-7a—v1)-4—fluoro hen 1 1.1—difluoroeth 1 razine—Z-
carboxamide
Synthesized from tert-buty1 [(4aS,SS,7aS)-7a— (5 —amino—2—fluorophenyl)—5 -
trifluoromethy1—4a,5 ,7,7a—tetrahydro-4H—furo[3,4—d][1,3]thiaziny1]carbamate and 5-
(1,1-difluorocthy1)pyrazinc—Z-carboxylic acid according to the l procedure. 1H
NMR (600 MHz, CDC13) 5 ppm 2.03 (t, J=18.8 Hz, 3 H), 2.82 (d, 1212.0 Hz, 1 H), 3.14
(d, 1:124 Hz, 1 H), 3.35 — 3.46 (m, 1 H), 3.77 - 4.07 (m, 1 H), 4.20 - 4.93 (m, 4 H),
7.08 (dd, 1211.7, 9.0 Hz, 1 H), 7.56 (d, J=4.5 Hz, 1 H), 7.80 - 7.93 (m, 1 H), 8.87 (s, 1
H), 9.43 (s, 1 H), 9.59 (br. 3., 1 H)
3- 4218 55.7215 —2—amino-5— trifluorometh 1)-4a.5 7.7a—tetrah —
furgL3,4-dH léLthiaZin-h—V1)—4-fluorophgny1)—5—('trif1uoromethy_l)pyrazine—Z—
OVVN
N NH2
O ‘Y
F FH
F
sized from tert—butyl [(4aS,SS,7aS)-7a- (5—amino—2—fluor0pheny1)—5—
trifluoromethy1-4a,5,7,7a-tetrahydro-4H-furo[3,4—d] [1,3]thiaziny1]carbamate and 5-
trifluoromethylpyrazine-Z—carboxylic acid according to the general procedure. 1H
NMR (400 MHz, CDC13) 5 ppm 2.80 (dd, J=13.6, 3.8 Hz, 1 H), 3.11 (dd, J=13.8, 2.9
Hz, 1 H), 3.30 - 3.44 (m, 1 H), 3.87 (d, J28.3 Hz, 1 H), 4.25 — 5.14 (m, 4 H), 7.07 (dd,
, 8.8 HZ, 1 H), 7.57 (dd, J=6.8, 2.8 Hz, 1 H), 7.86 (dt, J=8.4, 3.6 HZ, 1 H), 8.89 (s,
1H). 9.53 (S, 2 H)
Exam le 13: N— 3- 4213 SS 7213 amino trifluoromethvl)-4a.5.7.7a—tetrah dro-4H-
carboxamide
sized from tert—butyl [(4aS,SS,7aS)~7a— (5-amino-2—f1uorophenyl)—5-
trifluoromethyl—4a,5,7,7a~tetrahydro-4H-furo[3,4—d] [1,3]thiazin—Z—yl]carbamate and 5-
(methoxymethyl)pyrimidine-2—carboxylic acid according to the general procedure. 1H
NMR (400 MHZ, CDC13) 5 ppm 2.79 (dd, J=13.6, 3.8 Hz, 1 H), 3.11 (dd, , 2.8
Hz, 1 H), 3.32 — 3.39 (m, 1 H), 3.49 (s, 3 H), 3.84 (d, J=8.3 Hz, 1 H), 4.34 - 4.73 (m, 6
H), 7.05 (dd, J=11.6, 8.8 Hz, 1 H), 7.55 (dd, J=6.8, 2.8 Hz, 1 H), 7.88 (dt, J=8.4, 3.6 Hz,
1 H), 8.63 (s, 1 H), 9.34 (d. J=1.0 Hz, 1 H), 9.60 (s, 1 H)
Exam 1e 14: N— 3- 4aS 58.7aS —2-amino—5— trifluorometh l ~4a.5—dih dro—4H—
2H3 )methyloxy [Eyrazine—Z—
carboxamide
Synthesis of 14—(2) 5—]g2H3)methyloxy[pyrazine-Z-carboxylic acid
11N\
IfN\
oco3 N\ 00:33
*r —‘"’
Me02C N [330020 N/ II
H020 N
Part (I): (2H_3)methyl 5—[(2H; meth 10x razine-Z—carbox late
Freshly cut sodium metal (160 mg) was added portionwise over 10 mins to
(2H3)methan(2H)ol (5 mL) and the on was stirred until the sodium had dissolved.
This solution was then added to methyl 5-chloropyrazine—2-carboxylate (1.02 g) in
(2H3)methan(2H)ol (5 mL) and the solution was allowed to stir at RT for 1 hr. The
solution was then concentrated under reduced pressure to a volume of about 2 mL, and
water (50 mL) was added. The mixture was ted with EtOAc (2 x 50 mL), the
combined organic portions were dried over MgSO4 and evaporated to afford the title
compound (745 mg). 1H NMR (400 MHz, CDC13) 5 ppm 8.30 (d, J=1.3 Hz, 1 H),
8.91 (d, J=1.3 Hz, 1 H)
PCTIEP2012/050833
Part (II ): 5-1t2H;)methyloxylgyrazine-Z—carboxylic acid
To a stirred solution of (2H3)methyl 5-[(2H3)methyloxy]pyrazinecarboxy1ate in 1,4-
dioxane (5 mL) was added water (5 mL) followed by lithium hydroxide monohydrate
(300 mg). After stirring for 1 hr, the reaction mixture was trated under d
pressure to about 5 mL and extracted with diethyl ether (25 mL). The organic layer
was extracted with 1N NaOH (aq., 10 mL), and the combined aqueous portions were
acidified to pH 2 with 6N hydrochloric acid. After cooling in a fridge, the mixture was
filtered to afford the title compound as a pale brown powder (660 mg). 1H NMR (400
MHZ, CDC13) 8 ppm 8.21 (d. J=1.3 Hz, 1H), 9.01 (d, J=1.3 Hz, 1 H). 10.12 (br s., 1 H)
furo 3.4
2H; )methyloxy I ne-2—carboxamide
NWo/ jiH
OWN H
NYNHz
tert—Butyl ((4aS,SS,7aS)—7a—(5—amino-2—1'luorophenyl)—5-(trifluoromethyl)—4a,5,7,7a—
tetrahydro—4H—furo[3,4—d][1,3]thiazin—2—yl)carbamate (100 mg) was dissolved in DCM
(2 mL) and 5—[(ZH3)methyloxy]pyrazine—2—carboxylic acid (55 mg), N,N—
diisopropylethylamine (112 mg) and nzotriazol-1—yloxy)tripyrrolidin—1—
yl)phosphonium hexafluorophosphate (180 mg) were added. The reaction mixture was
stirred at RT for 18 h, and sodium bicarbonate (sat, aq., 25 mL) was added. The
mixture was extracted with EtOAc (2 x 40 mL), the combined c portions were
dried over MgSO4, ated and purified by silica gel chromatography (2 % to 25%
EtOAc in hexanes) to afford the amide (127 mg) as a white solid. The amide was
dissolved in DCM (2 mL) and TFA (1 mL) was added. After stirring at RT for 2 h, the
reaction mixture was evaporated and sodium bicarbonate (sat, aq., 25 mL) was added.
The mixture was extracted with EtOAc (2 x 40 mL), and the combined organic portions
dried over MgSO4 and ated to afford the title compound as a white solid (104
mg). 1H NMR (400 MHZ, CDC13) 6 ppm 2.87 (dd, J=13.6, 3.8 Hz, 1 H), 3.21 (dd,
J=13.6. 2.8 Hz, 1 H). 3.39 - 3.53 (m, 1H), 3.95 (d, J=8.3 Hz, 1 H), 4.65 (d, J=8.3 Hz, 1
H), 4.72 (quin, .1272 Hz, 1 H), 4.87 (br s, 2 H), 7.12 (dd, J=11.9, 8.8 Hz, 1 H), 7.60 (dd,
126.9, 2.7 Hz, 1 H), 7.95 (dt, J=8.5, 3.6 Hz, 1 H), 8.16 (d, J=1.0 Hz, 1 H), 9.02 (d,
J=1.0 Hz, 1 H), 9.52 (s, 1 H)
PCT/EP20121050833
Exam 1e 15: N— 3— 4aS SS 7218 amino~5— trifluorometh 1 —4a.5 7 7a—tetrah dro—4H-
furo 3,4-d 1.3 thiazin-7a— 1 -4.5-difluoro hen 1 —5— difluorometh 1
carboxamide
Synthesized from tert—butyl [(4aS,SS,7aS)-7a— (5~amino-2,3~dif1u01'ophenyl)~5—
trifluoromethyl—Arafi,7,7a—tetrahydro-4H—furo[3 ,4—d] [1,3]t111azin~2—y1]carbmnate and 5—
difluoromethyl-pyrazine-2—c2u'b0xy11c acid according to the general procedure. 1H
NMR (400 MHZ, CDC13) 8 ppm 2.90 (dd, J213.8, 3.7 Hz, 1 H), 3.19 (dd, J213.8, 2.7
Hz, 1 H), 3.31 — 3.49 (m, 1 H), 3.95 (d, J=7.6 Hz, 1 H), 4.44 — 5.15 (m, 4 H), 6.81 (t,
J255.8 Hz, 4 H), 7.22 — 7.35 (m, 1 H), 8.08 (ddd, J211.2, 6.8, 2.7 Hz, 1 H), 8.94 (s, 1 H),
9.53 (s, 1 H), 9.67 (s, 1 H)
Exam 1e 16: N— 3- .7aS ~2—amin0 rometh 1 -4a.5.7.7a-tetrah dl‘O-4H-
furo 3.4-d 1.3 thiazin-7a— 1 -4 5—difluoro hen 1 -5—methox razine—2—carboxamide
OwNl
F NH
YNHg
F
Synthesized from utyl [(4aS,SS,7aS)—7a— (5-amino—2,3-difluor0phenyl)~5~
t1‘ifluoromethy1—4a,5 ,7,7a—tetrahydro—4H—furof3 ,4-d] hiazin—2-y1]carbamate and 5-
methoxypyrazine-Z-cm‘boxylic acid according to the general procedure. 1H NMR (400
MHz, CDC13 + MeOD) 8 ppm 2.83 (dd, J=13.9, 3.8 Hz, 1 H), 3.14 (dd, , 3.0 Hz,
1 H), 3.29 — 3.39 (m, 1 H), 3.87 ((1, 128.3 Hz, 1 H), 4.04 (s, 3 H), 4.60 (d, J28.3 Hz, 1
H), 4.67 (quin, 126.3 Hz, 1 H), 7.11 ~ 7.21 (m, 1 H), 8.03 (ddd, J211.6, 6.9, 2.7 Hz, 1
H), 8.15 ((1, 121.3 Hz, 1H), 8.96 (d, J21.3 Hz, 1 H)
Exam 1e 17: N— 3- 4218 SS 7218 amino—5- trifluorometh 1 -4a.5 7.7a-tetrah dro—4H-
furo[3,4—dU 1.31thiazin—7a—yl)—4,5~difluoropheny1)methylpyrazinecarboxamide
~76—
2012/050833
Synthesized from tert—butyl [(4aS,SS,7aS)-7a- (5-amino—2,3—difluoropheny1)~5—
oromethyl—4a,5,7,7a~tetrahydro—4H—furo[3 ,4—d] [l ,3]thia7.in-2~yl]carbamate and 5—
methylpyrazine—2—carboxy1ic acid according to the general procedure. 1H NMR (400
MHZ, CDC13 + MeOD) 8 ppm 2.68 (s, 3 H), 2.84 (dd, J=13.6, 3.8 Hz, 1 H), 3.15 (dd,
J=13.9, 3.0 Hz, 1 H), 3.30 - 3.42 (In, 1 H), 3.88 (d, J=10.4 Hz, 1 H), 4.61 (d, J=8.6 Hz,
1H), 4.68 (quin, J=7.2 Hz, 1 H), 7.13 ~ 7.25 (m, 1 H), 8.05 (ddd, J=11.6, 6.8, 2.8 Hz, 1
H), 8.46 (s, 1 H), 9.30 (d, J=1.3 Hz, 1 H)
Exam 1e 18: N— 3- 4aS.SS.7aS amino—5- trifluorometh 1 —4a.5.7.7a—tetrah dro-4H-
carboxamide
Synthesized from tert—butyl [(4aS,SS,7aS)—7a- (5—amino—2,3-difluorophenyl)—5~
romethyl—4a,5,7,7a~tetrahydro—4H~furo[3,4-d][1,3]thiazin—2-y1]carbamate and 5»
(fluoromethyl)pyrazine—2-carb0xylic acid according to the general procedure. 1H
NMR (400 MHZ, CDC13) 8 ppm 2.89 (dd, J=13.6, 3.8 Hz, 1 H), 3.19 (dd, J=13.6, 3.0
Hz, 1 H), 3.43 (dd, J=7.5, 3.4 Hz, 1 H), 3.86 — 3.99 (m, 1 H), 4.39 — 4.67 (m, 3 H), 4.74
(quin, .1271 Hz. 1 H), 5.76 (d, J=45.5 Hz. 2 H), 8.10 (ddd, J=11.4, 6.8, 2.8 Hz, 1 H),
8.77 (s, 1 H), 9.46 (s, 1 H), 9.69 (s, 1 H)
Alternate Preparations of the compounds of Examples 1 and 8 are described herein
below. For these alternate prepartions 1H NMR and 13C NMR spectra were recorded on
a Varian 400 MHz or 500 MHz instrument with VNMR 6.1C software.
2012/050833
Alternative Pre aration of N— 3— 4aS SS 7aS —2-amino—5— trifluorometh 1 -4a.5 7.7a—
tetrah dr0—4H—furo 3.4-d 1.3 thiazin-7a-
carboxamide {Example 1 l
1— 14 S nthesis of tart—But 12— 1.1.1-trifluorobut—3-en—2- lox acetate
0HC\/ OTMS
aq'NaOH / odk k O
———————~—>
F C/i\<¢9
CF3TMS
cat. TBAF 3 l/Njg;
BU4N H304 3
toluene 0 °C
A on vessel was charged with toluene (3.2 L)_. THF (0.60 L) and acrolein (0.40 L,
.985 mol) at It under nitrogen. (Trifluoromethyl)trimethylsi1ane (1.003 kg, 7.059
mol) was added at 17 °C. The reaction mixture was cooled to 2.5 °C and TBAF (0.01
M in THF, 0.400 L, 0.004 mol) was added over 2 h. During addition of TBAF, the
temperature of the reaction mixture increased to 65 °C. The reaction mixture was
cooled to 0 °C, and after 2h, tetra—n-butylammonium hydrogen sulfate (0.171 kg, 0.503
mol) was added, followed by tert-butyl cetate (0.987 kg, 5.064 mol). Sodium
ide (50% wt in water, 4.2 kg, 52.6 mol) was added over 2h while maintaining the
temperature under 10 0C. After 2h at 0-5 ”G, to the on mixture was added water
(2.9 L) and methyl tert—butyl ether (6.0 L). The aq. phase was extracted one more time
with methyl tert-butyl ether (6.0 L). The organic phases were combined and washed
with 14% aq. NaCl (3 x 1.6 L). The organics were concentrated under vacuum to
afford the title compound as an oil (1.150 kg, 94.5%) which was used in the subsequent
stage without additional purification. 1H NMR (500 MHZ, CDC13) 5 ppm 5.86 — 5.74
(m, 1H), 5.59 (d, J = 17.5 Hz, 1H), 5.56 (d, J = 10.9 Hz, 1H), 4.37 — 4.30 (n1, 1H), 4.11
(d, J: 16.5 Hz, 1H), 4.06 (d, J: 16.4 HZ, 1H), 1.40 (s, 9H); 13C NMR (125 MHz,
CDC13) 6 ppm 168.51, 128.49 ((1. J: 1.7 Hz), 123.86, 123.71 (q, J: 281.8 Hz), 82.22.
78.67 (q, J = 31.5 Hz), 66.60, 28.02.
1— 15 S nthesis ofNMethox ~N—meth 1-2— 1 1.1—t1i11uorobut—3—en2— 10x acetamide
(RioJ< HCOOH (4V) OiNO
//\E;3 MeONHMeHCI //\E;a
CDLDCM
stage 2
To a reactor containing tert—butyl 2~(1,1,1-trifluorobut—3—enyloxy)acetate (1.150 kg,
4.788 mol) was added formic acid (6.2 kg) at rt. The reaction e was heated to
55—60 °C for 4—5 h. The formic acid was evaporated under vacuum (T = 40-45 0C) and
chased with toluene (2 x 3.0 L). To the e was added CH2C13 (2.0 L) and further
concentrated under vacuum. To the resulting residue was added CHgClg (4.6 L) and
the solution was cooled to 0 °C, followed by N,N-carbony1diimidazole g, 6.49
mol) in five portions. The mixture was stirred for 30 mins, and ND-
dimethylhydroxylamine hydrochloride (0.67 kg, 6.72 mol) was added in portions while
maintaining temperature below 10 °C. The reaction mixture was warmed to rt and
stirred over 14 h. The reaction mixture was cooled to 3.2 °C and imidazole (100.7 g,
1.48 mol) was charged in two portions. The reaction mixture was warmed to rt and
water (1.4 kg) was added, followed by methyl tert—butyl ether (14.0 L). The organic
phase was washed with 2.0 N aq. HCl (1.0 L and 0.7 L), followed by sat. aq. NaHC03
(1.2 L) and sat. aq. NaCl (1.20 L). The organics were concentrated to afford the title
compound as an oil (0.95kg, 87.2%). 1H NMR (500 MHz, CDCl3) 5 ppm 5.85 — 5.76
(m, 1H), 5.62 (d, J = 17.2 Hz, 1H), 5.56 (d, J = 10.4 Hz, 1H), 4.49 — 4.34 (m, 3H), 3.68
(s, 3H), 3.67 (s, 1H), 3.18 (s, 3H), 3.08 (s, 1H); 13C NMR (126 MHZ, CdCl3) 5 ppm
1699*, 1634*, 128.61, 123.87 ((1, J: 282.0 Hz), , 78.54 (q, J: 31.3 Hz), 66.12,
61.52, 60.56, 36.20, 32.24. Note: this compound is a 3:1 mixture of amide bond
rotamers. $Carbony1 chemical shifts ted indirectly through 1H—13C HMBC
(heteronuclear multiple-bond correlation).
HRMS Calculated for C8H13F3N03 [M+H]+228.0848; found 228.0836.
1— 16 S nthesis of 1~ 2—Fluoro hen 1 1.1.1-triflu0robut—3—en 10x ethanone
W°$N°RAVK©01:3 I CF3
nBuLi, THF
stage 3
To a solution 1—bromo—2-t1uorobenzene (0.967 kg, 5.527 mol) in THF (6.2 L) at —75 °C,
was added n—butyllithium (2.50 M in hexane, 2.09 L, 5.22 mol) while maintaining
temperature below —65 CC (ca. 100 min.) After 15 mins, a on of N—methoxy—N-
methyl—2—(1,1,1~trifluorobut—3-en—2—yloxy)acetamide (0.949 kg, 4.178 mol) in THF (1.6
L) was added while ining temperature below ~65 °C (ca. 70 min). After 2.5 h
at —78 0C, the reaction was quenched by on of sat. aq. NH4C1 (3.0 L) and methyl
utyl ether (9.0 L). The reaction mixture was warmed to rt, the aq. phase was
extracted again with methyl tert—butyl other (2.5 L). The organic phases were
combined, washed with sat. aq. NaCl (2 x 0.3 L) and concentrated under vacuum to
afford the title compound as an oil (1.007kg, 80.0%). 1H NMR (500 MHZ, CDCl3) 6
ppm 7.96 (td, J = 7.6, 1.8 Hz. 1H), 7.62 — 7.54 (m, 1H), 7.33 — 7.25 (m, 1H), 7.20 —
7.12 (m, 1H), 5.86 (ddd. J: 17.5, 10.4, 7.3 Hz, 1H), 5.60 (dd, J = 20.5, 13.8 Hz, 2H),
4.91 — 4.76 (m, 2H), 4.39 (dq, J = 12.8, 6.4 Hz, 1H); 13(3 NMR (125 MHz,CDC13) 8
ppm 193.55, 162.14 (d, JCF = 254.1 Hz), 135.36 (d, Jan: 9.2 Hz), 130.62 (d, JCF = 3.2
20121’050833
Hz), 128.49, 124.85 (d, JCF = 3.3 Hz), 123.89, 122.93, 122.72 ((1, JCF = 24.5 HZ), 116.50
((1. JCF = 23.7 HZ), 78.97 (q. JCF = 31.4 Hz), 74.56 (d. .13: = 12.4 Hz).
HRMS Calculated for C12H10F4Og [M+H]+ 263.0695; found 263.0709.
NHN20H HCI, H02
0 F N F
aOAc |
Aro MeOH AD
CF3 CF3
stage 4
To a reactor was added ylarnine hydrochloride (0.34 kg, 4.95 mol), sodium
acetate (0.47 kg, 5.70 mol) and MeOH (2.68 L). To this suspension was charged a
solution of 1-(2-fluorophenyl)—2—(l.1,l~trifluorobut—3—en-2—yloxy)ethanone (0.998 kg.
3.806 mol) in MeOH (1.8 L) and the reaction mixture was heated to 40—50 °C. Upon
tion (ca. 2 h) the reaction mixture was cooled to rt, and filtered over Celite (0.5
wt) and rinsed with EtOAc (3.0 L). The filtrate was concentrated under vacuum and to
the resulting residue was added methyl rert-butyl ether (6.3 L), water (0.94 L) and sat.
aq. NaHC03 (2.5 L). The organic phase was washed once with water (1.6 L) and sat.
aq. NaCl (0.1 L). The organic phase was concentrated under vacuum to afford the title
compound as an oil (1.03 kg, 95.0%). 1H NMR (500 MHz, CDC13) 6 ppm 7.49 — 7.35
(m. 2H), 7.24 — 7.06 (m. 2H), 5.78 — 5.65 (m, 1H), 5.54 — 5.40 (m, 2H). 4.89 — 4.81 (m,
1H), 4.53 (d, J :: 12.6 Hz, 1H), 4.47 (d, J = 12.6 Hz, 0.5H), 4.27 — 4.18 (m, 11-l), 4.13 —
4.05 (m, 0.5H).
HRMS Calculated for C12H11F4N02 278.0804; found 278.0780.
Note: 1—(2—Fluorophenyl)-2—(1,1,1-trifluorobut~3~en~2~yloxy)ethanone oxime exists as
an equilibrium of structural isomers, which accounts for the less-than-whole—number
al values.
1—18 S ntheis of ‘3aR* 4S*.6aS* —6a-'2—fluoro hen 1—4—
rometh l hexah drofuro 3.4-c isoxazole
| . F
A0 hydroqumone 23:
O ‘0
CF3 xylenes
130 OC H
To a solution of 1—(2—fluorophenyl)(1,1,1—trifluorobut~3~en-2—yloxy)ethanone oxime
(1.085 kg, 3.328 mol) in xylenes (6.9 L) was added hydroquinone (862g, 0.8 mol) at rt.
The solution was heated to 128 "C (internal temperature) for 18 h. The solution was
cooled to rt, and hexanes (7.0 L) was added, followed by 4.0 M aq. HCl (2.4 L). The
—80—
PCTIEP2012/050833
reaction mixture was stirred for l h, and filtered. To the solid was added water (2.0 L),
methyl utyl ether (7.0 L) and 25% wt. aq. NaOH (0.4 L). The aq. layer was
extracted once with methyl tert-butyl ether (7.0 L), the organics were combined, washed
with 27% aq. NaCl (2.0 L) and trated under vacuum to a black oil (512.0g, 56%).
1H NMR (500 MHz,CDC13)8 ppm 7.64 - 7.52 (m, 1H), 7.39 — 7.31 (m, 1H), 7.19 (td, J
= 7.7, 1,2 Hz, 1H), 7.11 (ddd, J: 11.9, 8.2, 1.0 Hz, 1H), 4.54 (d. J: 10.1 Hz, 1H), 4.34
—4.23 (m, 1H), 4.26 — 4.17 (m, 1H). 4.16 (d, J = 10.2 Hz, 1H), 4.10 (d, J = 8.5 Hz, 1H),
3.71 (d, J = 20.2 Hz, 1H); 13C NMR (125 MHz, CDC13) 8 ppm 160.59 ((1, JCF = 247.0
Hz), 130.50 (d, JCF = 8.7 Hz), , 124.69 (d, JCF = 3.3 Hz), 124.45 (q, JCF =: 281.8
Hz), 124.43 ((1, JG}: = 11.9 Hz), 116.66 (d, JCF = 22.7 Hz), 83.70 (q, JCF = 32.1 Hz),
78.17 ((1, JCF = 3.1 Hz), 77.63. 54.53.
HRMS Calculated for C13H11F4N02 [M+H]+ 278.0804; found 278.0802.
1-(192 Synthesis of) 28*.3R* 48*
(trifluoromethyl )tetrahydrofuran~3~yl )methanol
F F
a Zn, AcOH
0 ‘o THF, water 0
F3C H F3C OH
racemic
Zinc (389.2 g, 5.95 mol) was placed in a on vessel, and water was added (893 mL).
Acetic acid (135 mL, 2.38 mol) was added while maintaining the temperature below
°C. After 15 min, 6a-(2—fluoropheny1)(trifluoromethyl)hexahydrofuro[3,4—
c]isoxazole (550.0 g, 1.98 mol) was added as a on in THF (665 mL). The
reaction mixture was stirred over 16 h at rt. Methylene chloride (1.89 L) was added.
followed by 28% aq. NH4OH (552 mL) while the temperature was kept below 30 °C.
The mixture was stirred for 30 min, and then filtered over Celite (80 g) g with
methylene chloride (378 mL). The aq. layer was extracted with methylene chloride
(1.89 L). The organics were combined, washed with sat. aq. NaCl (1.0 L) and
concentrated under vacuum to afford an oil (502 g, 90.6%). The crude residue was
used in the following step without additional purification.
HRMS Calculated for C12H13F4N02 [M+H]+ 280.0961; found 280.0972.
1120) Synthesis of (125,312,413 2Amino-4—g 2-fluorophcnyl )-2~
(trifluoromethyl )tetrahydrofuranyl )methanol {25.35 )—2.3 -bis( benzoyloxy zsuccinate
O 932
' OH
F HO
D-DBTA
NHz 63.7. o
EtOH water 0
'IIII ..,,|
F03 F30 OH
To a solution of 4—amino—4—(2—fluorophenyl)-2—(trifluoromethyl)tetrahydrofuran—3—
yl)methanol (0.502 kg, 1.798 mol) in ethanol (4.865 L) was added dibenzoyl-D-tartaric
acid (0.642 kg, 1.798 mol). The resulting suspension was heated to 67 0C. Water
(94.0 mL, 5.2 mol) was added over 15 min while maintaining temperature >66 0C.
The resulting solution was cooled to to 45 °C while precipitation occurred. The slurry
was reheated to 60 0C, and then cooled to ambient temperature at 5 °C/hour. The
slurry was ed, and the solid was rinsed with premixed and cooled solution of
ethanol (950 mL) and water (20 mL). The solid was dried until constant weight under
vacuum (370 g, 97.6% 99). 1H NMR (500 MHZ, CD3OD) 6 ppm 8.13 (d, J = 7.2 Hz,
4H), 7.66 4 7.58 (m, 3H), 7.54 — 7.45 (m, 5H), 7.36 ~ 7.20 (m, 2H), 5.92 (s, 2H), 4.79 -
4.66 (m, 1H), 4.40 — 4.28 (m. 1H), 4.04 (dd. J = 12.1. 3.4 Hz, 1H), 3.92 (dd. J = 12.1.
.4 Hz, 1H), 3.30 — 3.24 (m, 1H); 13C NMR (125 MHZ, DMSO) 5 ppm 169.61, 165.81,
160.23 ((1, J: 246.1 Hz), 133.00, 131.34 ((1, J: 9.1 Hz), 129.65, 129.55, 128.08,
127.97 ((1, J: 3.5 Hz), 124.95 (d, J = 3.3 Hz), 116.56 (d, J = 23.5 Hz), 77.48 (q, JCF =
31.0 Hz), 76.33, 73.20, 65.61 (d, J = 3.1 Hz), 57.11.
HRMS ated for C12H13F4N02 [M+H]+ 280.0961; found 2800967 (for amino
alcohol).
The absolute stereochemistry of the title nd was assigned by comparison with a
sample prepared starting from oenriched (S)—2-(t1ifluoromethyl)oxirane.
Chiral HPLC parameters:
Equipment, ts, and Mobile Phase:
E I ui I ment:
HPLC column: Chiralcel OD, 4.6 x 250 mm, 10 um, Daicel Chemical
Industries, Ltd., catalog no. 14025.
Solvent Delivery System: Agilent 1100 HPLC ternary pump, low pressure mixing
with in—line de- asser, or e uivalent.
Autosampler: Agilent 1100 autosampler, 0.1 to 100 uL range, or
euivalent.
Detector: Ailent 1100 variable wavelength detector or ec nt.
Chromatographic Software: Agilent ChemStation software version A.09.03 or higher
for HPLC, Waters Em-ower 2 Build 2154 or - Iuivalent.
Volumetric Glassware Class A.
Volumetric 1 nette Class A.
~82—
or Calibrated El pendorf ad'ustable volume, or euivalent.
Analytical balance, ca-able of wei-hin ' i 0.1 mg.
Reagents:
Heotane: HPLC ; ade, Baker (catalo; no. 9177—03) or e uivalent.
IIx7 Pro nanol HPLC grade, Baker (catalo; no. 9095—03) or e uivalent.
Trleth lamme drich (catalo no. T0886) or - - uivalent. |
Mobile Phase:
Add 70 mL 2-propanol and 930 mL heptane (measured separately with a 100 mL and
lOOO—mL ted cylinders) and 1.0 mL triethylamine (measured with volumetric
glass pipette) to an appropriate flask and mix. Degas in—linc duiing use.
Diluting Solution: 2-Propanol
HPLC Parameters:
HPLC column: Chiralcel OD, 4.6 x 250 mm, 10 um, Daicel
Chemical Industries, Ltd, catalo no. 14025.
Temerature:
Howraew
Gradient: _
ion Volume:
Detection:
Data ac-uisition time:
Total run time: 30 min
Column Maximum Pressure: 35 Bar
Needle Wash: 2- ro n anol
>“Flow rate ma be ad'usted i 0.2 ml/min to obtain s-ecified retention times.
Retention Times for es and ties:
Compound Peak Retention Time
(Relative Retention Time, RRT)
.6 min i 10%
(RRT 1.00)
-83—
(Relative Retention Time, RRT)
19.2 min
iNH2 (RRT 0.93)
F36 H
(Enantiomer)
A Typical Chromatogram from a Chiral HPLC Isolation of Compound l—(20) is
ted in Figure 1.
'u, EtOAc, 1N NaOH
cliH F30 H
F3C 0“
To chiral salt ((25, 3R, 4S)—4-Amino—4—(2~fluoropheny1)—2-
oromethylfietrahydrofurany1)methanol (ZS, 3S)-2,3 -bis(benzoyloxy)succinate
(0.361 kg, 0.556 mol) was added BtOAc (1.08 L) and the suspension was cooled to —
3 0C. 1.0 N aq. NaOH (1.30 L) was added over 20 mins while maintaining T < 5 °C.
After 5 mins, benzoyl isothiocyanate (80.0 mL, 594 mmol) was added over 8 mins
while maintaining T < 5 0C. After 1 h, EtOAc (722 mL) was charged. The aq. layer
was d, and the organics were washed with sat. aq. NaHC03 (361 mL) and sat. aq.
NaCl (361 mL). The organics were filtered over celite (90 g) and rinsed with EtOAc
(360 mL). The organics were concentrated under vacuum to afford a residue which
was re-dissolved into CH2C12 (1.1 L) and concentrated to afford the title compound as
yellow foam (261 g, 99% yield accounting for residual solvents) which was used in the
following step. 1H NMR (500 MHZ, DMSO) 8 ppm 12.04 (5, 21-1), 11.20 (3, 21-1), 7.95
(d, J = 7.4 Hz, 2H), 7.69 — 7.60 (m, 1H), 7.56 — 7.42 (m, 2H), 7.37 — 7.28 (m, 1H), 7.24
— 7.12 (m, 2H). 5.59 (t, J = 4.5 Hz, 1H), 5.03 (d, J : 9.7 Hz, 1H), 4.92 (d, J z 9.7 Hz,
1H), 4.75 — 4.63 (m, 1H), 3.92 — 3.74 (m, 2H), 2.77 — 2.66 (m, 1H); 13C NMR (125
MHz, DMSO) 8 ppm 179.98, 167.85, 159.75 (d, la: 2 245.0 Hz), 133.44, ,
129.88, 129.81, 129.04, 128.85, 126.31 ((1, JCF = 9.8 Hz), 124.36, 116.83 (d, JCF = 23.4
Hz), 76.11 (q, JCF = 31.0 Hz). 74.37 (d, JCF = 6.1 Hz), 68.77 (d, JCF = 3.4 Hz), 57.03,
52.23.
l-lRMS Calculated for C20H13F4N303S [MM-11+ 441.0896; found 441.0818.
1— 22 S nthesis of N— 2—fluoro hen 1 —5— trifluorometh 1)-4a.5.7.‘7a-
tetrahvdro-4H-furol 3 .4—d H 1,3 thiazin—2—yl zbenzarnide
F H H F
N H
\H/ ‘Bz szo, pyridine ‘82
o o
S \‘Sf
CHZCIZ
H H
F3C OH FSC
A solution of N—((3S,4R,5S)—3—(2—fluorophcnyl)—4—(hydroxymcthy1)-5—(trifluoromcthyl)—
tetrahydrofuran—3—ylcarbamothioyl)benzamide (258.3 g, 583.8 mmol) in CH2C12(1.55
L) was cooled to —19.4 °C. ne (118 mL, 1.46 mol) was added while maintaining
temperature at —20 OC, and then the reaction mixture was cooled to -24 °C. In another
en purged vessel, CH2C12 (258 mL) was added followed by
trifluoromethanesulfonic anhydride (108.0 mL, 642.2 mmol). The resulting solution
was added to the reaction mixture over 30 min, while maintaining temperature < -
19.7 °C. Upon completed addition, the reaction mixture was stirred for 30 min at —
°C to -15 °C, and then warmed to -11 °C over 20 min. Saturated aq. NH4C1 (646
mL) and water (390 mL) was added. The mixture was warmed to t ature
and the aq. layer was removed. The organics were washed with premixed saturated aq.
1.5 NH4C1 (646 mL) and water (390 mL). The aq. layers were combined, and extracted
once with CH2C12 (520 mL). The organics were combined, and concentrated under
vacuum to afford a light orange foam (250 g, 100%). The residue was used in the next
stage t purification. 1H NMR (500 MHZ, CDC13) 5 ppm 8.03 (d, J = 6.7 Hz,
2H), 7.52 (t, J: 7.0 Hz, 1H), 7.48 — 7.31 (m, 4H), 7.20 (t, J = 7.4 Hz. 1H), 7.12 (dd, J =
12.0, 8.4 Hz, 1H), 4.82 — 4.73 (m, 1H), 4.60 (d, J = 8.9 Hz, 1H), 4.03 (d, J = 8.3 Hz,
1H), 3.57 (d, J: 2.7 Hz, 1H), 3.20 (d, J: 13.6 Hz, 1H), 2.81 (dd, J: 13.8, 2.5 Hz, 1H);
13C NMR (125 MHz, CDC13) 8 ppm 171.50, 159.57 ((1, JCF : 247.2 Hz), 134.62, 132.49,
130.65 ((1, Jcp J: 8.8 Hz), 129.77, 128.51, 128.45, 125.14 (q, JCF = 281.8 Hz), 124.97
((1, JCF : 3.0 Hz), 124.66 (d, JCF : 10.3 Hz), 117.05 ((1, JCF = 23.5 Hz), 66.81 ((1, JG}: 2
5.2 Hz), 38.90, 23.20.
HRMS Calculated for C20H16F4N2033 [M+H]+ 425.0947; found 425.0945.
1— 23 S nthesis of 4aS.SS.7aS -7a— 2—fluoro hen l —5-(trifluorometh l —4a.5.7.7a-
tetrah -furo 3.4-d 1.3 thiazin-Z-amine
F H
N\ N‘Bz NH2
K2303 0 Y
O s
MeOH
H 3
F3C
—85—
W0 20121098213
To a solution of N—((4aS,55,7aS)-7a-(2—fluorophenyl)—5—(tiifluoromethyl)—4a,5,7,7a-
tetrahydro—4H—furo[3.4—d][1.3]thiazinyl)benzamide (250.2 g, 589.5 mmol) in
methanol (1.25 L) was added K2003 (81.5 g, 590.0 mmol). The suspension was
heated to 65 °C for 6 h. Upon cooling to ambient temperature, the solvent was
evaporated under vacuum. To the resulting residue, was added 1.0 N aq NaOH (1.18
L) and THF (502 mL). The heterogeneous mixture was heated to 45 °C for 1 h. The
mixture was cooled to ambient ature, and EtOAc (1.38 L) was added. The
aqueous layer was ted with EtOAc (0.75 L). The organics were combined,
washed with saturated aq. NaHCO3 (500 mL) and saturated aq. NaCl (500 mL). The
cs were concentrated under vacuum to afford the title compound as a brown oil
(184.1 g, 91.6 % yield accounting for residual solvents). 1H NMR (500 MHZ, DMSO)
6 ppm 7.49 — 7.42 (m, 1H), 7.40 — 7.33 (m, 1H), 7.26 — 7.15 (m, 2H), 6.26 (s, 2H), 4.77
— 4.54 (1n, 1H), 4.40 (d, J = 8.0 Hz, 1H). 3.80 (dd, J = 7.9, 2.3 Hz, 1H), 3.24
— 3.17 (m,
1H), 3.00 (dd, J = 13.9, 3.2 Hz, 1H), 2.85 (dd, J: 13.9, 3.9 Hz, 1H); 13C NMR (125
MHz, DMSO) 5 ppm 159.75 (d, JCF = 245.1 Hz), 149.51, 131.31 ((1, J3: = 3.9 Hz),
130.13 (d, JCF = 8.8 Hz), 128.08 (d, JCF = 10.4 Hz), 128.28 (q, JCF = 282.1 Hz). 124.87
((1, JCF = 3.0 Hz), 116.80 ((1, J = 23.8 Hz). 78.77, 76.80 (q, JCF = 30.8 Hz), 66.31, 36.37,
23.27.
HRMS Calculated for C13H12F4N20S [M+H]+ 321.0685; found 321.0677.
1. HNQ3 NO2
Hgso4
F TFA
N NH2 F
\Y NYNHZ HCI 0 2. HCI
s o
F e3
To a cooled vessel containing (4aS,5$,7aS)—7a—(2—fluorophenyl)—5—(trifluoromethyl)-
4a,5,7,7a~tetrahydro—4H—furo[3,4~d][1,3]thiazin—2-arnine (184.1 g, 574.8 mmol) was
added trifluoroaeetic acid (0.954 kg) in ns while the temperature was maintained
below 20 °C. The mixture was cooled to 3.5 °C and sulfuric acid (146 mL, 2.73 mol)
was added over 20 min while the temperature was maintained below 5 °C. Fuming
nitric acid (39.8 mL, 0.948 mol) was added over 30 min, while the temperature was
maintained below 10 °C. After 1.5 h at 0—10 °C, the reaction e was slowly
quenched by transferring into an aq. on of NaOH (575 g. 14.4 mol) in water (4.6
L) cooled to 5 °C. The resulting suspension was stirred for l h at 21 °C. The
suspension was then filtered and the solid rinsed with cold water (920 mL). The solid
was dried under vacuum until constant weight, and then dissolved into ethanol (1.05 L).
—86~
The solution was heated to 35 °C, and conc. HCl (55.6 mL, 0.690 mol) was added while
maintaining temperature below 40 °C. The suspension was then cooled to —5 OC. held
for 1 hr and filtered. The solid was rinsed with cold ethanol (420 mL) and dried until
constant weight to obtain the title compound (185.0 g, 87.3%). 1H NMR (500 MHZ,
DMSO) 6 ppm 11.80 (s, 2H), 8.45 — 8.36 (m, 1H), 8.31 (dd, J: 6.6, 2.5 HZ, 1H), 7.66
(dd, J: 11.1, 9.3 HZ, 1H), 4.96 — 4.72 (m, 1H), 4.58 (d, J: 10.0 HZ, 1H), 4.27 (d, J =
9.9 HZ, 1H), 3.76 — 3.66 (m, 1H), 3.39 (dd, J : 14.9, 3.6 Hz, 1H), 3.24 (dd, J: 14.3, 4.6
HZ, 1H); 13C NMR (125 MHZ, DMSO) 8 ppm , 163.33 (d, JCF = 257.8 Hz),
144.58, 127.61 ((1, JCF= 11.6 Hz), , 124.10, 119.28 ((1, JCF = 26.5 Hz), 77.38 (q.
.lcp = 31.5 Hz), 75.99. 65.88 ((1, Jcp= 4.8 HZ), 40.36, 23.98.
HRMS Calculated for C13H11F4N3038 [M+H]+ 36; found 366.0523.
N02 NH2
N NH2 HCl N\ NH2
Fe,HC|
0 Y o I
EtOH
F30 H
F30
Ethanol (0.975 L) was added to iron powder (62.5g, 1.12 mol) under nitrogen
atmosphere. Concentrated HCl (9.03 mL) was added at ambient temperature and the
suspension was heated to 65 °C for 1.5 h. The suspension was then cooled to 50 °C,
and sat. aq. NH4C1 (299 g) were added. The temperature of the reaction mixture was
allowed to reach 50 °C_, and (4215,53,7aS)—'7a~(2-fluoronitrophenyl)—5-
(trifluoromethyl)—4a,5 tetrahydro—4H-furo [3 ,4—d] [1 ,3]thiaZin-2—amine
hloride (75.0 g, 187.0 mol) was added in portions while maintaining
temperature below 68 °C. After 30 min, ethanol (0. 45 L) was added, and the reaction
mixture was cooled to 20—25 0C over 1 h. The suspension was stirred for 2 h and
filtered over Celite (75 g) rinsing with ethanol (0.972 L). The solution was
concentrated under vacuum to a brown solid. Water (0.9 L) was added followed by
3.0 N NaOH (0.187 L, 560 mmol) while maintaining temperature below 35 °C. The
resulting suspension was d for 1 h at 20-25 °C. The suspension was filtered, and
the solid was rinsed with cold water (0.38 L). The solid was dried under vacuum at
40—45 °C over 24 h to obtain the title compound (57.7 g, 95.5 %). 1H NMR (500 MHZ,
DMSO) 8 ppm 6.81 (dd. J : 12.5, 8.6 Hz, 1H), 6.62 (dd, J: 7.0, 2.9 Hz, 1H), 6.50 —
6.42 (m, 1H), 6.16 (5, 21-1). 4.96 (5, 21-1), 4.72 — 4.54 (m, 1H), 4.35 (d, J = 7.8 HZ, 1H),
3.74 (dd, J: 7.8, 2.5 Hz,1H), 3.18 — 3.08 (m, 1H), 3.01 (dd, J: 13.9, 3.0 HZ, 1H). 2.84
(dd, J: 13.8, 3.8 HZ, 1H); 13C NMR (125 MHZ, DMSO) 5 ppm 156.20 (d, JCF : 243.0
PCTfEP2012/050833
Hz), 148.73, 145.49, 127.86 ((1, Jcp = 11.0 Hz), 116.79 (d, JCF = 24.8 HZ), 116.10 ((1, JCF
= 3.3 Hz), 114.10 (d. JCF = 8.0 Hz), 78.89, 76.5701.ch = 31.0 HZ). 66.35. 36.35. 23.11.
HRMS Calculated for C13H13F4NgOS [M+H]+ 336.0794; found 336.0789.
The title compound was subjected to an Ames test. (Salmonella typhimurium tester
strains TA98, TAlOO, TA1535 and TA1537 and ichia coli tester strain WP2 uv.
Mutation Research 1975, 3], 347; Mutation Research 1976, 38, 3; Proc. Nat. Acad. Sci.
USA 1976, 73, 950; Proc. Nat. Acad. Sci. USA 1975, 72, 5135) in the absence and
presence of rat liver S9. The nd was negative up to the highest
dose/concentration tested (SOOOug/plate).
1~ 26 S nthesis of N— 3— 4aS.SS 7aS amino—5~ trifluorometh l 7.7a~
tetrahvdro—4H—furo 3.4-d l thiazin—7a- l fluoro hen l —5-methox
carboxamide
N OMe N OMe
HO ‘I I
N/ N \N
F o o
NYNHZ N\ NH2
0 o Y
S 80012, s
F3C H DMI
F3C H
A suspension of oxypyrazine—Z-carboxylic acid (26.29 g, 0.17 mol) in N,N’—
dimethylimidazoline—Z—one (160 mL) was stirred at ambient temperature for 15 min,
then cooled to 2.2 0C. Thionyl chloride (14.7 mL, 0.202 mol) was added while
maintaining temperature under 5 °C. The resulting suspension was stirred at 0—10 °C
for 2 h while it transitioned to a clear solution. In another , (4aS,SS,7aS)—7a-(5-
amino—Z—fluorophenyl)(trifluor0methyl)~4a,5 ,7,7a-tetrahydro—4H—furo[3 ,4-
d][1,3]thiazin-2—amine (52.0 g, 0.155 mol) was dissolved into N,N’—
dimethylimidazoline-Z-one (160 mL). The ing solution was added to the solution
of acyl chloride while maintaining temperature below 10 °C. The reaction e
was stirred for 30 min. Water (780 mL) was charged while maintaining temperature
below 30 °C. The ion mixture was stirred for 30 min, and then EtOAc (780 mL)
was added. To this mixture was added, 50% aq. NaOH (84.8 g) until the pH of the
aqueous layer reached 11. The aq. layer was extracted with EtOAC (260 mL). The
organics were ed, washed with sat. aq. NaCl (260 mL) and water (260 mL).
The organics were filtered over Celite pad (26 g) and rinsed with EtOAc (260 mL). The
organics were concentrated under vacuum to afford a solid. To the solid was added 1-
propanoi (728 mL), and the suspension was heated to 75 °C until a clear solution
formed. The solution was cooled to ~10 °C and held for l h. The solid was filtered,
rinsed with cold l-propanol (104 mL) and dried under vacuum (35 °C) until constant
-88—
weight to afford the title compound (62.1 g, 84.9 %). 1H NMR (500 MHZ, DMSO) 5
ppm 10.56 (s, 2H). 8.88 (d, J: 1.2 Hz. 1H), 8.39 (d, J: 1.2 Hz. 1H). 7.95 — 7.83 (m,
2H), 7.18 (dd, J = 12.0, 8.8 Hz, 1H), 6.25 (s, 2H), 4.76 — 4.60 (m, 1H), 4.36 (d, J: 8.1
Hz, 1H), 4.01 (s, 3H), 3.88 (dd, J: 7.9, 2.3 Hz, 1H), 3.23 — 3.11(m, 2H), 2.91 (dd, J =
13.8, 3.6 Hz, 1H); 13C NMR (125 MHz, DMSO) 5 ppm 162.11, 161.93, 156.13 ((1. Jcr :
242.9 Hz), 149.38. 142.01, 138.35, 135.09, 133.98, 128.53 (d, Jcp = 11.6 Hz), 126.06 (q,
JCF : 282.0 Hz), 123.32, 121.93 (d, .13: = 8.6 Hz), 116.76 ((1,ch = 25.1 Hz), 78.86 ((1,
JCF = 6.9 Hz), 76.94 (q, Jcp = 30.5 Hz), 66.37, 54.75, 36.44, 23.53.
HRMS Calculated for C19H17F4N5038 [M+H]Jr 472.1066; found 472.1052.
Specific optical rotation [0.]D +1105 (c 0.519, MeOH)
Specific optical rotation parameters:
ent:
Polarimeter: Perkin Elmer, model 341 or equivalent.
Cell: Microglass cell, 100 mm pathlength, 1.0 mL ty,
Perkin—Elmer Cat. # 047.
Balance: Calibrated analytical e capable of weighing i 0.1
Water Bath: NESLAB RTE 1121 Chiller or equivalent.
Volumetric glassware: Class A.
Quartz Standard ID number 098799. or equivalent.
Polarimeter: Perkin Elmer, model 341 or equivalent.
Reagents:
Methanol: HPLC grade, Baker (catalog no. 9093—03) or equivalent
Instrument parameters:
Lamp: Na/Hal, Perkin-Elmer Cat. # 754.
Cell: Microcell (100mm), Perkin—Elmer Cat. #B004- 1693.
Cell Path: 100 mm (1 ter)
Mode: OROT
Wavelength: 5 89 nm
Cell Temperature: 20°C
Integration time: 2 seconds
Aperture: MICRO
Water bath temperature: 20 i 1°C
—89-
2012/050833
Alternative Pre aration of N— 3— 4aS SS 7aS ~2—amino—5— trifluorometh 1 —4a 5 7 7a—
tetrahvdro—4H—furo 3.4—d 1 3 thiazin-7a— 1 fluoro hen l fluorometh l) ’
2—carboxamide Example 8)
N L1H;/N NHz \H/E j/\F 1
HO / N
F o
O 2
S O
EtOAc, TSP E
F3C H
—(Fluoromethyl)pyra7.ine—2-carboxylic acid (32.6 g, 1.05 equiv) and (4aS,SS,7aS)-7a-
no~2—11uorophenyl)—5~(trilluoromethyl)-4a,5,7,7a-tetrahydro—4Hluro[3,4-
d][1,3]thiazin—2—amine (70.0 g, 1.0 equiv)I were charged to a reactor and ethyl acetate
(EtOAe, 630 mL) was added to the mixture to give a suspension. A solution of n-
e phosphonic acid ide (T3P, 146 g, 1.10 equiv, 50 wt% in EtOAc) was
added at ambient temperature while controlling the internal temperature below 30 °C.
The reaction mixture was stirred at 40-45 ”C >3 hours and monitored by HPLC. The
on mixture was cooled to 15-20 “C and water (140 mL) was charged. After 10-
15 minutes charged 28% ammonium hydroxide (175 mL) while controlling the
temperature below 30 °C. EtOAc (245 mLO was added and the reaction mixture was
stirred for 30 minutes at ambient temperature. The aqueous phase was separated and
back-extracted with EtOAc (490 mL). The organic phases were combined and washed
with 15% aq. NaCl (140 mL) and water (140 mL). The organic layer was filtered over
Celite (1.0 Wt) and rinsed with EtOAc (140 mL). The solution was trated under
vacuum to obtain a beige solid (quantitative crude yield) which was recrystallized from
l—propanol to afford N-(3~((4aS,SS,7aS)—2-amino-5—(trifluoromethyl)-4a_.5,7,7atetrahydro-4H-furo
[3 ,4-d] [1,3]thiazinm7a—yl)~4-fluorophenyl)—5-(fluoromethyl)pyrazine~
2-carboxamide as a white solid (70.0 g).
1H NMR (500 MHz, DMSO) 8 10.89 (s, 1H), 9.30 (s, 1H), 8.89 (s, 1H), 7.95 (dd, J =
7.3, 2.7 Hz, 1H), 7.94 — 7.89 (m, 1H), 7.21 (dd, J = 12.0, 8.8 Hz, 1H), 6.22 (s, 2H), 5.71
(d, J = 46.3 Hz, 2H), 4.77 — 4.61 (m, 1H), 4.37 (d, J = 8.1 Hz, 1H), 3.87 (dd, J = 8.0, 2.7
Hz. 1H), 3.20 (dt. .12 7.0. 3.5 Hz. 1H). 3.15 (dd. J: 13.9, 3.1 Hz. 1H). 2.91 (dd, J:
13.8, 3.8 Hz, 1H).13C NMR (126 MHz, DMSO) 5 161.32 (s), 155.82 (d. J = 243.4 Hz),
153.71 ((1, J = 18.7 Hz), 148.77 (s), 144.71 ((1, J: 1.9 Hz), 143.30 (s), 141.01 (d, J: 5.6
Hz), 134.36 ((1, J = 2.0 Hz), 128.20 ((1, J = 12.1 Hz), 125.57 (q, J = 2830 Hz), 12312 (d,
PCT/EP20121’050833
J: 3.6 Hz), 121.64 ((1, J: 8.6 Hz), 116.35 ((1, J = 25.2 Hz), 82.55 (d, J = 165.8 Hz),
78.37 (3), 76.44 (q. J = 30.6 Hz), 65.89 ((1, J = 5.3 Hz). 35.89 (3). 23.01 (s).
HRMS Calculated for C19H17F5N50-23 [M+H]+ 474.1023; found 474.1032.
ic Optical Rotation: [(111320 = +102.4
1A preparation of (4aS,SS,7aS)—7a—(5-amino-2—fluorophenyl)—5-(trilluoromethyl)~
4a,5,7,7a-tetrahydro—4H—furo[3,4~d][1,3]thiazin~2—amine is described herein above in
step 1—(25) in the ative preparation of N—(3—((4aS,SS,7aS)—2~amino—5—
(trifluoromethyl)—4a,5 ,7,7a—tetrahydro—4H—furo [3 ,4—d] [1,3 ] thiazin—7a—yl)—4~
fluorophenyl)—5—methoxypyrazine—2-carboxamide (Example 1).
In. vitro ar assay:
Quantification of AE peptide in culture of neurons from rat fetus brain
(_ l) Rat primary neuronal culture
y neuronal cultures were prepared from the cerebral cortex of embryonic
day 18 Wistar rats (Charles River, UK). Specifically. the embryos were aseptically
removed from nt rats under ether anesthesia. The brain was isolated from the
embryo and immersed in HBSS (Sigma Aldrich #H9269) containing lOmM HEPES
(Gibco #15630—056). The cerebral cortex was collected from the isolated brain under
a stereoscopic microscope. The cerebral cortex fragments ted were
enzymatically treated in an enzyme solution containing 0.05% trypsin—EDTA solution
(GIBCO, #25300) at 37°C for 20 minutes to disperse the cells. The cells were then
washed twice and then gently resuspended in Neurobasal medium (Gibco #21103)
supplemented with 2% B27 supplement (GIBCO #17504—044). 0.5 mM amine
(GIBCO #25030), 1x N2 (GIBCO #17502-048), ml Pen/Strep (GIBCO 15140—
122) and 5% heat inactivated FCS (PAA #A15-701). The cell dispersion was filtered
through a 40—pin nylon mesh (BD Falcon #352340) to remove the remaining cell mass,
and thus a neuronal cell suspension was obtained. The al cell sion was
diluted with the medium above and then plated in a volume of 100 uL /well at an initial
cell density of 3.25 X 105 cells/ml in poly- D~lysine coated 96—well culture plate
(Greiner #655940). The plated cells were cultured in the culture plate at 37°C in 5%
COg—95% air for 24hrs. The total amount of the medium was replaced with ‘assay
Neurobasal medium’ (as above excluding heat inactivated PCS), and then the cells were
cultured for a further five days.
WO 98213
(2) Addition of compound
The drug was added to the culture plate on Day 6 of culture as follows. 8 point
compound serial dilutions were generated in DMSO at a concentration of x1000 that of
the final assay concentration (FAC). Compound solutions were then ed by adding
999u1 of ‘Assay Neurobasal media’ (as described in above section) to lul of DMSO
compound stock. The total amount of the medium was removed from each of the cell
plate wells, and l40uL/well of ‘Assay Neurobasal media’ was added followed by 60ul
of compound solution. . The final DMSO tration was 0.1%.
(3) Sampling
The cells were cultured for either 1 or 3 days after addition of the compound for
ABx—40 and ABX~42 assays respectively. lSOul of sample medium was collected and
used as the ELISA sample.
(4) Evaluation of cell survival
Cell survival was ted using an Alamar assay according to the following
procedure. After collecting the sample to be used in the ELISA assay, 50rd of 20%
Alamar blue solution (Invitrogen #DALI 100) in assay Neurobasal media, was added to
50u1 of remaining sample within each well. Cells were then incubated at 37°C in 5%
C02~95% air for 1hr.
Measurement. of fluorescence intensity for each well was the carried out at
0nrn using a Pherastar plus plate reader (BMG labtech). Upon measurement,
wells having no cells plated and containing only the medium and Alamar solution were
set as background (bkg).
(5) Ali ELISA
Human/Rat [3 d (42) ELISA Kit Wako (#290—62601) and Human/Rat [3
d (40) ELISA Kit Wako (#294-62501) from Wako Pure al Industries,
Ltd. were used for AB ELISA. AB ELISA was carried out according to the protocols
3O recommended by the manufacturers, bed in the documents accompanying the kits.
The results were shown as percentage of the control groups and ICSO values for each
compound were determined using four parameter logistic fit model using the XLFITS
software package (IDBS).
The compounds of the present invention have an AB42 production reducing
effect.
The compound of the general formula (I) or pharmaceutically acceptable salt
thereof according to the present invention has an AB42 production reducing effect.
Thus, the present invention can particularly provide a prophylactic or therapeutic agent
for a neurodegenerative disease caused by AB such as Alzheimer—type dementia or
Down‘s syndrome.
As measured by the above in vitro assay, nd Examples 1 to 18 showed
ICSO values of less than 0.1 uM as shown in Table 5:
Table 5:
Examgle ICso (11M) Examgle ICso (uM)
1 0.008 11 0.010
2 0.004 12 0.006
3 0.004 13 0.044
4 0.008 14 0.002
0.012 15 0.007
6 0.006 16 0.009
7 0.008 17 0.05 1
8 0.006 18 0.015
9 0.007
0.010
Claims (18)
1. A compound of formula (I): A Y Si TN/ l X NH F (0 N NH2 0 Y or a pharmaceutically able salt thereof, wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, 10 difluoroethyl, methoxy, ethoxy, methoxymethyl or -C EN.
2. A compound as claimed in claim 1 wherein X is hydrogen, or a ceutically acceptable salt thereof. 15
3. A compound as claimed in claim 1 or claim 2 wherein A is N, or a pharmaceutically acceptable salt thereof.
4. A compound as claimed in any one of claims 1 to 3 n Y is methyl, monofluoromethyl, difluoromethyl, trifluoromethyl or methoxy, or a pharrnaceutically 20 acceptable salt f.
5. A compound as claimed in any one of claims 1 to 4 wherein the compound is selected from: N-(3-((4aS,5S,7aS)-2—amino(trifluoromethyl)—4a,5,7,7a-tetrahydro-4H—furo[3,4- 25 d] [ l ,3 ]thiazin—7a—yl)—4-fluorophenyl)methoxypyrazine—2—carboxamide,- N—(3-((4aS,5S,7aS)amino-5—(trifluoromethyl)—4a,5,7,7a-tetrahydro-4H-furo[3,4- d] [ l ,3]thiazin-7a-yl)fluorophenyl)cyanopicolinamide ; N—(3-((4aS,5S,7aS)amino-S-(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d] [ l ,3]thiazin—7a-yl)fluorophenyl)—5-(difluoromethyl)pyrazine-2—carb0xamide ; N-(3 —((4aS,5S,7aS)amino(trifluoromethyl)-4a,5 ,7,7a—tetrahydro-4H—furo [3 ,4- d] [ 1 ,3 ]thiazin-7a—yl)fluorophenyl)(trifluoromethy1)picolinamide ; N—(3-((4aS ,5 S,7aS)—2-amino(trifluoromethyl)-4a,5,7,7a-tetrahydro-4H-furo [3 ,4- d][1,3]thiazin-7a-y1)fluorophenyl)methy1pyrazine—2-carboxamide ; N-(3-((4aS,5S,7aS)amin0(trifluoromethy1)-4a,5,7,7a-tetrahydro-4H-fur0 [3 ,4- d] [ 1 ,3 ] thiazin—7a—yl)fluorophenyl)-5—methy1picolinamidc ; N—(3-((4aS,5S,7aS)—2—amino-5—(trifluoromethyl)-4a,5,7,7a—tetrahydro-4H—furo[3 ,4— d][1 ,3 ]thiazin-7a—y1)fluoropheny1)ethy1picolinamide ; N—(3 -((4aS,5S,7aS)amino-5—(trifluoromethyl)—4a,5,7,7a—tetrahydro-4H-furo [3 ,4— 10 d] [ l ,3 ]thiazin—7a—yl)fluorophenyl)—5-(fluoromethyl)pyrazinecarboxamide ; N—(3-((4aS,5S,7aS)~2-amino(trifluoromethy1)-4a,5,7,7a-tetrahydro—4H-fi1ro [3 ,4— d] [l ,3]thiazin-7a—yl)fluorophenyl)—5—methoxypicolinamide ; N—(3—((4aS,5S,7aS)amino—5~(trifluoromethyl)—4a,5 ,7,7a-tetrahydro-4H—furo [3 ,4— d] [l ,3]thiazin—7a-yl)—4—fluoropheny1)—5-ethoxypyrazine—Z—carb0xamide ; 15 N—(3-((4aS,5S,7aS)—2-amino(trifluoromethyl)—4a,5,7,7a—tetrahydro-4H—fi1ro [3 ,4— d] [ l ,3 ] thiazin—7a-yl)fluorophenyl)—5—(l ,1~difluoroethyl)pyrazine—2-carboxamide ; N-(3 —((4aS ,5 S,7aS)amino(trifluoromethyl)—4a,5 ,7,7a—tetrahydro-4H-furo[3 ,4- d] [ l ,3 ] thiazin—7a—yl)~4~fluorophenyl)-5 uoromethyl)pyrazinecarboxamide ; N—(3-((4aS,5S,7aS)amino(trifluoromethy1)-4a,5,7,7a-tetrahydro-4H-fur0 [3 ,4- 20 d] [1 ,3 ]thiazin-7a-y1)—4-fluoropheny1)(methoxymethyl)pyrazine-Z-carboxamide: ; N— {3 —[(4aS,5 S,7aS)—2-amino—5-(triflu0romethyl)-4a,5-dihydro-4H—furo [3 ,4 d] [ l ,3]thiazin-7a(7H)-y1] —4—fluorophenyl} [(2H3)methy1oxy]pyrazine—2— carboxamide,- N—(3-((4aS ,5S,7aS)—2-amino—5-(trifluoromethyl)-4a,5,7,7a-tetrahydro—4H—furo [3 ,4— 25 d] [l ,3 ]thiazin—7a—y1)-4,5~difluorophenyl)—5—(difluoromethyl)pyrazine-2—carboxamide ; N—(3-((4aS,SS,7aS)—2—amino—5—(trifluoromethy1)—4a,5,7,7a-tetrahydro-4H—fi1ro [3 ,4- d] [l ,3 ]thiazin—7a—yl)-4,5—difluoropheny1)—5-methoxypyrazine—2—carboxamide ; N—(3 -((4aS,5 S,7aS)—2~amino—5-(trifluoromethyl)-4a,5,7,7a—tetrahydro-4H—furo[3 ,4— d] [ 1 ,3 ]thiazin—7a-yl)—4,5-difluorophenyl)-5—methy1pyrazine—2-carboxamide ; 3O N—(3-((4aS,5S,7aS)—2-amino—5-(trifluoromethyl)—4a,5,7,7a—tetrahydro-4H—fi1ro[3 ,4- d] [l ,3 in-7a—yl)~4,5-difluorophenyl)—5-(fluoromethyl)—pyrazine—2—carboxamide; or a ceutically acceptable salt thereof.
6. A compound as claimed in claim 1 which is N—(3-((4aS,SS,7aS)amino—5- 35 oromethyl)-4a,5,7,7a—tetrahydro-4H—furo [3 ,4-d][1,3]thiazin-7a-yl) fluorophenyl)meth0xypyrazine—2-carboxamide, or a pharmaceutically acceptable salt thereof.
7. A compound as claimed in claim 1 which is (4aS,5S,7aS)-2—amino (trifluoromethyl)-4a,5,7,7a—tetrahydro-4H-furo [3 ,4-d] [l ,3]thiazin-7a—y1)—4— fluorophenyl)-5—(fluoromethyl)pyrazine—2-carboxamide, or a pharmaceutically acceptable salt thereof.
8. A compound as claimed in any one of claims 1 to 7, or a ceutically able salt thereof, for use in therapy.
9. A compound as claimed in any one of claims 1 to 7, or a pharmaceutically 10 acceptable salt thereof, for inhibiting beta-site d—B sor protein ng enzyme 1 (BACEl).
10. A nd as claimed in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for ng a neurodegenerative disease, wherein the 15 neurodegenerative e is Alzheimer—type dementia (AD) or Down's syndrome.
11. Use of a compound as claimed in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a neurodegenerative disease, wherein the neurodegenerative disease is 20 Alzheimer-type dementia (AD) or Down's syndrome.
12. A compound as claimed in any one of claims 1 to 7, or a ceutically acceptable salt thereof, for treating type 2 diabetes. 25
13. Use of a compound as claimed in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of type 2 diabetes.
14. A pharmaceutical composition comprising the compound as claimed in any one 30 of claims 1 to 7, or a pharmaceutically acceptable salt thereof, as an active ingredient in association with a pharmaceutically acceptable carrier.
15. A pharmaceutical product comprising, in combination, a first active ingredient which is a compound as claimed in any one of claims 1 to 7 or a pharmaceutically 35 acceptable salt thereof, and at least one further active ingredient useful in treating a neurodegenerative disease. —96-
16. The compound according to claim 1, substantially as herein described with reference to any one of the examples.
17. The use according to claim 11 or 13, ntially as herein described with reference to any one of the examples.
18. The pharmaceutical composition according to claim 15, substantially as herein described with reference to any one of the examples.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1101140.0 | 2011-01-21 | ||
GBGB1101140.0A GB201101140D0 (en) | 2011-01-21 | 2011-01-21 | Fused aminodihydrothiazine derivatives |
PCT/EP2012/050833 WO2012098213A1 (en) | 2011-01-21 | 2012-01-20 | Fused aminodihydrothiazine derivatives useful as bace inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ611365A NZ611365A (en) | 2015-04-24 |
NZ611365B2 true NZ611365B2 (en) | 2015-07-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012208526B2 (en) | Fused aminodihydrothiazine derivatives useful as BACE inhibitors | |
US9175013B2 (en) | Fused aminodihydrothiazine derivatives | |
JP5651692B2 (en) | Condensed aminodihydro-oxazine derivatives | |
AU2006331754A2 (en) | Compounds, screens, and methods of treatment | |
US20200024285A1 (en) | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | |
WO2014015125A1 (en) | Fused aminodihydrothiazine derivative salts and uses thereof | |
NZ611365B2 (en) | Fused aminodihydrothiazine derivatives useful as bace inhibitors | |
US11472806B2 (en) | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | |
GB2504615A (en) | Fused aminodihydrothiazine derivatives |